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Colorectal cancer (CRC) is a major health problem worldwide and a significant issue in 
New Zealand. Treatment for patients with CRC is morbid and costly, involving a 
combination of surgery, radiotherapy and chemotherapy. Although most patients will 
benefit from these forms of treatment, a significant proportion will suffer recurrence(s) 
and eventual death.  
Despite increased understanding of the molecular events underlying CRC development, 
established molecular techniques have only produced a limited number of biomarkers 
suitable for use in routine clinical practice to predict risk, prognosis and response to 
treatment. Recent rapid technological developments, however, have made genomic 
sequencing of CRC more economical and efficient, creating the potential to discover 
genetic biomarkers that have greater diagnostic, prognostic and therapeutic capabilities 
for the management of CRC.  
Translating potential gene biomarkers from genome-wide expression studies into 
clinical utility has typically relied on PCR-based technology and immunohistochemistry. 
These methods have technical limitations associated with them that are exacerbated 
by tumour heterogeneity. This makes validation and translation of biomarkers into 
clinical use difficult. 
This thesis utilised a novel RNA in-situ hybridisation assay, RNAscope, to investigate the 
RNA expression of two candidate prognostic gene markers in CRC patients. To 
circumvent tumour heterogeneity issues, and to improve reproducibility amongst gene 
expression studies, I adopted a gene selection process using copy number alterations 
as a criterion. Results showed RNAscope was able to measure the intra-tumoural gene 
expression of two potential candidate gene markers (GFI1 and TNFRSF11A) in archival 
formalin-fixed paraffin embedded CRC samples. Reduced gene expression levels was 
significantly associated with poor prognostic clinicopathological features that was 
similar to results shown previously by The Cancer Genome Atlas (TCGA) Network.  
iii 
 
RNAscope has the capability to produce quantitative gene expression levels at a cell-
specific level. To test this feature, RNAscope was combined with an image analysis 
platform (ImageJ) to quantify GFI1 and TNFRSF11A mRNA expression levels. Results 
showed cell-specific data could be produced allowing cell-type determination of gene 
expression levels. Compatibility of a variety of image analysis platforms with RNAscope 
was further investigated with histological and cell monolayer preparations, showing all 
image analysis platforms were suitable for the RNAscope assay.  
The limited literature available on the potential candidate gene biomarker, TNFRSF11A, 
in CRC prompted the investigation of the functional role of TNFRSF11A in an in vitro 
model. Reduced TNFRSF11A mRNA expression levels were hypothesized to increase 
proliferation and migration of CRC cells. Transfection of CRC cells with siRNA achieved 
a reduction in gene expression levels, however, results from the cell based functional 
assays did not conclusively support the initial hypothesis. An alternative hypothesis is 
that the results were representative of the molecular subtype for that cell line. Further 
work will be required to determine the functional role of TNFRSF11A in colorectal 
tumorigenesis, which may involve replicating the heterogeneous nature of CRC with an 
array of cell lines representing various molecular subtypes.  
Results from this thesis demonstrate the utility of RNAscope for assessing potential RNA 
biomarkers and investigating their role in tumorigenesis. Incorporating RNAscope with 
image analysis methods provides quantified data which could be clinically useful for 
setting diagnostic thresholds in companion diagnostics, particularly for the 
administration of immunotherapies. Furthermore, performing RNAscope on specimens 
that can be processed through whole slide scanners with or without computational 
modelling will allow spatio-temporal investigations of RNA within tissue at a single cell 
level. Such studies will lead to a better understanding of colorectal cancer development 
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Chapter 1. Introduction. 
1.1 Colorectal Cancer. 
Worldwide, colorectal cancer (CRC) accounted for 1.8 million new cases and nearly 900 000 
deaths in 2018, with over 4.7 million people living with a CRC diagnosis within the last 5 years 
(Bray et al., 2018). This disease represents a serious health problem in New Zealand with over 
3 000 new cancer cases and over 1200 deaths reported per year (Ministry of Health, 2016). 
The seriousness of this health problem is further reflected by New Zealand (and Australia) 
having the highest rates of CRC incidence in the world with an age standardised rate of 41.7 
for men and 32.1 per 100 000 in women (Ferlay et al., 2018). 
Furthermore, inequities in the rates of CRC amongst New Zealanders exist particularly for 
New Zealand (NZ) Maori and NZ Pacific populations relative to NZ non-Maori and non-Pacific 
population. Although both groups are more likely to come from different settings they are 
both likely to come from a low socio-economic group and present with later stage and/or 
metastatic disease.  Unfortunately, NZ Pacific have the worst outcomes (2-fold increased risk 
of death) , compared to NZ Maori (30% increased risk of death) and NZ non-Maori and non-
Pacific (Sharples et al., 2018).  
Risk of developing CRC appears to be increasing in countries with a western-style diet due to 
the consumption of red and processed meat, alcohol and smoking along with a sedentary 
lifestyle. CRC is also associated with chronic inflammatory bowel conditions such as ulcerative 
colitis and Crohns disease (Hamilton et al., 2000; Raskov et al., 2014).  
CRC involves the colon (large intestine) and the rectum (Figure 1.1), and is usually subdivided 
by tumour location into right sided (ascending and transverse colon), left sided (descending, 
sigmoid and recto-sigmoid colon), and rectum (Ponz De Leon and Gregoriol, 2001). This is 
because evidence indicates that tumour location may impact survival outcomes (Meguid et 
al., 2008; Wong, 2010; Sasaki et al., 2016; Creasy et al., 2018). Additionally, distinguishing 
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between colon and rectum is important as treatment and management options may differ 
(New Zealand Guidelines Group, 2011).  
 
Figure 1.1 Image of the small and large intestine. 
Image modified and reproduced from needpix.com under the Creative Commons Zero License for Public domain. 
1.1.1 Screening and Surveillance. 
The development of CRC is generally believed to take between 10 – 15 years providing 
clinicians an opportunity to screen for the pre-malignant and early malignant lesions (Al-
Sohaily et al., 2012). Evidence has shown that early detection and removal of precursor 
lesions (polyps and adenomas)  using endoscopic procedures can reduce the incidence and 
mortality from CRC (Atkin et al., 2010, 2017; Holme et al., 2014; Rees et al., 2016). 
To reduce NZ’s high incidence and mortality rates has involved the introduction of a NZ 
National Bowel Screening programme. This was rolled out in July 2017, targeting men and 
women between 60-74 years of age. It uses a non-invasive, user-friendly detection test called 
the faecal immunochemical test. This test detects the presence of blood in faeces which is 
associated with early signs of CRC. A positive test leads to a referral for colonoscopy for 
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further investigation to check for the presence of polyps/adenomas and/or CRC. It is expected 
that within this target population, seven out of 10 people referred for colonoscopy are likely 
to have a polyp and seven out of 100 people are likely to have a cancer detected (National 
Screening Unit, 2017). However, common problems encountered with screening 
programmes, include matching of resources to demand, developing quality assurance 
programmes and determining clinically recommended guidelines (Rees et al., 2016; Atkin et 
al., 2017). 
1.1.2 CRC Pathology and Histological Classification. 
CRC is the malignant transformation of normal colon epithelial cells to a generalised disorder 
of cell replication and differentiation which leads to the development of a morphological 
lesion (Ponz De Leon and Gregoriol, 2001). In 1990, Fearon and Vogelstein proposed a model 
for the development of CRC and formed the original accepted model for colorectal 
carcinogenesis (Figure 1.2) (Fearon and Vogelstein, 1990; Hamilton et al., 2000). They 
proposed that the development of CRC arises from a single pocket of stem cells from which 
one or several cells are affected by genetic alterations that give selective growth advantages 
(Fearon and Vogelstein, 1990; Hamilton et al., 2000). The first morphological recognised 
precursor lesion of CRC is the aberrant crypt foci (ACF). These are recognised as enlarged 
crypts with thickened epithelium and reduced mucin content. Through clonal expansion, the 
ACF develops into an adenoma (adenomatous polyp). Further genetic alterations and clonal 
expansion over time accumulate and facilitates the transition from an adenoma into 
carcinoma, with subsequent metastasis (Fearon and Vogelstein, 1990; Hamilton et al., 2000). 
Evidence from gene expression profiling has confirmed the temporal evolution from normal 
mucosa through to CRC (Tang et al., 2010). 
Some of these genetic alterations reported so far involve inactivation of tumour suppressor 
genes (APC, TP53 and DCC), mutations of oncogenes (KRAS), and genetic or epigenetic 
(hypermethylation) alterations to DNA mismatch repair genes (MLH1 and MSH2) (Hamilton 




Figure 1.2 CRC tumour progression as proposed by Fearon and Vogelstein (Fearon and Vogelstein, 1990). 
Image modified and reproduced with permission from Janne and Mayer, 2000, Copyright Massachusetts Medical 
Society. 
1.1.2.1 Adenomas (Adenomatous Polyps). 
Adenomas arise from the glandular epithelium of the colonic mucosa and have dysplastic 
morphology and altered cellular differentiation (Fearon, 2011). Adenomas can be 
histologically classified as either conventional adenomas or serrated polyps and vary in their 
clinical features and their relative risk of developing into CRC (Table 1.1).  
1.1.2.2 Conventional Adenomas. 
Conventional adenomas are believed to represent the precursor lesion of the majority of CRC 
(Rosty et al., 2013; Sachdev et al., 2019). Macroscopic appearance of adenomas can either be 
elevated, flat or depressed (Hamilton et al., 2000). Elevated adenomas can either be 
pedunculated (possessing a “stalk”), or sessile (appearing flat with no stalk amongst a 
background of normal mucosa) (Hamilton et al., 2000; Ponz De Leon and Gregoriol, 2001). 
Flat and depressed adenomas appear to have a mucosal reddening or subtle changes in 
texture or highlighted with chromoendoscopic dye techniques(Hamilton et al., 2000).  
Conventional adenomas are generally believed to develop from the bottom of the crypt and 
progress towards the luminal surface (Hamilton et al., 2000). Inactivation of the APC/ 
CTNNB1(β-catenin) pathway initiates the process of hypercellularity with enlarged, elongated 
to ovoid, hyperchromatic, stratified nuclei with loss of polarity (Hamilton et al., 2000; Fleming 
et al., 2012). Conventional adenomas can be further sub-classified into tubular, tubulovillous 
and villous adenomas based on their histological architecture pattern (Table 1.1) (Fleming et 
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al., 2012). Adenomas are classified as neoplastic with malignant potential correlated to type, 
size and degree of dysplasia. Adenomas that are larger than 1cm, have high-grade dysplasia, 
or are predominately villous in architecture are considered “advanced”, and require more 
aggressive endoscopic surveillance to prevent progression to cancer (Ponz De Leon and 
Gregoriol, 2001; Fleming et al., 2012). 
1.1.2.3 Serrated Polyps. 
Serrated polyps are microscopically distinguished from conventional adenomas by their 
serrated “saw-tooth” morphology and hypermaturation of the epithelium that lines the 
colonic crypt (Fleming et al., 2012; Yamane et al., 2014; IJspeert et al., 2015). These can be 
further sub-classified into three main types, hyperplastic polyps (HP), sessile serrated 
adenomas or polyps (SSA/P), or traditional serrated adenoma (TSA) based on their histological 
architecture, cytological dysplasia and level of serration of the crypts (Table 1.1) (Fleming et 
al., 2012; Rosty et al., 2013; Yamane et al., 2014). Macroscopically, serrated polyps are 
generally sessile or flat making endoscopic detection of serrated polyps difficult. The 
occurrence of SSA/P post-colonoscopy is high due to them being easily missed, or 
incompletely excised and their rapid growth (Fleming et al., 2012; Rosty et al., 2013).  
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Approximately 90% of sporadic CRC are adenocarcinomas arising from the colonic 
mucosa epithelium. These are categorised into either well-differentiated (>95% gland 
formation), moderately-differentiated (50-95% gland formation) or poorly-
differentiated (<50% gland formation) tumours based on the histological tumour grade 
(Hamilton et al., 2000). Approximately 70% of colorectal adenocarcinomas are 
moderately differentiated with 10% well-differentiated and 20% poorly-differentiated 
(Fleming et al., 2012). There are a number of histological variants of the traditional 
colorectal adenocarcinoma which include: mucinous adenocarcinoma; signet-ring cell 
carcinoma; medullary carcinoma; serrated, and adenosquamous, (Hamilton et al., 
2000). Other types of CRC that make up the remaining 10% include: squamous cell 
carcinoma, adenosquamous carcinoma, neuroendocrine, spindle cell carcinoma, small 
cell carcinoma and undifferentiated carcinomas (Fleming et al., 2012). 
A diagnosis of invasive carcinoma (malignant) is considered when the muscularis 
mucosae is breached by neoplastic cells (Figure 1.3). Additional helpful features for 
confirming a diagnosis of invasion are presence of a desmoplastic reaction (fibrous 
proliferation surrounding tumour cells) and necrotic debris within the glandular-lumen. 
Invasion confined to the lamina propria and muscularis mucosae is referred to as high-
grade dysplasia to avoid confusion and overtreatment of patients, and has no risk of 
nodal or distant metastasis (Hamilton et al., 2000; Fleming et al., 2012). Further invasion 
occurs with the tumour growing into the lumen and penetrating the bowel wall into 
surrounding organs and tissues. Metastasis to local lymph nodes or to distant body sites 
can occur via lymphatic or haematological spread (Hamilton et al., 2000; Ponz De Leon 
and Gregoriol, 2001). The predominant site of distant metastasis in CRC is the liver, due 
to it receiving a large portion of venous blood from the colon and rectum via the portal 
vein.  Metastasis to other body sites such as the lung, brain, bone marrow and other 




Figure 1.3 Histological representation of the colon.  
1.1.3 CRC Staging.  
The tumour, node, metastasis (TNM) staging system was developed by the American 
Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) 
and is the most clinically useful system available (Egner, 2010; Maguire and Sheahan, 
2014). The TNM staging system is used at the time of diagnosis to provide an indication 
about prognosis and inform treatment options based on the size and extent of the 
primary tumour (T), regional lymph node involvement (N) presence or absence of 
distant metastases (M) (Egner, 2010; Burrell et al., 2013). It is also used as a criterion 
for selection and stratification within clinical trials (Egner, 2010). The current staging of 
CRC follows the American Joint Committee of Cancer, 7th edition and is based on the 




Table 1.2 Criteria for T, N and M categories and the stage grouping criteria based on the AJCC Cancer 









Figure 1.4 Schematic representation of Tumour invasion and Stage Grouping relative to the TNM stage.  
 
1.1.4 CRC Treatment Management and Prognosis. 
The only curative treatment option available at present is complete surgical excision 
with adjuvant therapy for high risk tumours (Table 1.3). Determining prognosis and the 
most appropriate treatment for individual patients is strongly related to the anatomic 





Table 1.3 Treatment management for the various stages of CRC. 
 
 
The overall survival rates for patients with metastatic disease have improved from 12 
months to over 30 months due to better-refined use of traditional chemotherapy drugs 
(5-FU) coupled with new cytotoxic agents (oxaliplatin and irinotecan) and targeted 
therapies (EGFR and VEGF inhibitors) (Tenner and O’Neil, 2014). However, variation in 
outcomes for patients with the same tumour stage does occur (Maguire and Sheahan, 
2014).  
Approximately 30% of patients presenting with CRC will be Stage 3 and 25% of patients 
presenting will be Stage 2 (Dotan and Cohen, 2011). The use of adjuvant therapy 
(FOLFOX) has been reported to be clinically beneficial for Stage 3 patients with 
improvements in disease-free survival (DFS) and overall survival to over 70% both at 5 
year and 10 years follow-up (André et al., 2009, 2015), and this regimen has become 
established as standard practice in New Zealand (New Zealand Guidelines Group, 2011). 
Stage 2 patients are likely to have a 70-80% chance of cure from surgery alone (Dotan 
and Cohen, 2011). However, there is a sub-group of Stage 2 patients that present with 
morphological high-risk features (e.g. lymphatic and/or vascular invasion; poorly 
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differentiated histology; perforated or obstructed bowel at presentation). These 
patients have poorer prognosis with a recurrence risk the same as for Stage 3 patients, 
and they show a trend for potential benefit from the administration of adjuvant therapy 
(Teixeira et al., 2010; Dotan and Cohen, 2011). However, some clinical trials have shown 
no clear improvement between high and low-risk Stage 2 patients from receiving 
FOLFOX (Kuebler et al., 2007; Teixeira et al., 2010; Dotan and Cohen, 2011). The benefit 
of low-risk Stage 2 patients receiving adjuvant therapy is debatable and is left to the 
clinician/patient to discuss the merits and risks involved. It is recognised that these 
patients have increased toxicity to oxaliplatin (Dotan and Cohen, 2011) and the survival 
benefit from receiving adjuvant therapy is minimal at 3.6% better than surgery alone 
(Gray et al., 2007). To establish a clinical trial to demonstrate a survival benefit of 5% in 
low-risk Stage 2 patients would require the participation of 9000 patients. The 
likelihood of subjecting large numbers of patients to unnecessary toxicity makes this 
potentially unethical (Dotan and Cohen, 2011). 
Thus, one of the major/current challenges when treating and managing patients with 
CRC is identifying which patients are at risk for recurrence and targeting adjuvant 
therapy appropriately to achieve favourable patient outcomes. This has led to the 
search for molecular biomarkers that could help resolve these issues (Dotan and Cohen, 
2011; Morley-Bunker et al., 2016). However, this first requires increased understanding 
of the molecular pathogenesis of CRC to target therapy appropriately, thereby 
improving the outcome of patients and avoiding futile, costly treatment in patients who 
will not benefit (Sridharan et al., 2014).  
1.1.5 Pathogenesis and Molecular classification. 
Colorectal carcinogenesis develops through an accumulation of genetic and epigenetic 
alterations within normal colorectal epithelial cells that lead to transformation into 
carcinoma cells (Hanahan and Weinberg, 2000; Ogino and Goel, 2008; Al-Sohaily et al., 
2012; Raskov et al., 2014).These genetic and epigenetic alterations can be categorised 
into three general molecular pathways, which are characterised by chromosomal 
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instability (CIN), microsatellite instability (MSI) and the CpG island methylation 
phenotype (CIMP)  
1.1.5.1 CIN pathway. 
CIN is believed to account for approximately 70-85% of sporadic CRC and encompasses 
the adenoma-carcinoma sequence proposed by Fearon and Vogelstein (Fearon and 
Vogelstein, 1990; Thiagalingam et al., 2001; Boland and Goel, 2010; Fearon, 2011; Al-
Sohaily et al., 2012; Bogaert and Prenen, 2014). It is characterised by structural 
rearrangements and/or aneuploidy of chromosomal abnormalities affecting genes 
necessary in colorectal carcinogenesis. This leads to higher frequency of aneuploidy, 
loss of heterozygosity and chromosomal rearrangements (Thiagalingam et al., 2001; Al-
Sohaily et al., 2012) leading to mutations of several tumour suppressor genes e.g. APC, 
SMAD4, TP53 and oncogene KRAS. 
The sequence of key initiating events in the adenoma-carcinoma sequence involve the 
inactivation of the tumour suppressor gene, APC gene and the activation of the proto-
oncogene KRAS (Figure 1.5). 
 
 
Figure 1.5 CIN molecular pathway of colorectal cancer and the pathological basis.  
Characterised by clinical markers along with well-known genes implicated in  tumorigenesis (Morley-
Bunker et al., 2016). *DFS represents 5-year disease free survival for invasive cancer (Phipps et al., 2015). 
Inactivation of the tumour suppressor gene, APC, through LOH or mutation is an early 
event/initiating event in transformation of the normal mucosa and is important in 
progression of CRC (as it is seen at the same frequency between ACF, adenomas, and 
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adenocarcinoma) The APC gene is responsible for cellular proliferation within the colon 
through the WNT/wingless signalling pathway. Loss of APC results in the protein being 
unable to bind to the transcription factor CTNNB1 (β-catenin) and induce its 
degradation. This leads to a CTNNB1 build up within in the cytoplasm. CTNNB1 binds to 
TCF/LEF transcription factors and translocates into the nucleus where it activates genes 
responsible for cell progression (c-myc and cyclin D1), cell proliferation, angiogenesis 
and apoptosis (Al-Sohaily et al., 2012; Zoratto et al., 2014). Activation of the 
WNT/wingless pathway can also occur through mutations in CTNNB1, transcription 
factor TCF-4, or AXIN1 and AXIN2 (Al-Sohaily et al., 2012). 
Another common genetic alteration in the transformation of adenoma into carcinoma 
involves genetic alteration of the RAS family of proto-oncogenes, particularly the KRAS 
gene. KRAS mutations leave KRAS continually active resulting in activated downstream 
signalling cascades (e.g. MAPK and PI3K pathways) responsible for cellular growth, 
motility, differentiation, survival, apoptosis and inflammation (Fearon, 2011; Al-Sohaily 
et al., 2012). These events leads to the establishment of the two main types of ACF 
which can be  microscopically recognised, including ACF with features of a hyperplastic 
polyp (increased RAS proto-oncogene mutations) and dysplastic ACF (micro-adenomas) 
with mutation of the APC gene (Hamilton et al., 2000; Ponz De Leon and Gregoriol, 
2001). These ACF are the progenitor phenotype (Batlle et al., 2002) in which further 
genetic alterations occur over time.  
The most common cytogenetic alteration is chromosome 18q loss of heterozygosity 
(LOH) which occurs in  50-70% of CRC cases (Al-Sohaily et al., 2012; Grady and Pritchard, 
2014; Kudryavtseva et al., 2016). Loss of 18q is associated with poor prognosis for 
advanced CRC and a predictor for poor response to 5-FU based therapy (Al-Sohaily et 
al., 2012; Grady and Pritchard, 2014; Kudryavtseva et al., 2016). The tumour suppressor 
genes of DCC and SMAD4 are affected by deletion of 18q. SMAD4 is a key component 
of the TGF-β/BMP signalling pathway which is responsible for cell differentiation, 
apoptosis and other cellular processes (Kudryavtseva et al., 2016). Loss of SMAD4 
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protein is frequent in up to 50% of CRC cases (Tanaka et al., 2008; Grady and Pritchard, 
2014).  
17p LOH is another common cytogenetic abnormality that occurs late in CRC 
development (Al-Sohaily et al., 2012). This abnormality affects the tumour suppressor 
gene, TP53, by removing one allele with the remaining allele frequently carrying TP53 
mutation. This often occurs at the time of transition from adenoma to carcinoma 
(Fearon, 2011; Al-Sohaily et al., 2012). TP53 is involved in coding genes responsible in 
the cell-cycle checkpoints, promoting apoptosis, cellular metabolism and restricting 
angiogenesis. Mutated TP53 allows tumour cells to escape normal cell-cycle 
checkpoints and continue to grow and acquire invasive properties (Fearon, 2011) 
1.1.5.2 MSI pathway. 
MSI accounts for 10-15% of sporadic CRC cases and is characterised by an accumulation 
of mutations within microsatellite regions which can lead to loss of function in genes 
associated with CRC (Boland et al., 1998; Merok et al., 2013). Microsatellite instability 
occurs through a dysfunctional mismatch repair (MMR) system involving DNA MMR 
genes (MLH1, MSH2, MSH6 and PMS2). These genes are responsible for correcting DNA 
replication errors. Microsatellite regions have short repeated sequences of nucleotides. 
DNA polymerase, when replicating the DNA strand, is prone to slipping along these 
regions and inserting errors into the sequence. The MMR genes are responsible for 
correcting these errors before DNA replication is complete. Errors in the microsatellite 
regions commonly lead to frameshift mutations and high levels of microsatellite 
instability (Boland and Goel, 2010; Al-Sohaily et al., 2012; Sinicrope and Sargent, 2012; 
Zoratto et al., 2014). These genes may be affected through germline pathogenic variants 
giving rise to the hereditary familial MSI (Lynch syndrome) pathway (Figure 1.6 A). More 
commonly, sporadic cases occur through epigenetic silencing of these genes by 
promoter hypermethylation in tumour cells characterizing the CIMP 
phenotype/pathway (Figure 1.6B) (Ionov, Peinado and Malkhosyan, 1993; Goel et al., 




Figure 1.6 Two MSI molecular pathways of CRC.  
A) Familial (Lynch Syndrome) MSI molecular pathway, and B) CIMP molecular pathway for sporadic CRC 
and their pathological basis as characterised by clinical markers along with genes implicated in  
tumourigenesis ((Morley-Bunker et al., 2016). *DFS represents 5-year disease free survival for invasive 
cancer (Phipps et al., 2015). 
Microsatellite instability tumours can be characterised diagnostically using a 
standardised pentaplex panel of microsatellites recommended by the National Cancer 
Institute: BAT-25, BAT-26, D5S346, D2S123, D17S250 (Boland et al., 1998; Boland and 
Goel, 2010). Tumours are classified as either MSI-High (MSI-H) if two or more markers 
of instability are found, MSI-Low (MSI-L) for one marker, and MSI-Stable (MSS) for no 
markers (Al-Sohaily et al., 2012) (Kudryavtseva et al., 2016). Immunohistochemistry 
(IHC) can also be used to determine MSI status by detecting a loss of the proteins for 
MLH1, MSH2, MSH6 and PMS2 (Pritchard and Grady, 2011; Kudryavtseva et al., 2016). 
MSI-H tumours are more likely to arise in the proximal colon, are associated with female 
gender (Boland et al., 1998; Goel et al., 2003; Merok et al., 2013), older age (Goel et al., 
2003; Sinicrope et al., 2014), poor differentiation, mucinous or medullary features, 
prominent lymphocytic infiltration and have a more favourable survival outcome than 
MSI-L and MSS tumours (Goel et al., 2003; Sinicrope et al., 2014). 
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1.1.5.3 CIMP pathway. 
This pathway involves the epigenetic hypermethylation of the 5’-CpG-3’ dinucleotide. 
CpG sites can occur at high frequency within the promoter regions of genes forming 
CpG islands and increased methylation of CpG islands can silence adjacent genes. CIMP-
high (CIMP-H) tumours account for approximately 15–20% of sporadic CRC cases and 
are characterised by hypermethylation of the MLH1 gene producing MSI (Hinoue et al., 
2009; Fearon, 2011; Al-Sohaily et al., 2012; Bogaert and Prenen, 2014).  
CIMP-H tumours are strongly associated with BRAF V600E mutations (and female 
patients (Jass, 2007)), whereas CIMP-low (CIMP-L) tumours are associated with KRAS 
mutations (and male patients) (Hinoue et al., 2009; Fearon, 2011; Al-Sohaily et al., 2012; 
Bogaert and Prenen, 2014). This is a crucial distinction from a clinical perspective as 
BRAF status is used to distinguish familial (Lynch syndrome) from sporadic MSI tumours. 
CIMP status has been shown to have prognostic implications; CIMP-H tumours are 
associated with a low cancer mortality, although the presence of a BRAF mutation 
appears to be associated with worse outcome (Ogino et al., 2009). CIMP-H/MSI-H 
tumours are associated with poorer outcomes than CIMP-L/MSI-H (Kudryavtseva et al., 
2016). 
Another clinically relevant phenotypic characteristic of CIMP-H tumours is that they 
develop from the precursor lesion, sessile serrated adenoma (SSA), through the 
histological serrated neoplastic pathway. Endoscopically, SSAs are typically located 
within the proximal colon and can be difficult to recognise due to the flat or minimally 
raised appearance of the polyp (Fearon, 2011; Al-Sohaily et al., 2012). Failure to 
recognise and remove SSAs has been implicated in higher rates of interval CRC in the 
right colon (Ogino et al., 2009; Leggett and Whitehall, 2010). Multiple sessile serrated 
polyps are seen in the relatively rare sessile serrated polyposis syndrome where 50% of 
patients will develop CRC (Boparai et al., 2010). Emerging evidence from studies using 
tumour markers (MSI status, KRAS/BRAF mutational status) and clinicopathological data 
suggests the existence of an alternative serrated pathway with CRC developing from the 
tumour precursor lesion, the traditional serrated adenoma (TSA) (Figure 1.7) (Jass, 
18 
 
2007; Sinicrope et al., 2014; Phipps et al., 2015). Similar to tumours from the CIN 
pathway, these tumours are characterised by an MSS/CIMP-L phenotype and almost 
exclusively contain a KRAS mutation. Furthermore, patients with TSA-derived tumours 
exhibit worse outcomes than patients with CIN-derived tumours.  
 
Figure 1.7 Alternate Pathway for CRC and its pathological basis. 
Characterised by clinical markers along with well-known genes implicated in tumourigenesis (Morley-
Bunker et al., 2016). *DFS represents 5-year disease free survival for invasive cancer(Phipps et al., 2015).  
1.1.5.4 Other Pathways. 
Patient tumours that do not necessarily align to a particular molecular pathway are 
being researched to better understand and/or identify characteristic genetic and non-
genetic features shared between them. The evolving molecular techniques have 
enabled the identification of new high-penetrance CRC susceptibility genes, and 
allowed identification of novel biomarkers (Esteban-Jurado et al., 2014). A significant 
recent example is the identification of multi- case, non-Lynch syndrome CRC families 
with high-risk germline pathogenic variants in POLE, POLD1 (The Cancer Genome Atlas 
Network, 2012; Palles et al., 2013) and NTHL1 genes (Weren et al., 2015). Pathogenic 
variants in POLE and POLD1 lead to a loss of DNA proofreading activity and are 
associated with a hypermutated, MSI stable/low status (Seshagir et al., 2012; The 
Cancer Genome Atlas Network, 2012; Palles et al., 2013) with tumour development 
suggested to follow a similar path to the classical adenoma-carcinoma sequence (Figure 
1.8) (Briggs and Tomlinson, 2013; Palles et al., 2013).  
Pathogenic variants in NTHL1 affect base-excision repair and are associated with a non- 
hypermutated state (Weren et al., 2015). Screening for variants in POLE, POLD1 and 
NTHL1 has been proposed for patients with unexplained personal or familial history of 
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multiple adenomas and/or early onset CRC. Identified pathogenic variant carriers are 
able to be offered early, frequent and regular colonoscopy surveillance (Palles et al., 
2013; Esteban-Jurado et al., 2014; Weren et al., 2015).  
 
Figure 1.8 Polymerase proofreading associated polyposis pathway for CRC and pathological basis.  
Characterised by clinical markers along with well-known genes implicated in their tumourigenesis 
(Morley-Bunker et al., 2016). 
 
In summary, current evidence suggests that colorectal tumours can be categorized into 
three broad molecular pathways. The majority are sporadic MSS tumours that develop 
through the traditional CIN pathway. Most MSI tumours are sporadic, occurring as a 
result of CpG island methylation leading to epigenetic silencing of DNA MMR genes. 
These tumours are associated with BRAF mutations and manifest clinically through the 
serrated neoplasia pathway. The remainder of MSI tumours are usually due to familial 
Lynch syndrome with germline pathogenic variants in MMR genes and are CIMP-L and 
BRAF wild type. 
1.1.6 Tumour Heterogeneity and Clonal Evolution of CRC. 
CRC is a complex disease as evidenced by the variation in clinical responses to treatment 
despite having similar histopathological characteristics or same staging. This can be 
explained by inter and intra-tumoural heterogeneity within a tumour (Figure 1.9) 
(Blanco-Calvo et al., 2015). Inter-tumour heterogeneity is the variation in treatment 
response for patients with tumours from the same tissue and cell type. The cell type of 
origin can significantly influence the tumour genetics and treatment response (Burrell 
et al., 2013). Intra-tumour heterogeneity refers to the genetic, epigenetic and 
proteomic variation of different clonal populations of cells within a single tumour mass 
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in a patient or between multiple tumours within the same patient (Saunders et al., 2012; 
Burrell et al., 2013; Blanco-Calvo et al., 2015; Gay, Baker and Graham, 2016). This is 
believed to occur in a single cell which acquires a mutation that is passed onto its 
progeny cells, which over time acquire further genetic and epigenetic alterations. These 
events lead to a malignant transformation and evolution of clonal populations of cells 
(Jass, 2007; Saunders et al., 2012).  
Different evolutionary pressures lead to the evolution and selection of clonal 
populations of cells that may behave differently in relation to each other (due to a 
selective phenotypic advantage) within the tumour microenvironment (Burrell et al., 
2013; Blanco-Calvo et al., 2015; Gay, Baker and Graham, 2016). Selection of sub-clonal 
populations of cells can either evolve in a linear fashion where a sub-clone replaces the 
former sub-clone, or co-exist together, or evolve in a branched fashion generating sub-
clones which evolve in parallel, thus producing genetic diversity over time (Thirlwell et 
al., 2010; Burrell et al., 2013). 
Selective pressures can affect the intratumoural heterogeneity, such as 1) the 
intermingling and interaction(s) of subclones, natural variation and response in cells to 
selection pressure, 2) tumour microenvironment and interactions between stroma e.g. 
fibroblasts and physical barriers (blood vessels), and 3) cell plasticity to modify cell 
behaviour in response to the tumour microenvironment (Saunders et al., 2012; Gay, 
Baker and Graham, 2016). Finally, the new microenvironment at the metastatic site can 
also place selective pressures on the tumour to select different clonal population 
leading to the genetic differences between metastatic and primary tumours (Burrell et 




Figure 1.9 Intertumour and Intratumoural heterogeneity. 
Reproduced with permission from (Burrell et al., 2013) Copyright Springer Nature. 
The molecular heterogeneity of CRC is one of the limitations in identifying clinically 
useful biomarkers. Expanding genetic technology has led to new molecular 
classifications that better reflect this heterogeneity. These new technologies are 
discussed below followed by their application to improved molecular classification and 
genetic biomarkers. 
1.1.6.1 Contemporary genetic technology 
Understanding the molecular heterogeneity of CRC has involved performing genome-
wide analysis of CRC genomes. Genome-wide analysis has historically been conducted 
using hybridisation based microarray platforms or low-throughput Sanger sequencing 
(Kim, Lee and Chung, 2013). This has permitted the identification of small-scale 
alterations involving point mutations or single nucleotide polymorphism (SNP),large 
scale alterations involving chromosomal rearrangements or copy number alterations 
(CNA) (Kim, Lee and Chung, 2013) and differentiation of clonal subpopulations within 
the tumour (Bedard et al., 2013). Advancing DNA sequencing technologies - next 
generation sequencing (NGS) increased the power of genome-wide analysis (Kim, Lee 




1.1.6.1.1 Next generation sequencing  
The advent of NGS technologies has allowed researchers to perform in-depth 
sequencing of exomes, whole genomes and transcriptomes, to better define the 
molecular characteristics of CRC and its subtypes and correlate them to the clinical 
outcome (Kelley and Venook, 2011; Guan et al., 2012). The cost for performing 
genomic-based tests is becoming cheaper (approximately US$1000) and more cost 
effective as technological advances focus on higher capacity and faster turnaround 
times (Muzzey, Evans and Lieber, 2015). Validation of results can be performed using 
readily accessible genomic data- bases. This will facilitate better understanding of CRC 
pathogenesis and its classifications and reveal more molecular biomarkers for 
diagnostic, prognostic and predictive purposes. Using this technology, The Cancer 
Genome Atlas (TCGA) Network (2012) reported a comprehensive molecular 
characterization of tumours from 276 CRC patients, identifying key and novel genomic 
aberrations that underlie different gene expression patterns, including copy number 
variation, gene mutations, sequence and methylation changes (The Cancer Genome 
Atlas Network, 2012; Azad and Diaz  Jr., 2014; Sridharan et al., 2014). More recent 
studies have built upon The Cancer Genome Atlas findings and set out to better 
characterize molecular subtypes of CRC in relation to clinical outcomes and/or therapies 
using NGS technology. As such they have identified potential biomarkers discussed 
subsequently for prognosis, prediction and targeted drug therapies (Budinska et al., 
2013; De Sousa et al., 2013; Marisa et al., 2013; Sadanandam et al., 2013; P Roepman 
et al., 2014). Additionally, the versatility of NGS technology allows it to be performed 
on circulating tumour cells and cell-free DNA which are readily obtainable from 
patients’ blood samples. Utilizing these specimens can potentially identify CRC and its 
metastases at an earlier time-point and allow for monitoring treatment response (Allen 
and El-Deiry, 2010; Misale et al., 2012; Kin et al., 2013). 
1.1.6.2 Refining the molecular classification of CRC 
As a result of new genetic technologies, numerous studies are identifying novel genes 
that are significantly expressed within the tumours of their patient cohorts, which could 
provide potential targets for therapeutic and clinical use (Loboda et al., 2011; The 
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Cancer Genome Atlas Network, 2012; Budinska et al., 2013; De Sousa et al., 2013; 
Marisa et al., 2013; Sadanandam et al., 2013; P Roepman et al., 2014). Examples include 
epithelial mesenchymal transition genes; stem-cell genes and Wnt signalling genes for 
differentiating CRC subtypes and their responsiveness to 5-fluorouracil (5-FU) based 
therapy; immune response genes and their regulation of the tumour 
microenvironment. Understanding the biological significance of these genes and their 
involvement in tumourigenesis will lead to future refinements in the molecular and 
clinical classification of CRC. An example of this is the collaborative paper published in 
2014 by Sadanandam et al. and De Sousa E Melo et al (Sadanandam et al., 2014). Each 
group previously classified CRC into tumour subtypes on a gene expression basis 
involving large independent cohorts. One classified CRC into five subtypes using a 
prognosis-derived expression profile based on histological and clinical outcomes 
(Sadanandam et al., 2013).The other classified CRC into three subtypes using an 
expression profile based on the cell of origin and response to therapy (De Sousa et al., 
2013). The authors then sought to reconcile the different molecular classification 
systems and correlate their findings to CRC tumour subtype classification (Figure 1.10) 
(Sadanandam et al., 2014). Re-analysis found strong similarities between the 
classification systems and showed that one provided further subdivisions for the other. 
Each classification system could equally be applied to the respective datasets yielding 
unique information predicting the patient’s response to 5-FU based adjuvant therapies 
and/or developing resistance to cetuximab treatment. Their classification systems 
support the current understanding of molecular pathways of CIN, MSI and CIMP 
(Sadanandam et al., 2014). Furthermore, their classification systems represent the next 
step in classifying CRC using gene expression profiling based on prognosis, morphology, 
cell of origin and molecular pathways, whilst taking into account the effect of tumour 
heterogeneity on CRC treatment management (Nagtegaal and van Krieken, 2013). 
These classifications and future refinements offer the potential for more accurate 




Figure 1.10 Reconciliation of two molecular classification systems and their integration with clinical 
and biological features for CRC.  
Abbreviations: CIN, Chromosomal instability; MSI, Microsatellite instability; TA, Transit-amplifying; CR-
TA, cetuximab resistant transit-amplifying cells; CS-TA, cetuximab sensitive transit-amplifying;  TBD, to 
be determined; SSA, sessile serrated adenoma (Morley-Bunker et al., 2016). 
*De Sousa E Melo et al. three tumour sub-types.  
#Sadanandam et al. five tumour sub-types. 
This approach has since been seized upon by the formation of the Colorectal Cancer 
Subtyping Consortium (CRCSC) which is a collaborative international community-based 
approach designed to share large-scale data and bio-informatics analytics (Guinney et 
al., 2015). Their intention was to assimilate all gene expression based CRC subtyping 
platforms in an effort to provide a comprehensive approach to identify core subtype 
patterns that correlated with all clinical and patient outcomes (Guinney et al., 2015; 
Dienstmann et al., 2017). This has resulted in the identification of four consensus 
molecular subtypes (CMS1 – CMS4) which best describe the molecular heterogeneity of 
CRC. The distinguishing features of CMS1 is hypermutated, MSI and strong immune 
response (MSI immune). CMS2 is epithelial with marked WNT and MYC signal activation 
(Canonical). CMS3 is epithelial with marked metabolic dysregulation (Metabolic). CMS4 
is characterised by marked TGF-β activation, stromal invasion and angiogenesis 
(Mesenchymal) (Guinney et al., 2015). These CMS subtypes have been shown to have 
prognostic and predictive value in clinical trials using bevacizumab or cetuximab with 
either FOLFOX or FOLFIRI for the treatment of advanced CRC (Lenz et al., 2019).  
25 
 
1.1.7 Genetic biomarkers for prognosis and treatment response.  
The increased understanding of CRC pathogenesis, and the shortcomings in existing 
clinicopathological staging, have focused interest on molecular biomarkers that have 
the potential to predict prognosis and guide therapy more accurately for individual 
patients (Brentani et al., 2005; Brenner, Kloor and Pox, 2014). Table 1.4 summarizes 
those clinically available biomarkers described in the literature to date and their 
intended application. While a significant number of biomarkers have been proposed, 
few have gained US Food and Drugs Administration (FDA) approval. Only three markers 
(MSI status, BRAF and KRAS mutation) have been implemented in routine clinical 
practice (Brenner, Kloor and Pox, 2014). Microsatellite instability status is used to 
prioritize patients for genetic testing for Lynch syndrome. MSI-H tumours are also 
associated with a better prognosis than MSS lesions and there is evidence of reduced 
response to 5-FU based chemotherapy. Hence, there is potential for MSI status to guide 
decisions regarding chemotherapy; however, data remain conflicting (Ribic et al., 2003; 
Kim et al., 2007; Sargent et al., 2010; Dotan and Cohen, 2011; Hutchins et al., 2011; 
Hveem et al., 2014). BRAF mutation status is used to differentiate those with non-
familial MSI-H, CIMP-H tumours, and testing for KRAS mutation status is now applied 
routinely to predict response to anti-EGFR antibody treatment in meta- static CRC 
(Lipton  M. Sieber, O. et al., 2013; Brenner, Kloor and Pox, 2014).  
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The majority of markers listed in Table 1.5 remain experimental and lack proven clinical 
efficacy. Numerous genetic and molecular changes have been discovered and proposed 
as prognostic and/or predictive markers, or potential drug target therapies. However, 
further investigation is warranted to establish their clinical utility (Oh et al., 2012; 
Schlicker et al., 2012; The Cancer Genome Atlas Network, 2012; Budinska et al., 2013; 
Sadanandam et al., 2013; Paul Roepman et al., 2014). 
Gene expression profiling using microarray and sequencing technology has 
revolutionised cancer biology over the last 15 years (Chibon, 2013). Researchers are 
now able to measure thousands of gene expression levels simultaneously, which allows 
identification of genetic signatures and individual molecular biomarkers that could 
potentially be used in resolving or influencing treatment decisions (Table 1.4), 
particularly if clinical outcomes vary greatly depending on disease stage (Tan and Tan, 
2011). These technologies have already been translated into clinical use in the area of 
breast cancer, with the release of Oncotype DX (Genomic Health Inc., Redwood City, 
California, USA) in 2004 and FDA approved MammaPrint (Agendia BV, Irvine, California, 
USA) in 2007 (Maak et al., 2013; Rodriguez-Gonzalez et al., 2013). Attempts have been 
made to emulate the translational success of biomarkers in breast cancer with CRC. An 
18-gene expression test (ColoPrint) was developed in 2010 to assist with clinical 
decision making by determining prognosis for Stage 2 and 3 CRC patients (Salazar et al., 
2011). Although validated in a recent prospective study (Salazar et al., 2011), it remains 
to be seen whether patients offered ColoPrint have an improved outcome over those 
not offered the test. To address this further, the multicentre PARSC (Prospective 
Analysis of Risk Stratification with ColoPrint) trial was initiated with the aim of 
comparing ColoPrint and clinical factors for predicting recurrence- free survival in Stage 
2 CRC patients (Maak et al., 2013). Another diagnostic test, Oncotype Dx (a 12-gene 
expression test), was released in 2010 for the purpose of prognosis and prediction of 
treatment benefit for patients with Stage 2 and Stage 3 colon cancer. Only the 
prognostic element of the test has been shown to be successful in clinical trials, but its 
performance can be outweighed by either T4 staging or MMR status. The test has yet 
to be shown as a significant predictor for 5-FU based treatments in published studies 
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(Kelley and Venook, 2011). Interestingly, no genes proposed by either of these 
commercial assays overlap (Lugli and Zlobec, 2012). 
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Table 1.5.1 Genetic biomarkers for CRC that are undergoing clinical trials or laboratory investigations (continued) 
 
Abbreviations: CIMP, CpG island methylation phenotype; CIN, Chromosomal instability; CRC, colorectal cancer; MSI-H/L/S, Microsatellite instability – high/low/stable; 
EGFR, epidermal growth factor; Ref, References. 
a Microsatellite markers - BAT-25, BAT-26, NR-21, NR-24, NR-27 
bCIMP marker regions - NEUROG1, IGF2, SOCS1, CACNA1G,and RUNX3 
c CIN marker regions – APC, BUB1, BUBR1, and FBWX1/CDC4 





Although gene expression profiling has promised much and led to numerous studies 
looking to find a robust prognostic classifier, the translation of markers from these 
technologies into clinical practice has been limited to date. A survey of 33 expression 
studies (De Sousa et al., 2013) performed between 2004 and 2013 found only one gene 
common to classifiers in five studies with 1406 genes unique to individual classifiers (De 
Sousa et al., 2013). The variable results reflect both biological complexity and the 
technical limitations associated with early microarray studies including design 
limitations, lack of power, technical variability with specimen processing, tumour 
heterogeneity and the multitude of genes investigated (Baehner et al., 2011).  
Validation of gene expression profiling results uses an independent cohort of patients 
and commonly utilizes qRT-PCR. The quantitative qRT-PCR method is considered the 
gold standard for validation, however, qRT-PCR does not overcome the issue of 
intratumoural heterogeneity that exists in tumour samples. It is also prone to 
interference from non-tumour material within the specimen. Another limitation is that 
the actual location of the gene expression within the tumour cannot be visualised. IHC 
also enables the analysis of gene expression of proteins in different cells and is 
commonly used to build on microarray-based mRNA expression findings. However, IHC 
may not be appropriate to verify results from microarray-based experiments as many 
genes show a low correlation between mRNA transcript abundance and corresponding 
protein levels (Chen et al., 2002). Moreover, data from IHC is less quantitative (Taylor 
and Levenson, 2006) and can vary between laboratories due to factors such as antibody 
specificity, antibody dilution, detection systems and inter-operator variability (Taylor 
and Levenson, 2006; Walker, 2006). 
More suitable methods are therefore required to verify and assess the application of 
potential diagnostic and prognostic markers whilst taking into account the effects of 
tumour heterogeneity. RNAscope® (Advanced Cell Diagnostics, Inc. (Hayward, CA)) an 





Although RNA based in-situ hybridisation methods have been used in laboratories since 
the 1970s, their sensitivity and specificity have been impacted by numerous variables 
associated with specimen preparation, complex methodology and visualisation (Wang 
et al., 2012). A new RNA in situ hybridisation technology, RNAscope, has recently been 
developed by Advanced Cell Diagnostics Inc. (Hayward, California, USA). RNAscope 
encompasses novel technology involving a novel probe design and a hybridisation-
based amplification system that improves the sensitivity and specificity of RNA in situ 
hybridisation techniques (Figure 1.11). 
The probe design used for RNAscope is a double-Z design. The target probe can be 
thought of being as a “Z” in appearance, involving a target region of approximately 18-
25 base sequence in size hybridising to the complementary strand of RNA. The target 
region is followed by a spacer sequence, then by a 14 base tail sequence. A pair of target 
probes (double Z) hybridise to the target region of the complementary strand of RNA. 
The tail-ends of the double Z probes (28 base sequence in size) provide the binding sites 
for the preamplifier to bind to. The preamplifier has a further 20 binding sites that the 
amplifier can bind too, which additionally has 20 binding sites for the label probe (Wang 
et al., 2012).  
The signal amplification scheme can best be thought of as building a Christmas tree 
upside-down. The label probe can either be fluorescent or chromogenic (utilising either 
Fast-Red + alkaline phosphatase or 3,3’-diaminobenzidine (DAB) with horseradish 
peroxidase coupled reactions) allowing for easy visualisation under fluorescent or 
bright-field microscopy (Wang et al., 2012). Therefore, RNAscope has the ability to 
identify single-molecules within an individual cell whilst preserving the histological 
context of the tissue, thus helping to visualise intratumoural heterogeneity. The 
suppression of background noise and increasing the amplification signal allows clear 
detection of mRNA expression targets that are easily visualised using bright-field or 
fluorescent microscopy (Wang et al., 2012). Highly sensitive and specific probes can be 
designed and synthesised for RNAscope assays that differentiate intercellular RNA 
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expression patterns (i.e. levels and location), as well the identification of isoforms or 
different RNA species.  
 
 
Figure 1.11 RNAscope Z probe design and hybridisation process workflow. 
A) Z probe design B) Z-probes bind to target mRNA sequence, pre-amplifier binds to tail-end of the pair 
of Z-probes, amplifiers bind to sites along pre-amplifier, chromogenic or fluorescent labelled probes bind 
to sites along the amplifier. Binding of three Z-probe pairs along mRNA transcript allows signal detection.  
Thus, RNAscope is capable of overcoming many of the limitations associated with qRT-
PCR and IHC to validate microarray-based mRNA expression data. Furthermore, 
RNAscope can be performed on both fresh frozen (FF) tissue and formalin-fixed 
paraffin-embedded (FFPE) tissue, with multiplexing of probes.  
This has made RNAscope an attractive method to use to study RNA species with the aim 
of identifying and translating RNA biomarkers into clinical diagnostic use. As such, 
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RNAscope technology is increasingly being utilised in cancer research by international 
laboratories using both FF and FFPE specimens (Ukpo et al., 2011; Barry et al., 2013; 
Burd et al., 2013). Applications of RNAscope include the detection of high-risk HPV 
mRNA types in head and neck cancer (Ukpo et al., 2011; Bishop et al., 2012; Dreyer et 
al., 2013; Du et al., 2013; Schache, Liloglou, Risk, Jones, X. J. Ma, et al., 2013; Mirghani 
et al., 2014) and cervical cancer  (Evans et al., 2014); determination of therapeutic 
response in breast cancer to current drug therapies (Bordeaux et al., 2012; Naipal et al., 
2014; Vassilakopoulou et al., 2014) and immune-therapies (Schalper et al., 2014) and 
investigations of the tumour microenvironment (Staudt et al., 2013). Additionally, 
RNAscope can be performed in liquid suspension, allowing for detection of RNA 
transcripts using flow cytometry (Payne et al., 2012; Hanley et al., 2013), and permitting 
circulating tumour cells to be analysed for mRNA biomarkers for diagnostic, prognostic 
and predictive purposes.  
Within the area of gastric cancer and CRC, RNAscope has been used in a variety of 
situations, including 1) the investigation of therapeutic response to targeted therapies 
(Kim et al., 2013; Kwak et al., 2015), 2) understanding the underlying molecular 
pathways involved in carcinogenesis (van Beelen Granlund et al., 2013; Dawson et al., 
2014; Graule et al., 2018) 3) differentiating between tumour subtypes (Sordal et al., 
2014), 4) the investigation of stem cells within tumours (Barry et al., 2013; Jang, Lee and 
Kim, 2013; Ziskin et al., 2013) and 5) the visualisation of interplay between tumour and 
microenvironment, especially as stromal markers could play a key role in classifying CRC 
(Nagtegaal and van Krieken, 2013). 
RNAscope can be used to generate a variety of information from the specimen for the 
researcher. RNA expression can be determined and used to confirm the presence or 
absence of a marker, and measured in a similar manner to IHC using a semi-quantitative 
scoring system. However, the potential that RNAscope can offer by combining with 
image analysis platforms enables the measurement of RNA expression and spatial 
localisation at a single cell level.  
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1.3 Image Analysis. 
The high sensitivity and specificity of RNAscope to detect a single molecule of RNA 
within a single cell allows powerful quantitative information to be collated (Wang et al., 
2012; Carvajal-Hausdorf et al., 2014a). However, computer-assisted image analysis 
techniques are required to assist with the subcellular resolution of RNA markers 
(Himmel et al., 2018).  
There are a number of image analysis software programmes that can assist with image 
processing and quantification, such as open-source (e.g. ImageJ [National Institutes of 
Health, USA] FIJI [enhanced version of ImageJ], MATLAB [Mathworks, USA], CellProfiler 
[Carpenter Lab/Broad Institute]) and commercial (e.g. SpotStudio® 
[Definiens/Advanced Cell Diagnostics] Inform® [Caliper/Perkin Elmer], ImageScope® 
[Aperio Technologies/Leica], HALO® [Indica Labs]) (Schindelin et al., 2012; Carvajal-
Hausdorf et al., 2014a; Heindl, Nawaz and Yuan, 2015; Himmel et al., 2018). These 
software programmes are able to utilize image segmentation and feature extraction-
based signal quantification methods to measure signals within cells or tissue regions 
(Carvajal-Hausdorf et al., 2014a). They can also cater for those researchers with little 
knowledge of the behind scene algorithms used for identification of cells and markers 
as well as those who are more technically minded (Heindl, Nawaz and Yuan, 2015; 
Himmel et al., 2018).  
These image analysis software programmes have been developed out of a need to 
provide objective, robust quantification of markers, particularly IHC staining patterns. 
This is because there is a greater emphasis placed on using quantitative measurements 
to correctly identify patients that would benefit from treatment or selection for a 
clinical trial e.g. HER2 ; PD-1 and PD-L inhibitors (Carvajal-Hausdorf et al., 2014a; 
Hamilton et al., 2014; Schalper et al., 2014). The advantages that image analysis 
provides are standardised, objective tissue measurement; automation and improved 
productivity and efficiency (Hamilton et al., 2014). 
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The ability to combine molecular data with image analysis techniques and data would 
facilitate greater understanding between genotype and phenotype. This will be 
important as we move towards a personalised medicine approach requiring precise 
disease classification; identification of companion biomarkers and drug targets for 
individual patients (Gurcan et al., 2009; Hamilton et al., 2014; Cooper et al., 2015). 
Combining RNAscope with image analysis provides an opportunity for tissue-based 
biomarkers (e.g. mRNA expression) to be discovered, validated and translated into 
clinical use because it allows  analysis of the marker (amount and location) within the 
tissue context (Carvajal-Hausdorf et al., 2014a; Himmel et al., 2018). 
The promise that tissue-based genetic biomarkers offers are that they could be utilised 
within the clinical setting to identify difficult to detect precursor lesions e.g. sessile 
serrated adenomas (SSA) endoscopically. This could result in increased detection rates, 
lower recurrence rates, improved surveillance management programmes leading to 
improved patient outcomes. Tissue-based genetic biomarkers could also be used 
individually or as part of a panel of genetic biomarkers that may permit improved 
classification of CRC molecular subtypes on histological examination which will provide 
prognostic and treatment response information.  
Furthermore, the utility of using genetic biomarkers with RNAscope are that it can be 
incorporated into current laboratory workflows and deployed onto automated 
platforms permitting higher throughput of samples and shorter turnaround times. This 
provide laboratories with complimentary assays to current IHC and as an alternative to 
current molecular testing e.g. NGS of samples which may careful handling and 
processing and analysis which may be required to be performed in a  referral setting. 
This could have important impacts for turnaround times allowing diagnostic results to 
be returned in a more timely fashion to the clinicians and allaying patient anxiety and 
permitting quicker implementation of treatment options and improving patient 
outcomes.  This would be important in helping to address some of the inequalities faced 
by New Zealanders in the form of accessing and receiving proper treatment for CRC. 
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1.4 Emerging/Potential Gene Biomarkers  
The TCGA produced result summaries lists for mRNA expression, genomic copy number 
alterations, mutations, microRNA and methylation status that were ranked in 
statistically significance for their association with poor prognostic outcomes.  From the 
mRNA expression result summaries over 1300 genes were ranked. The gene GFI1 was 
ranked 1st equal for reduced mRNA expression and poor prognostic outcomes (Table 
1.6). GFI1 was selected as a potential candidate gene biomarker to validate in a different 
patient cohort using the RNAscope method.   
Table 1.6  Gene ranking for mRNA expression levels and their statistical significance associated with 
poor prognostic outcomes from the TCGA study. 
 
To account for any confounding effects of tumour heterogeneity, an approach 
incorporating gene copy number alterations (CNA) as a criterion for gene selection was 
adopted. This approach may circumvent non-reproducibility issues associated with 
tumour heterogeneity as detection of CNA, especially DNA copy loss, is less likely if only 
present in a small proportion of tumour cells. Therefore, candidate prognostic gene 
biomarkers that show an association between gene expression and CNA makes a clear 
distinction that changes in gene expression levels are due to CNA versus changes 
associated with gene regulatory machinery and are potentially likely to be evident 
across a significant proportion of the tumour cells. 
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To validate this approach, TNFRSF11A was selected as it was the highest ranked gene 
that was affected by known copy number alterations.  This gene also showed reduced 
mRNA expression level was associated with poor prognostic outcomes, but was ranked 
12th in the TCGA results. Conversely, the deletion of 18q was ranked 6th in the TCGA 
result list for genomic copy number alterations associated with poor prognostic 
outcomes (Table 1.7). 
Table 1.7 Ranking of genomic copy number regions associated with poor prognostic outcomes from 
the TCGA study. 
 
Therefore, TNFRSF11A was a key candidate gene selected as it was the highest ranked 
gene from the mRNA expression list which was also affected by a change in copy 
number due its position on the chromosome arm 18q which is known to be deleted in 
aggressive tumours.  
 
1.5 Research Direction and Aims. 
Genome-wide expression studies using microarrays and RNAseq have increased our 
understanding of CRC development. Translating potential gene biomarkers from these 
studies for clinical utility has typically relied on PCR-based technology and IHC. 
However, these techniques often suffer from limitations because of tumour 
heterogeneity, or a lack of correlation between protein and corresponding mRNA 
transcript levels. The work presented in this thesis aimed to investigate the utility of 
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RNAscope to assess candidate CRC prognostic marker genes and correlate their 
expression with disease phenotype. 
Hypothesis: The RNA in situ hybridisation method, RNAscope, will allow the successful 
demonstration and validation of potential gene biomarkers that have been selected on 
CNA basis from the TCGA study. 
The aims of this thesis were to: 
1) Investigate the utility of RNAscope for measuring mRNA expression levels of 
potential gene biomarkers, identified by TCGA to be associated with poor 
prognostic outcomes, in a series of archival FFPE CRC cases.  
 
2) Determine suitability of image analysis methods with RNAscope for the 
quantification of mRNA expression. 
 
3) Investigate the biological function of the candidate RNA biomarker TNFRSF11A 
in CRC cells. 
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Chapter 2. Materials and Methods. 
2.1 Patient Samples. 
A cohort of 112 consecutively collected primary colorectal cancer cases of varying 
histology, grade, age and gender were obtained from the Christchurch Cancer Society 
Tissue Bank (Ethics approval #16STH92). Before obtaining tissue samples, informed 
consent was obtained from each patient.  
The cohort consisted of 10 colorectal cancer cases represented by whole histological 
sections from formalin fixed paraffin embedded (FFPE) tissue. The remaining 102 
colorectal cancer cases were represented in the form of tissue microarrays (TMA). The 
TMA consisted of duplicate 1mm cores mined from their respective FFPE tumour 
samples that were representative of the tumour stage at diagnosis. 
All cases were retrieved and outsourced to SCL Christchurch to be sectioned at a 4µm 
thickness and placed on SuperFrost charged glass slides. For each case, a Hematoxylin 
& Eosin stained section slide and five unstained sections were returned. The unstained 
sections would be used for RNAscope and Immunohistochemistry assays.  
2.2 Cell Culture. 
The colorectal cell lines WiDr (ATCC® CCL-218™) and SW480 (ATCC® CCL-228™) used in 
this study had been stored in liquid nitrogen within the Mackenzie Cancer Research 
Group. Both colorectal cell lines were grown and passaged into T75 flasks containing 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin 
(Anti/Anti) and incubated at 37˚C in 5% CO2 conditions.  
Thawing of cells involved placing the cell culture storage vial in a 37˚C water bath for 1-
2 minutes until such time as there was a small amount of frozen cell culture material 
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remaining (approximately 10%). Cells were then aspirated into a 15mL centrifuge tube, 
and diluted in 1:10 with pre-warmed DMEM media which was added slowly to prevent 
osmotic shock for cells. The cells were then gently centrifuged at 157 RCF for five 
minutes. Following centrifugation, the supernatant was removed and 5mL of pre-
warmed DMEM media was added to the cell pellet. The cells were gently homogenised 
before being transferred into a T25 flask and placed into an incubator at 37˚C in 5% CO2 
conditions for 24 hours. Cells were checked the following day to determine cell viability 
using an Olympus CX40 microscope. Once cells appeared to have recovered and 
established steady growth and reached 60-80% confluency, they were then passaged 
into a T75 flask to establish steady growth. 
Passaging of cells involved removing DMEM media from the flask and discarding. The 
cells were then washed with sterile phosphate buffered saline (PBS) to remove 
remaining cellular debris and cell media constituents. Cells were then incubated with 
1mL of TrypLE (Gibco Invitrogen, Carlsbad, CA, USA), for up to 3-5 minutes until 80% 
appeared rounded and had detached from the flask. Fresh DMEM media was added to 
the cell suspension , the cell suspension  was homogenised, split at a 1:5 ratio, and 
placed into a new T75 flask containing pre-warmed DMEM media with 10% fetal bovine 
serum (FBS) and 1% Antibiotic-Antimycotic (Anti/Anti) solution (all from Gibco 
Invitrogen, Carlsbad, CA, USA). Cells were then cultured in at 37˚C in 5% CO2. For 
experiments, cells were used when they reached 60-80% confluency. 
To create frozen stock of both cell lines, adherent cells were trypsinised with TrypLE 
and resuspended with 10mL of DMEM media to wash remaining TrypLE from the cells. 
Cells were then transferred to a 15mL tube and centrifuged at 157 RCF for 5 minutes. 
After centrifugation, the supernatant was removed and 1mL of a freeze mix solution 
(70% DMEM media (7mL); 20% FBS (2mL); 10% DMSO (1mL)) was then added to the 
cell pellet. The cell pellet was then homogenised before transferring 1mL into a 
labelled cryovial. The cryovial was then placed into a “Mr Frosty Freezing Container” 
(Thermo Scientific, Waltham, MA, USA) and placed in -80˚C freezer. After 48 hours, 
the cryovials were transferred to the liquid nitrogen Dewar for long term storage.  
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2.2.1 Preparation of Cytospin (Cell Monolayer) Slides. 
Cytospin slides of the WiDr and SW480 cell lines were produced by taking cells cultured 
in a T75 flask, trypsinising the adherent cells and resuspending them in complete DMEM 
media with 10% FBS and 1% Anti/Anti. A cell count was performed using the Countess 
automated Cell Counter (Invitrogen, Carlsbad, CA, USA).  
The cell suspension was split into two labelled 15mL centrifuge tubes with one tube to 
be used for qRT-PCR analysis and the other tube used for making cytospin slides. Both 
tubes were centrifuged for 5 minutes at 352 RCF. Following centrifugation, the 
supernatant from the tube was removed and discarded. The remaining cell pellet was 
then resuspended in 5mL of 10% neutral buffered formalin (obtained from the 
Anatomical Pathology department, Canterbury Health Laboratories, Christchurch) and 
left at room temperature for 1 hour to allow the formalin to fix the cells. Afterwards the 
cells were centrifuge for 5min at 626 RCF and had the formalin removed before 
resuspending the cell pellet in 5mL PBS and left for 30mins. Another centrifugation step 
was performed at 626 RCF for 5 minutes with the PBS removed and the cells 
resuspended in 10mL 70% ethanol. The cells were stored at 4oC overnight. 
The aliquot was centrifuged at 626 RCF for 5 minutes and the supernatant removed and 
discarded. The cell pellet was then resuspended in 2mL of fresh 70% ethanol. This 
adjusted the cell concentration of the aliquot to between 0.3 -0.5 x 106 cells per mL. 
From the cell suspension, 200µL was then transferred into a Cytospin™ cartridge 
(Thermo Scientific, Waltham, MA, USA) containing a SuperFrost charged glass slide and 
then placed into the Cytospin™ 4 Cytocentrifuge (Thermo Scientific, Waltham, MA, USA) 
and spun at 400 rpm for 5 minutes. Following centrifugation, the glass slide containing 
the prepared cell monolayer was removed and left to air-dry at room temperature 




RNAscope is an RNA in-situ hybridisation platform which allows detection and 
visualisation of mRNA transcripts within cells and tissue whilst preserving their 
morphological context. An overview of RNAscope is presented in Chapter 1.2. 
2.3.1 RNAscope Probes. 
The RNA probes for MLH1 probe was selected from the ACD RNAscope probe catalogue 
for human species (RNAscope Probe Hs-MLH1, Cat No. 422971). The RNA probes for 
TNFRSF11A and GFI1 were custom designed by ACD. The ZZ probes were designed to 
hybridise along the target RNA sequences as listed in the National Center for 
Biotechnology Information (NCBI) GenBank®. For TNFRSF11A this was 
NM_001270951.1, target region 1928-2981 and for GFI1 it was NM_001127215.1, 
target region 1053-2364. These probes have now subsequently been added to the ACD 
RNAscope probe catalogue for human species and are RNAscope Probe Hs-TNFRSF11A, 
Cat No.412281 and RNAscope Probe Hs-GFI1, Cat No.422981. The precise sequences 
are proprietary (Advanced Cell Diagnostics, Hayward, CA). All three probes were 
designed for chromogenic RNA-ISH.  
2.3.2 Tissue Section/Sample Preparation for RNAscope assay. 
2.3.2.1 FFPE sections. 
To prepare each case for RNAscope assay, the glass slides with the FFPE sections were 
deparaffinised in a series of steps using Xylene and 100% Ethanol and then left to air-
dry overnight. The following day, slides were then subjected to a series of pre-treatment 
steps following the Standard Treatment protocol. Briefly, deparaffinised slides were 
covered with Pre-Treatment 1 solution and incubated for 10 minutes at room 
temperature. Slides were then rinsed in two changes of distilled H20. Slides were then 
placed in a boiling solution (100 -104˚C) of Pre-Treatment 2 for 15 minutes. Slides were 
then removed and rinsed in two changes of distilled H20, rinsed once in 100% ETOH and 
left to air dry. After slides have air-dried, a hydrophobic barrier was drawn around the 
tissue section using an ImmEdge™ pen (Vector Laboratories Inc. Burlingame, CA, USA) 
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to contain future treatments. After tissue section and hydrophobic barrier were dry, 
slides were placed in a HybEZ™ Slide Rack, covered with a solution of Pre-Treatment 3, 
and incubated at 40 ˚C for 30 minutes within the HybEZ™ Oven. After incubation, slides 
were then rinsed in two changes of distilled H20 before the slides were then ready for 
hybridisation with the various RNA probes. 
2.3.2.2 Cytospin (Cell Monolayer) slides.  
The sample preparation method for the cultured colorectal cell lines (Materials and 
Methods section 1.2.1), followed the manufacturer’s instructions for PBMC and Non-
adherent cells (Part 1). Briefly, cells were dehydrated further by immersing them in a 
series of four ethanol solutions (50%, 70%, 100%, 100%) at room temperature for five 
minutes per solution respectively. The slides were then removed from the final 100% 
ethanol solution and then dried in a 37˚C incubator for 30 minutes. A hydrophobic 
barrier was created around each cell monolayer using a hydrophobic barrier pen and 
left to dry for 1-2 minutes. Slides were then placed in a HybEZ™ Slide Rack, covered with 
a solution of Pre-Treatment 3, and incubated at 40 ˚C for 30 minutes within the HybEZ™ 
Oven. After incubation, slides were then rinsed in two changes of distilled H20 before 
progressing onto hybridisation with probes. 
2.3.3 Hybridisation with RNA probes. 
For both FFPE and cytospin slides, hybridisation was conducted following the 
manufacturer’s instructions in FFPE Detection kit (Brown) Part 2.  
After completion of the sample preparation (pre-treatment) steps for either the FFPE 
sections (Section 3.3.2.1) or the Cytospin slides (Section 3.3.2.2) slides were removed 
from distilled H20 and placed back in a HybEZ™ Slide Rack and placed into the HybEZ™ 
Humidity Control Tray. Three probe types (target gene, positive control [housekeeping 
gene, PPIB] and a negative control [bacterial gene, DapB]) were used separately for the 
hybridisation steps. Four to six drops of the individual probes were then added to the 
tissue section (enough to cover all cells on the slides) or the cytospin slides. Slides were 
covered by placing the lid of the HybEZ™ Humidity Control Tray on and then placed in 
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the HybEZ™ Oven and incubated at 40 ˚C for 2 hours. Following incubation, slides were 
then removed the HybEZ™ Humidity Control Tray and placed into two changes of Wash 
Buffer for 2 minutes at room temperature.   
Six incubation steps followed to consecutively hybridise pre-amplifier and several 
amplifiers to these probes. The first four incubations involving AMP 1 – AMP 4 were 
performed at 40˚C. Each sample slide (including controls) was first incubated with AMP 
1 for 30 minutes, followed by AMP 2 for 15 minutes, AMP 3 for 30 minutes and AMP 4 
for 15 minutes. The last two incubations were then performed at room temperature. 
AMP 5 for 30 minutes, followed by AMP 6 for 15 minutes. Each of these hybridisation 
steps alternated with a washing step involving two sequential two minute incubations 
at room temperature in fresh Wash Buffer.  
To detect the hybridisation signals, 120 - 150 μL of diaminobenzedine (DAB) made from 
mixing equal volumes of BROWN-A and BROWN-B, was pipetted onto each cell 
preparation and left in a covered HybEZ™ Slide Rack at room temperature for 10 
minutes. Following incubation, the slides were removed, excess DAB was discarded and 
the slides were rinsed twice with distilled H20.  
2.3.4 Counterstaining and Coverslipping of Specimens. 
Cells hybridised with RNAscope probes were counter-stained in a staining dish 
containing Surgipath® Gills Haematoxylin II (Leica Biosystems, Richmond, IL, USA) for 
two minutes at room temperature. Slides were then removed and transferred through 
a series of staining dishes containing distilled H20, 0.02% Ammonia Water and distilled 
H20. During this process, slides were gently agitated by moving them up and down 3-5 
times in each staining dish.  
Stained specimens were dehydrated by progressing through a series of staining dishes 
containing ethanol of increasing concentration (70%, 100% and 100%) for 2 minutes per 
dish. Slides were then transferred to a staining dish containing Xylene for 5 minutes.  
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Slides were then removed and 1-2 drops of SurgiPath DPX mounting medium was 
added. The cells were covered with a 40 x 60mm glass coverslip and left to air-dry before 
microscopic assessment. 
2.3.5 RNAscope Scoring. 
The mRNA expression levels for all three probes were visually assessed initially using an 
Olympus CH2 light microscope.  
Specimens were determined to be positive for mRNA expression if brown punctuate 
dots could be seen within cells. If no brown punctuate dots within cells was scored as 
negative mRNA expression. Specimens that exhibited positive mRNA expression were 
then semi-quantitatively assessed for the number of probe signals per cell for each case 
using the ACDBio scoring system (Figure 2.1). The scores ranged between 0 and 4. The 
scoring criteria is “0” =Negative; “1” = 1-3 probes per cell at 40x magnification; “2” = 4-
10 probes per cell at 40x magnification; “3” = >10 probes per cell at 40x magnification; 
“4” = >10 probes per cell occupying >10% of slide or at 20x magnification.  
 
Figure 2.1 ACDBio RNAscope scoring sheet for assessing mRNA expression levels within samples. 
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Specimens were initially, assessed and scored by myself, with a score of 0-4 given to 
each gene investigated, comments relating to overall representation of the tumour 
cells, staining and scoring were additionally recorded. 
Assessment with a Pathologist (Dr Martin Whitehead, Canterbury Health Laboratories) 
was performed using an Olympus BX50 microscope at 20x and 40x magnification. 
Specimens were scored by a pathologist who was blinded to initial my results. Time 
involved per slide was approximately 3 – 5 minutes. The Pathologist scores were 
correlated with my initial results, any discrepancies in scoring were reviewed together 
with a consensus agreement made as a final decision. 
2.4 Microscopy. 
Images were captured using a Zeiss Apotome Microscope and associated software 
((AxioVersion 4.5. Apotome software, Carl Zeiss Microscopy, LLC, Thornwood, New 
York, USA) using the The EC plan-Neofluar 40x/1.3 oil Dic M27 objective. Exposure and 
white balance was corrected using the “automatic” adjustment features with Gamma 
exposure set at >0.45. All digital photo images were saved in a .TIF file format. 
2.4.1 Whole FFPE Sections. 
For the 10 histological FFPE colorectal cancer cases, three representative digital photo 
images that best represented the following: 1) tumour epithelial cells; 2) normal 
mucosal epithelium; 3) lymphocytes within stromal areas and germinal centres; 4) 
stromal cells within areas adjacent to tumour invasion and in muscularis major were 
captured. This was performed on each case for each individual probe (MLH1, GFI1 and 
TNFRSF11A). Therefore, for each histological FFPE colorectal cancer case, a total of 12 
digital photo images were taken for each individual probe.  
2.4.2 Cytospin (Cell Monolayer) slides. 
For each colorectal cell line (WiDr and SW480), 10 representative images were captured 
for each individual probe (PPIB, MLH1, GFI1 and TNFRSF11A).  
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2.5 Image Analysis. 
Quantification of mRNA expression levels was performed on the 10 histological FFPE 
colorectal cancer cases and the colorectal cell line cytospin slides using the acquired 
digital photo images.  
2.5.1 ImageJ/FIJI. 
Each digital image was uploaded into the freeware software called ImageJ (Schneider, 
Rasband and Eliceiri, 2012). Within ImageJ the images were adjusted for brightness and 
contrast, and sharpened to allow clear recognition of cell outlines and probe signals. 
2.5.1.1 Manual Count/Cell counter Plugin. 
Cell counter is a plugin within ImageJ which is useful for manually counting objects and 
marking them with a different coloured counter. Cell nuclei and probe signals could be 
manually counted and marked with this tool (Figure 2.2). Approximately 100 cells per 
image were counted (where the cell outline could be visualised and in focus) along with 
the corresponding probe signals within those cells. After each image was counted, the 
cell markers could be saved for each corresponding image, so that they can be retrieved 
in the future. For each case, 300 cells per cell type (tumour epithelial cells; normal 
mucosal epithelial cells; stromal cells and lymphocytes) and their corresponding gene 
probe signals were counted. Hence, for the 10 histological FFPE colorectal cancer cases 
assessing MLH1 mRNA expression, approximately 3000 tumour epithelial cells, 3000 
normal mucosal epithelial cells, 3000 stromal cells and 3000 lymphocytes were counted 
along with the probe signals for MLH1 with the results recorded into a Microsoft Excel 
spreadsheet. This process was then repeated again on images when assessing GFI1 and 
TNFRSF11A mRNA expression across each cell type for each case.  
For cytospin slides, 10 digital images for each probe per cell line was uploaded to Cell 
counter and the cells and probe signals counted. The results were recorded into a 




Figure 2.2 Original histological FFPE CRC case with MLH1 mRNA probe signals (brown) present. 
A) original image B) result image following manual counting using the ImageJ Cell Counter plugin, the user is able to identify and label cells with a counter in this instance “1” 





2.5.1.2 Colour Deconvolution. 
Colour deconvolution is a plugin within ImageJ which is useful for performing pigment 
segmentation on an image. It does so by subtractive mixing of colours, histological 
stains into separate channels corresponding up to three determined colours (Ruifrok 
and Johnston, 2001).  
Briefly, original images were opened within ImageJ and converted into RGB. The Colour 
Deconvolution plugin was selected. Vectors were created from the dropdown box and 
selecting the histological staining method of H DAB (Haematoxylin and DAB). Three 
colour images were then generated with Colour 1 representing Haematoxylin and being 
Blue/Purple in appearance, Colour 2 representing DAB appearing brown in colour and 
Colour 3 representing “background” appearing green (Figure 2.3). 
Segmentation and quantification of DAB probe signals was performed by selecting the 
DAB image (Colour 2). A threshold method Renyi Entropy (Kapur, Sahoo and Wong, 
1985) was applied. This segments the probe signals from the image by assigning a 
foreground colour to the probe signals and assigning a background colour (e.g. white or 
black) to all remaining features/pixels in the image. Applying the threshold turned the 
DAB image into a binary image consisting of black dots on a white background. 
Segmented probe signals on the image were measured by selecting “analyse particles” 
from the Analyse drop-down menu. Confirmation of DAB probe signals to be included 
in final results was performed by overlaying the results image with the “Markers 
Counter Window” saved from the Manual counting using the Cell Counter plugin. The 
Markers Counter window provided the location of the 100 cells counted from which 
DAB probe signals could be confirmed and counted and exclude other signals that might 
be dark chromatin or nucleoli. A results and summary tables were then saved to a 




Figure 2.3 Colour Deconvolution process. 
A) selection of H-DAB from Colour Deconvolution plugin and the resulting images of colour separation, 
cells (Colour 1- purple) DAB probe signals (Colour 2 - brown) background (Colour 3 - green). B) threshold 
image using RenyEntropyi before (red signal), application of threshold into binary image (white signals 
on black background)  C) result image of analysed DAB probe signals (left) overlayed onto Markers 
Counter Window to confirm location of DAB probe signals with previously 100 counted cells. 
2.5.2 SpotStudio. 
The workflow for the SpotStudio tool (ACDBio) involved importing the original images 
used in ImageJ and converting the file formats from a .TIF file-format to a .JPEG file-
format (Figure 2.4). The image was then selected and the desired regions of interest 
(ROI) containing the 100 cells previously identified in ImageJ were selected by freehand 
“tracing” around the cells using the mouse (Figure 2.4(A)).  
Threshold settings were then applied to the ROIs for the detection of cells and DAB 
probe signals. The threshold settings are based on the stain type used to detect probe 
signals (e.g. DAB stain), Hematoxylin staining levels (light nuclei or dark nuclei), nuclei 
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diameter (small or big nuclei and degree of splitting), probe signal (DAB) staining levels 
(light or dark spots) and the spot (probe signal) diameter (size of individual spots and 
those considered clusters). These were adjusted using a sliding scale and directly 
applied to the ROI. Any changes to the threshold settings could be visualised using a 
Preview window. The threshold settings were adjusted until detection of cells and probe 
signal were visually acceptable before being saved (Table 2.1 and Figure 2.4(B)).  
The ROIs were analysed be selecting the “Batch Run”. Before release of results, a quality 
control (QC) step is performed. This allows confirmation of successful segmentation and 
exclusion of incorrectly segmented cells/probe signals from results (Figure 2.4(C)). Upon 
completion of the QC step, final results are released and exported to a Microsoft Excel 
spreadsheet. The final results provide a list of counted individual cells, the number of 
spots per cell; total cells detected; histogram of the number of spots per bin category 
e.g. 0-1; 1-3;3-6;6-10;>10 (Figure 2.4(D)). 






Image Resolution 0.161 
Stain Type DAB 
Haematoxylin Level 0.15 
Nucleus Diameter (µm) 7.5 
Spot Stain Level 0.20 




Figure 2.4 SpotStudio workflow process. 
A) original image uploaded, B) selection of ROI and application of threshold settings, C) resulting cell segmentation and DAB spot signal detection for QC approval, D) final 
quantification of cells and spot signals with a corresponding histogram binning results in relation to RNAscope scoring system. 
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2.5.3 Trainable Weka Segmentation. 
Trainable Weka Segmentation (WEKA) is a computer plugin available in ImageJ. The 
plugin comprises a variety of machine learning algorithms and image features to 
produce pixel based segmentations (Arganda-Carreras et al., 2017). This tool enables 
quantification of cell numbers and probe signals within each image of the colorectal 
cancer histological whole slide cases and the cytospin preparation.  
The original images used from the ImageJ Manual Cell Counting assessment were 
uploaded into ImageJ. The WEKA plugin was accessed from the Main Menu Plugins 
command. Upon initializing the WEKA plugin, a graphical user interface (GUI) with the 
opened image is presented (Figure 2.5(A)). On the left side of the GUI are two panels 
comprising the Training classifier and General options. The right hand side consists of a 
panel listing the classes and the list of traces assigned to each class and the option to 
add the current ROI to a class.  
Using the selection tools from the toolbar of ImageJ/FIJI, objects such as nuclei, 
RNAscope (DAB) probe signals and background were selected from the image and 
placed in different classes. The training classifier uses these classes as input for the 
machine learning algorithm to classify and segment objects from the image. A result 
overlay is displayed on the original image enabling assessment of classification and 
segmentation performance (Figure 2.5(B)). Selections can be repeated several times for 
the training classifier to learn and refine classification of objects until the operator is 
satisfied with the classifier’s performance. 
The WEKA trainable classifier was then able to generate a results image with the 
segmented objects present. The image was converted to 8-bit (255 colours) before 
applying the Huang threshold (Huang and Wang, 1995) to further optimise  
segmentation. The watershed binary process (Vincent and Soille, 1991) was then 
applied to segment those cells or probe signals that were touching each other to display 
individual nuclei and probe signals separately (Figure 2.5(C)). The threshold images 
were then analysed to count the number of probe signals and cell nuclei present using 
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the “analyse particles” option (Figure 2.5(D)). This enabled the size of particles and 
circularity to be adjusted before selecting objects for measurement. Cells and probe 
signals were then counted for each image and results exported to a Microsoft Excel 
spreadsheet. A results image overlay saved with the original image saved as a .TIFF file 




Figure 2.5 WEKA workflow process. 
A) upload of original image into the WEKA training classifier within ImageJ, B) classified image of segmented cells and DAB spot signal detection C) results image of cell 
segmentation following application of the watershed algorithm D) threshold image of DAB signal E) result overlay image for DAB spot signal detected. 
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2.5.4 LEICA ImageScope RNA-ISH V2 algorithm. 
LEICA ImageScope software programme using the RNA-ISH (Version 2.0) algorithm was 
used to quantify the number of cells and mRNA expression levels present in each digital 
photo. Before starting analysis, the file format of the digital image had to be changed 
from a .TIF file format into a .SVS file format. Image resolution was adjusted by 
measuring the distance on the scale bar with the ruler function, with the resulting 
distances and magnification adjusted accordingly. Subsequent images were then 
calibrated to this resolution.  
Image analysis was then performed by selecting the Image Analysis tab and selecting 
“RNA ISH algorithm”. Optimisation of the RNA-ISH algorithm was necessary to ensure 
accurate cell and RNA probe signal identification within the image. This involved 
adjusting. Cell Detection and Signal Detection parameters. The Cell Detection 
parameters encompasses nuclei, cytoplasmic and tissue features that can be 
segmented and quantified. Similarly, the Signal Detection parameters encompasses 
signal detection thresholds, size of signal, strength of signal or cluster for segmentation 
and quantification. These can be adjusted separately and monitored in the “Algorithm 
Tuning Window” to achieve the best representation of cells and signals is selected. A 
full list of parameters are provided in Appendix A.  
Upon optimisation of the RNA-ISH algorithm (this could be saved as a local MACRO that 
could be used at a later time on different images if required) each individual image was 
then uploaded and analysed. The RNA-ISH algorithm provided a final image displaying 
the location of cells and signals based on the parameter settings set along with a list of 
quantified outputs relating to the total number of cells and RNAscope signals present, 
average RNAscope signals per cell, and number of cells binned according to the ACD 




Figure 2.6 Images from the LEICA RNA-ISH workflow. 
A) original image uploaded into the LEICA Imagescope programme B) processed image of segmentation of cells (blue) and DAB probe signals (brown) C) results screen 






Immunohistochemistry was performed using the Roche VENTANA BenchMark ULTRA 
System (Ventana Medical Systems, Inc, Tucson, Arizona, USA). For both the 10 
colorectal cancer cases histological slides and the TMA specimens, 4µm sections were 
cut, placed onto SuperFrost Plus glass slides by (SCL Christchurch). The slides were then 
deparaffinised in xylene and placed in 100% ethanol. Slides were then taken to the 
Anatomical Pathology department of Canterbury Health Laboratories for 
immunohistochemistry. Prior to slides being loaded onto the BenchMark ULTRA 
System, control tissue sections were cut and placed onto the slides by a Medical 
Laboratory Scientist.  
Slides were then loaded onto the BenchMark ULTRA System and subjected to heat 
induced epitope retrieval using “Cell Conditioner 1” at 95˚C for 64 minutes, followed by 
incubation with one drop of the VENTANA pre-dilute MLH-1 (M1) mouse monoclonal 
primary antibody (final concentration 1.4µg/mL) for 16 minutes at 36 ˚C. Detection was 
achieved with the ultraView Universal DAB Detection Kit, before each section was 
counterstained with haematoxylin, and coverslipped, before being assessed 
microscopically.  
Microscopic assessment was performed by a Pathologist (Dr Martin Whitehead). 
Positive MLH1 staining was considered when tumour carcinoma cell nuclei displayed 
any traces of brown positive staining. Negative MLH1 staining was determined as 
tumour cell nuclei appearing “Cambridge blue” with no traces of brown staining for 
MLH1 whilst other types of cell nuclei on the slide appeared positive. An equivocal result 
was considered when there were very few tumour cells (e.g. 1-2) present displaying a 
faint positive or possible negative staining, while stromal cells, lymphocytes may also 
appear faint for MLH1 but there is a certain “brown blush” to the section. Inconclusive 
staining, may result when there is brown staining within the cytoplasm (overstaining) 
or on the nuclear membranes. Inconclusive staining may also arise from no positive 
staining in normal tissue elements e.g. stromal cells, lymphocytes etc. 
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2.7 Gene Knockdown. 
2.7.1 siRNA.  
A set of three short interfering RNAs for TNFRSF11A were purchased from Thermo 
Fisher Scientific™. These were called Invitrogen Stealth™ RNAis (HSS112930, 
HSS112931 and HSS112932), and had been designed to achieve greater knockdown, 
improved cell viability and minimal off-target effects.  
All three siRNA constructs were 25bp in length (Table 2.2). The primer sequence was 
designed to achieve maximal knockdown by targeting the coding region and the exons 
9 and 10 which cover all mRNA transcripts.  
Table 2.2 Primer sequence for the siRNA for gene knockdown of TNFRSF11A 
siRNA name 5’ to 3’ sequence G-C content* 
HSS112930 GCG AAG AUG CCA GGA UGC UCU CAU U 52% 
HSS112931 ACA CAG AGC ACA GUG GGU UCA GAA A 48% 
HSS112932 CCC AUG UUU ACU UGC CCG GUU UAA U 44% 
*obtained using the ENDMEMO DNA/RNA GC calculator (ENDMEMO, 2017) 
The siRNA constructs were received in freeze-dried powder form and were 
reconstituted in 1mL of RNase-free water (provided) to give a final concentration of 
20µM. Working aliquots of 100µLof each siRNA constructs were then made into 
separate RNAse free tubes. A scrambled siRNA control was also selected to act as a 
negative control for the purposes of assessing subsequent gene knockdown against. The 
negative control featured a low G-C content. And was reconstituted in the same manner 
as the Stealth siRNAs. 
2.7.2 Transfection methods. 
Gene knockdown of TNFRSF11A was achieved by transfecting Stealth™ RNAi siRNAs into 
colorectal cell lines using the following forward transfection procedure. Firstly, WiDr 
colorectal cell line cells were plated at a cell density of 30 000 cells in 500µL of DMEM 
supplemented with 10% FBS per well into a 24well-plate. The 24-well plate was then 
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incubated at 37˚C at 5% CO2 overnight to achieve a cell confluency of 30-50%. Following 
24 hours incubation, the Stealth™ RNAi was combined with transfection reagent 
Lipofectamine™ RNAiMAX (Invitrogen) before adding to each well of the 24 well plate. 
This involved diluting 6 pmol (0.3 μL) of Stealth™ RNAi duplex in 50 μL Opti-MEM® I 
Reduced Serum Medium (Gibco Invitrogen, Carlsbad, CA, USA) without serum and 
gently mixed in a microcentrifuge. In a separate microcentrifuge tube, dilute 1 μL 
Lipofectamine™ RNAiMAX in 50 μL Opti-MEM® I Reduced Serum Medium and mixed 
gently. The diluted Stealth™ RNAi duplex was then combined with the diluted 
Lipofectamine™ RNAiMAX, gently mixed and left to incubate for 10-20 minutes at room 
temperature. The Stealth™RNAi duplex-Lipofectamine™ RNAiMAX complexes were 
then added to each well of containing cells and mixed gently by rocking the plate back 
and forth. The 24-well plate was then incubated at37°C in 5% CO2 for 48 hours.  
Finally, cells were harvested from the 24 well-plate using TrypLE to dissociate the 
adherent cells from the well surface and collecting them in DMEM media and placed 
into labelled centrifuge tubes before being centrifuged at 626 RCF for 5 minutes to form 
a cell pellet. Supernatant was then removed and discarded and the cell pellet was then 
frozen at -80˚C until such time that RNA extraction was performed. 
Establishing the appropriate concentration of siRNA and reagents to apply to individual 
colorectal cell lines to achieve the greatest level of gene knockdown for future cell 
based functional assays was required. The initial testing conditions are presented in 
(Figure 2.7). The final volume of 600μL within each well as described in the above 
method gave a final Stealth™ RNAi concentration of 10nM. Higher concentrations of 
Stealth™ RNAi used in the optimisation process was achieved by increasing the volume 




Figure 2.7 Template of testing conditions used to determine optimal siRNA concentration for future 
gene knockdown experiments.  
2.8 Cell Based Functional Assays. 
The WiDr colorectal cell line was used as part of the cell based functional assays and 
followed the cell culture method as previously described (Materials and Methods 1.2). 
WiDr colorectal cells were grown and passaged into T75 flasks containing 15mL DMEM 
supplemented with 10% FBS and 1% Anti/Anti and incubated at 37˚C in 5% CO2 
conditions. Cells were used in cell based functional assays when they were between 
passages 10 – 20. 
WiDr cells were harvested from the T75 flasks and seeded into 96-well plates 24 hours 
prior to the siRNA gene transfection. A total of 4 x 103 cells were seeded into the 
individual wells of a 96-well plate in the presence of 100µL of DMEM supplemented 
with 10%FBS only. This was carried out in triplicate. The cells were then left for 24 hours 
in in 37˚C at 5% CO2. A total of three 96-well plates were seeded for the purposes of 
measuring cell proliferation (CyQuant NF), cell viability (MTT assay) and confirming 
siRNA knockdown (qRT-PCR). Following 24 hours incubation, siRNA transfection was 
performed to the following conditions: Cells only; scrambled siRNA (negative control); 
and 10nM for TNFRSF11A siRNA (siRNA added in with RNAiMAX (0.3µL) with OptiMEM). 
Plates were then left for 48hrs in 37˚C at 5% CO2. After 48hrs, the plates were removed 
and processed in accordance with the intended assay.  
64 
 
2.8.1 Cell proliferation.  
The CyQUANT® NF Cell Proliferation assay (Molecular Probes, Invitrogen Corp., USA) 
follows the principle of similar cell proliferation assays that use the incorporation of a 
DNA-binding dye such as bromodeoxyuridine (BrdU) during DNA synthesis. The 
CyQUANT NF assay incorporates the use of a fluorescent DNA-binding dye and a plasma 
membrane permeabilization agent to permit the dye to transfect the cell and bind to 
cell DNA and provide a measurement of cell numbers. Prior to performing the CyQUANT 
NF assay a 1X dye binding solution was prepared using supplied reagents within the kit. 
This was made by adding 22 µL of CyQUANT NF dye reagent to 11 mL of 1X Hank’s 
balanced salt solution (HBSS). 
Using the 96-well plate designated for cell proliferation, the CyQUANT NF assay was 
performed according to the manufacturer’s protocol. To each well, 100 µL of the 1X dye 
binding solution was added. The plate was then covered and incubated at 37˚C in5% 
CO2 for 1 hour. The plate was then removed and the fluorescence measurements 
performed using a Varioskan® Flash microplate reader (Thermo Scientific, Waltham, 
MA, USA ). 
2.8.2 Cell Viability. 
Measurement of cell viability is a measure of living cells active metabolism. The MTT 
assay protocol is based on the cell’s metabolism converting the water soluble MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) compound into an 
insoluble formazan product. This produces a colour change from yellow to purple. 
Injured or dead cells are unable to metabolise and therefore show no signal. The colour 
formation serves as a useful and convenient marker of only the viable cells. The 
measured absorbance at OD 590 nm is proportional to the number of viable cells. 
For the 96-well plate designated for cell viability, the MTT assay was performed by 
removing the cell media from the plate before adding 100µL MTT reagent onto the cells. 
The plate was covered and left to incubate for 3 hours at 37˚C in 5% CO2. Afterwards, 
100µL solubilisation reagent (89% isopropanol, 10% Triton X-100 and 0.1M HCl) was 
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added to each well, and gently mixed through pipetting to dissolve formazan crystals 
into a purple coloured solution. The plate was covered with aluminium foil and placed 
on an orbital shaker for an additional 30 minutes to allow formazan crystals to 
completely dissolve. The plate was then removed and absorbance measurements made 
using a Varioskan® Flash microplate reader (Thermo Scientific, Waltham, MA, USA).   
2.8.3 Cell Migration. 
The cell migration assay used as part of the cell based functional assay was the in vitro 
scratch assay (wound healing assay). This is a simple, low cost method that involves 
forming a scratch along a confluent monolayer of cells. The cells at the edge of the gap 
will then migrate into the space until cell-cell contacts are re-established. This provides 
a simple method that replicates the effects of cell migration in vivo (Liang, Park and 
Guan, 2007).  
The WiDr colorectal cell line was used as part of the cell based functional assays and 
followed the cell culture method as previously described (Materials and Methods 1.2). 
WiDr colorectal cells were grown and passage into T75 flasks containing 15mL DMEM 
supplemented with 10% FBS and 1% Anti/Anti and incubated at 37˚C in 5% CO2 
conditions.  
Baseline measurements of WiDr cell line migration without siRNA transfections. 
Using 96 well plate, seeded wells with 1 x 104 cells per 100µL in DMEM with 10% FBS 
and 1% Anti/Anti. Cells were left for 24 hours to settle and attach. To three individual 
wells, the cell media was replaced with fresh DMEM and 2% FBS only, this would serve 
as a negative control. To a further three individual wells, cell media was replaced with 
fresh DMEM and 10% FBS and 1% Anti/Anti. This set of wells would serve as a positive 
control. The plate was then placed in an incubator for 24 hours at 37˚C at 5% CO2.  After 
24 hours, the plates were removed and using a P10 micropipette tip a scratch was made 
from top to bottom of the well. The width of the scratch measures approximately 530 
pixels using the ImageJ straight line selection tool. Each well was then washed with 
DMEM + 10% FBS, 1% Anti/Anti media to remove any debris and dislodged cells from 
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the wells. Fresh DMEM media, 10% FBS and 1% Anti/Anti was then added to each of the 
wells. Photographs of the centre of the well, focussed on the artificial gap created were 
taken to represent baseline at time point zero hours. The plates were then placed back 
in the incubator at 37˚C in 5% CO2. Further photographs were taken at 8 hour and 24 
hour post-scratch from which comparison to baseline photographs were made to 
calculate the rate of migration. This was determined by measuring the change in wound 
area over time using ImageJ. 
WiDr cell line migration with siRNA transfection 
To investigate if the WiDr colorectal cell line migrate following siRNA transfection, cells 
were harvested from the T75 flasks and seeded into a 96-well plates. Cells were seeded 
at 1 x 104 per 100µL in DMEM + 10%FBS + 1% Anti/Anti and left for 24hrs to settle and 
attach prior to siRNA gene transfection. Following 24 hours incubation, siRNA 
transfection was performed to the following conditions: Cells; scrambled siRNA 
(negative control); and 10nM for TNFRSF11A siRNA (siRNA added in with 
RNAiMAX(0.3µL) with OptiMEM). Plates were then left for 24hrs at 37˚C in 5% CO2.  
After 24hrs, the plates were removed and using a P10 pipette tip a scratch was made 
from top to bottom of each well. Each well was then washed with DMEM + 10% FBS 
media only. Photographs of the centre of the well, focusing on the artificial gap created 
were taken at this point and represent baseline photos at time point zero hours. The 
plates were then placed back in the incubator at 37˚C in 5% CO2. Further photographs 
were taken at 8 hour and 24 hour post scratch from which comparison to baseline 
photographs were made to calculate the rate of migration. After 24 hours and 
completion of the assay, the cells were processed for RNA extraction using RNAGEM 
and subsequent qRT-PCR analysis to confirm gene knockdown. 
2.9 Total RNA extraction. 
For the colorectal cell line samples used as part of the Image Analysis experiments, total 
RNA extraction was performed using the QIAGEN RNeasy Mini Kit (Qiagen, Hilden, 
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Germany) as per the manufacturer’s instructions. 50µL of RNase-free water was added 
to elute the RNA.  
For the colorectal cell line samples used as part of the Gene knockdown experiments, 
two protocols were used. The QIAGEN RNeasy Mini Kit and the ZyGEM RNAGEM™ 
Tissue PLUS rapid RNA extraction kit (ZyGEM NZ Ltd, Hamilton, New Zealand). 
RNAGEM™ Tissue PLUS rapid RNA extraction kit. 
Total RNA was extracted using the ZyGEM RNAGEM™ Tissue PLUS rapid RNA extraction 
kit (ZyGEM NZ Ltd, Hamilton, New Zealand) as per the manufacturer’s instructions. 
Briefly, cell pellets were centrifuged at 3000g for 5 minutes, supernatant was removed 
and discarded, and the cell pellet was then resuspended in the RNAGEM extraction kit 
components, which was 5µL of 10 x Buffer (SILVER); 1 µL of RNAGEM and 44 µL of 
RNAse-free water to a total volume of 50µL. The sample was gently mixed before being 
placed on a T100™ thermal cycler (Bio-Rad, Hercules, CA, USA) and incubated at 75˚C 
for 5 minutes before rapid chilled to 4˚C for indefinite time period. DNAse treatment 
was then performed by adding 5µL of 10x DNase Buffer followed by 2µL of DNAse 1 to 
the sample, vortexed and placed back on the Thermocycler for another series of 
incubation steps, 37˚C for 5 minutes, followed by 75˚C for 5 minutes and then rapidly 
chilled to 4˚C for an indefinite period of time. The sample was then removed from the 
Thermocycler and used for cDNA synthesis. 
Total RNA was quantified using the NanoDrop ND 8000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). Briefly 1 µL of the 50 µL total for each sample was 
quantified. The absorbance of a diluted RNA sample was measured at 260 and 280 nm. 
The nucleic acid concentration was calculated using the Beer-Lambert law (Trumbo, 
Schultz et al. 2013), which predicts a linear change in absorbance with concentration. 
2.10 cDNA synthesis. 
cDNA synthesis for each colorectal cell line was performed using the Invitrogen™ 
SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad, CA, 
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USA) as per the manufacturer’s instructions. Briefly, 10µL of the RT Reaction Mix 
(oligo[dt]20, random hexamers, MgCl2 and dNTPs) was pipetted into to a 200µL PCR 
tube, along with 4µL of DEPC-treated water, 4µL of Total RNA and the RT-Enzyme mix 
(including, Superscript® III RT and RNaseOUT™) added last. The tube was gently mixed 
before being placed on a T100™ thermal cycler (Bio-Rad, Hercules, CA, USA) using the 
following incubation reaction steps: incubation at 25˚C for 10 minutes; incubation at 
50˚C for 30 minutes; incubation at 85˚C for 5 minutes, followed by rapid chill to 4˚C. 1µL 
(2 units) of E.coli RNase-H was added to the reaction mix and incubated at 37˚C for 20 
minutes. A non-template control was also included. The samples were then removed 
from the Thermocycler and stored at 4˚C or for longer storage period at -20˚C. The cDNA 
dilution factor used for colorectal cell lines was 1:20 dilution while for the cell-based 
functional assays a 1:10 dilution factor was used.  
2.11 qRT-PCR analysis. 
qRT-PCR was performed using the KAPA Probe Fast qPCR Kit Master Mix (2X) Universal 
(KAPA BIOSYSTEMS) as per the manufacturer’s instructions. TAQMAN primers were 
selected from ThermoFisher Scientific for the genes PPIB (Hs00168719_m1); MLH1 
(Hs00179866_m1); GFI1 (Hs00382207_m1) and TNFRSF11A (Hs00921372_m1). 
Each qRT-PCR reaction was carried out in a final volume of 10µL consisting of 5µL of the 
2X KAPA Probe Fast Master Mix, 1.5 µL of DEPC-treated water; 0.5µL of the TAQMAN 
probe and 3µL of diluted cDNA. For each qRT-PCR performed, a negative control and a 
non-template control were included to check for off target products. All samples were 
analysed in triplicate. PCR reactions were carried out using the Roche LightCycler®480 
System (Roche, Mannheim, Germany). The protocol for the reactions followed the steps 




Table 2.3 qRT-PCR thermocycler protocol used by the Roche LightCycler 480. 
Step Temperature Duration Cycles 
Enzyme activation 95˚C 3min Hold 
Denaturation 95˚C 1-3 sec 40 
Annealing/Extension 55-65˚C ≥20 sec 
 
After completion of the qRT-PCR reaction protocol, the data was then analysed using 
the Advanced Relative Quantification method (2-ΔCT method) relative to PPIB using the 
LightCycler software 1.5.0 (Roche, Mannheim, Germany).  
2.12 Statistical Analysis. 
The two-sample t-test with Satterthwaite’s adjustment for unequal variances was used 
to test for differences in means between gene copy number and mRNA mean 
expression levels. Fisher’s exact test was used to test homogeneity between RNAscope® 
and immunohistochemistry. Logistic regression was used to test for associations 
between semi quantitative gene expression levels and clinicopathological features for 
RNAscope® data. All tests were two sided with a p-value of ≤ 0.05 considered to be 
significant. ANOVA with Tukey post-hoc t-tests was used to investigate differences in 
mean mRNA expression levels and cell types. Bland-Altman analysis was used for 
method comparisons between image analysis methods and between image analysis 
methods and qRT-PCR.  Analysis was performed in R 3.3.1 (Vienna, Austria). Bland-
Altman plots were performed using using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. 
Student’s t-test was performed to test for significant differences between negative 
controls and samples with gene knockdown for cell proliferation, cell viability and cell 
migration experiments. Analysis and data was plotted using GraphPad Prism version 




Chapter 3. RNAscope. 
3.1 Introduction. 
Our understanding of the molecular basis of colorectal cancer has increased with the 
advent of molecular technologies that enable genome-wide expression analysis, such 
as microarrays and massively parallel sequencing (The Cancer Genome Atlas Network, 
2012) (Kelley and Venook, 2011; Guan et al., 2012). An example is the 2012 TCGA study 
which provided a comprehensive molecular characterization of colorectal cancer, key 
insights into colorectal cancer biology, and the identification of potential prognostic and 
therapeutic targets (The Cancer Genome Atlas Network, 2012). This paper has served 
as a foundation paper for other studies (Budinska et al., 2013; De Sousa et al., 2013; 
Sadanandam et al., 2013; Guinney et al., 2015) to expand upon. However, as with other 
genomic profiling studies, there has been a paucity of candidate markers translated into 
clinical practice (De Sousa et al., 2013; Morley-Bunker et al., 2016), possibly due to the 
confounding effect of tumour heterogeneity. 
A further reason may be the reliance on traditional technologies, such as PCR-based 
technology and IHC to verify findings from genome-wide studies. Both techniques suffer 
from limitations. Quantitative PCR-based methods are considered the “gold standard” 
for measuring gene expression because of its high sensitivity and specificity. However, 
its grind and bind approach before performing the assay “averages” gene expression 
amongst all cell types present within the specimen. Information about rare clonal 
populations of cells or specific cell types is “diluted” or lost through this process along 
with losing contextual information (Hanley et al., 2013) compromising the potential 
utility of a biomarker. Conversely, limitations of IHC are commonly associated with 
antibody development and antibody specificity (Schache, Liloglou, Risk, Jones, X. Ma, et 
al., 2013). Only 25% of the proteins within the human proteome have validated 
antibodies (Advanced Cell Diagnostics, 2012; Schache, Liloglou, Risk, Jones, X. Ma, et al., 
2013) and the sensitivity and specificity of many commercial antibodies have not been 
fully assessed (Schalper, 2014). Therefore, both techniques may have difficulty 
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accounting for tumour heterogeneity and providing an accurate measure of gene 
expression and protein levels. This makes standardization of techniques challenging 
(Bordeaux et al., 2012; Carvajal-Hausdorf et al., 2014a). A method that overcomes the 
fundamental limitations of PCR-based and IHC methods, to provide genotypic 
information, is RNAscope® (Advanced Cell Diagnostics, Inc.  (Hayward, CA).  
RNAscope is an RNA in situ hybridisation platform which encompasses novel technology 
involving a novel probe design and a hybridisation-based amplification system that 
improves the sensitivity and specificity of RNA in situ hybridisation techniques (Wang et 
al., 2012). RNAscope is able to identify single molecules within an individual cell whilst 
suppressing background noise and increasing the amplification signal. This allows for 
easy detection and visualisation of the mRNA expression targets using bright-field or 
fluorescent microscopy whilst keeping tissue morphology (Wang et al., 2012).  
RNAscope is a powerful technology that can be applied to biomarker research and aid 
potential biomarkers by applying or validating them in clinical applications (Wang et al., 
2012). RNAscope has been used in a variety of cancers ranging from head and neck 
(Ukpo et al., 2011; Bishop et al., 2012; Schache, Liloglou, Risk, Jones, X. J. Ma, et al., 
2013); gastrointestinal (Kim et al., 2013; Dawson et al., 2014; Sordal et al., 2014); breast 
(Bordeaux et al., 2012; Schalper et al., 2014; Vassilakopoulou et al., 2014); lung (Velcheti 
et al., 2014); along with studies involving tumour microenvironment (Staudt et al., 




3.2 Hypotheses and Aims.  
This study was designed to establish whether RNAscope could be successfully used on 
FFPE specimens to validate potential RNA biomarkers for CRC prognosis. MLH1 was 
selected to provide a technical comparison between RNAscope and IHC. MLH1 has a 
validated antibody that is clinically used to determine patients mismatch repair status 
in suspected Lynch syndrome cases. From the TCGA study, GFI1 and TNFRSF11A were 
both identified as highly ranked genes associated with poor prognostic outcomes in CRC 
patients. These genes were selected as potential gene biomarkers to assess with 
RNAscope.  
My hypotheses are 1) that RNAscope can be utilised on FFPE samples in a similar 
manner to IHC for the demonstration of mRNA expression, 2) that RNAscope can be 
utilised to validate potential colorectal gene biomarkers, and 3) that selection and 
validation of potential gene biomarkers could be standardised by integrating gene 
expression levels and copy number alterations.  
Specific Objectives were as follows:  
1) To perform the RNAscope assay on a small cohort of FFPE colorectal cases using 
the probes for gene MLH1. 
2) To compare MLH1 mRNA and protein expression levels using RNAscope and IHC, 
respectively. 
3) To investigate the relationship between Copy Number Alterations (CNA) and 
mRNA expression for GFI1 and TNFRSF11A from public database of CRC datasets 
(cBioPortal network.).  
4) To use RNAscope to measure the mRNA expression levels of GFI1 and 
TNFRSF11A and look for associations with clinicopathological outcomes. 
5) To investigate the relationships between mRNA expression levels of GFI1 and 
TNFRSF11A from public database of CRC datasets (cBioPortal) and to correlate 
these expression levels with clinicopathological features and patient outcomes.  
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3.3 Methods and Materials. 
Aim 1 involved using the 10 FFPE colorectal cancer cases represented by whole 
histological sections and performing the RNAscope assay on the sectioned slides. Aim 2 
and 4 involved using two tissue microarrays of 102 FFPE colorectal cancer cases in 
addition the 10 FFPE whole histological sections.  Aim 3 and 5 involved downloading 
and compiling gene expression data, DNA copy number data and clinicopathological 
data from the cBioPortal platform and performing analysis.  
3.3.1 Patient samples. 
A cohort of 112 primary colorectal tumour cases of varying histology, grade, age and 
gender were obtained from the Christchurch Cancer Society Tissue Bank (Ethics 
approval #16STH92) (Morrin et al., 2005). Before obtaining tissue samples, written 
informed consent was obtained from each patient. A tissue microarray (TMA) was 
utilised in this study. The TMA was made from 102 cases and consisted of duplicate 
1mm cores mined from FFPE tumour samples that were representative of the tumour 
stage at diagnosis. An additional ten cases used in the study were represented by whole 
histological sections from formalin fixed paraffin embedded (FFPE) tissue. 
3.3.2 RNA in situ hybridisation. 
The RNAscope assay (Section 2.3) was performed targeting MLH1, GFI1 and TNFRSF11A 
in addition to a positive control, PPIB, and a negative control (the bacterial gene, dapB) 
as described in Section 2.3.3.  
After completion of the RNAscope assay, slides, were counterstained with 
Haematoxylin and coverslipped before being microscopically assessed using the Zeiss 
Apotome Microscope. Associations between the mRNA expression levels of MLH1, GFI1 




IHC was performed targeting MLH1 as described in Section 2.6. A positive tissue control 
from normal bowel epithelium was included for quality control purposes. After 
completion of the IHC assay on the sectioned slides, these were counterstained with 
Haematoxylin and coverslipped before being microscopically assessed by a Pathologist 
and a scientist (myself), along clinical criteria. 
3.3.4 Public array datasets. 
A patient cohort was compiled from datasets available on the cBioPortal based that had 
tumour mRNA expression (microarray and RNA-seq) data; copy number alteration 
(CNA) data and clinical information available. These were downloaded from The Cancer 
Genome Atlas (TCGA) network (https://cancergenome.nih.gov/; Download: 10 August 
2016) and the cBioPortal for Cancer Genomics (http://www.cbioportal.org; Download: 
10 August 2016) (Cerami et al., 2012; Gao et al., 2013) and imported into an Excel 
spreadsheet. From a total of 629 patients and after removal of patient duplicates, only 
218 patients had CNA, gene expression and clinical information available (23 cases came 
from the TCGA Provisional Dataset). 
3.3.5 Statistical Analysis. 
All statistical analyses were conducted in the statistical programming environment R (R 
Development Core Team, 2013). For the CRC datasets obtained from the cBioPortal, the 
two-sample t-test was used to test for differences in means between CNA and mRNA 
mean expression levels. A linear regression model and ANOVA was used to investigate 
associations between mRNA expression differences and clinicopathological features. 
For the CRC TMA, the Chi-squared (2) test was used to determine if there were 
significant differences in mRNA expression for the respective genes and 
clinicopathological features for IHC and RNAscope methods. Confirmation of 
associations was performed using logistics regression and ANOVA.  
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3.4 Results.  
3.4.1 Application of the RNAscope assay on FFPE colorectal cancer cases. 
Familiarisation with the RNAscope method was performed using control slides of FFPE 
cultured cell pellets of human HeLa cells. Only the control probes PPIB (positive), and 
dapB (negative) were applied to the slides. Successful demonstration of mRNA probe 
signals for PPIB at was achieved on the control slides. Semi-quantitative score of >3 was 
observed for PPIB.    
RNAscope assay for MLH1 was successfully applied to whole histological FFPE sections 
of the 10 colorectal cancer cases. Collectively, the cases demonstrated MLH1 mRNA 
expression as brown punctuate dots within tumour epithelial cells types and other 
surrounding cell types (Figure 3.1). Clean staining was also observed for the control 
slides. Positive controls showed distinct brown punctuate dots for the probe PPIB with 
semi-quantitative scores of 2 or greater. No brown punctuate dots were observed in 
the Negative control slides for the bacterial dapB gene. Clean backgrounds were 
observed with no cross hybridisation or artefacts present on the slides that could make 
visualisation of mRNA expression difficult. Due to the ease of performing the manual 
method of RNAscope which yielded clear and interpretable staining, the method was 




Figure 3.1 Representative images of RNAscope performed on FFPE colorectal cancer cases. 
A) Positive Control (PPIB), B) Negative Control (dapB only), C) MLH1. Positive mRNA expression (probe 





3.4.2 Comparison between RNA in-situ hybridisation and 
immunohistochemistry assessment for MLH1. 
Following the use of RNAscope on the whole histological FFPE sections of the 10 
colorectal cancer cases, RNAscope was performed on the TMA cohort of patients. Initial 
results for the TMA cohort showed MLH1 mRNA expression could be demonstrated, 
however, variable levels of the positive control probe, PPIB, were evident across the 
individual TMA cores on the slide.  Inspection of the control slides that were run at the 
same time showed variable levels of mRNA expression of the positive control probe, 
PPIB, amongst the individual TMA cores on the slide. This indicated variable amounts of 
RNA and of good quality were present. The manufacturer defines a sample to contain 
abundant and good quality RNA present if the positive control slide, PPIB, achieves a 
semi-quantitative score of 2 or greater. Attempts to optimise the RNAscope method on 
the TMA cohort were performed to improve the demonstration of mRNA probe signal. 
These attempts focused on adjusting the Pre-Treatment Step 2 with adjustments of 
incubation times between 10 to 45 minutes. Inspection of the TMA slides showed no 
appreciable improvement in the demonstration of the mRNA probe signals for PPIB in 
individual TMA cores across different incubation times, with the level of expression 
remaining consistent. Further consultation with the manufacturer also suggested 
increased incubation times for Amplification Step 5 from 30 minutes to 1 hour to 
improve mRNA probe signal detection. Repeat RNAscope assays were performed with 
different Amplification Step 5 incubation times. No appreciable difference in mRNA 
probe signal intensity was observed for PPIB.  It was therefore decided to continue to 
follow the standard treatment protocol for colon tissue as recommended by the 
manufacturer for the demonstration of MLH1 in the TMA patient cohort. 
Expression of MLH1 mRNA has been correlated closely with protein expression (Jensen 
et al., 2013) so this gene was selected to compare the utility of RNAscope with a 
routinely used immunohistochemical diagnostic assay. RNAscope and IHC were 
successfully performed on a total of 112 colorectal tumour cases.  
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Microscopic assessment of MLH1 mRNA expression in tumour carcinoma cells showed 
different mRNA expression patterns in cases. A homogenous mRNA expression pattern 
where MLH1 probe signals were evenly dispersed throughout the tumour was found in 
8 cases. These cases were more readily identifiable and generally scored higher (i.e. had 
more signals per cell) than 43 cases that presented a heterogeneous expression with 
MLH1 probe signals observed in localised areas of the tumour. Microscopic assessment 
of MLH1 IHC found the majority of cases 93/112 demonstrated positive MLH1 staining 
within carcinoma cells. Variable positive expression levels were also observed between 
cases (Figure 3.2).   
Comparing the results between the two technologies found a concordance level of 
55.0% (62/112) of cases (Table 3.1). Positive mRNA expression, based on a semi-
quantitative score of 1 through to 4, correlated with positive protein expression in 
57.0% (53/93) of cases. A negative mRNA expression, a semi-quantitative score of 0 
based on occasional staining in <1/10 cells, correlated with a negative protein 
expression in 64.3% (9/14) of cases. To ascertain the possible reasons for the 
discrepancies between the RNAscope and IHC results, a review of the TMA cases 
subjected to the RNAscope was performed. Inspection of the TMA positive control slide 
showed variable levels of PPIB mRNA expression amongst the individual tissue cores. 
This indicated variable amounts of quality RNA present in the tissue cores. For analysis 
purposes those tissue cores on the TMA and whole histological sections that scored >2 
on the PPIB control slide were included in future analysis, representing samples with 
abundant and good quality RNA present.  
Re-analysis of cases with good quality RNA present, resulted in stronger concordance 
between RNAscope and IHC in 73.7% (56/76) of cases whilst 29 cases were excluded 
due to poor quality RNA present that scored 0 or 1 (Table 3.2). RNAscope and IHC were 
found not to be independent of each other (OR = 6.0; CI 1.59 - 22.62, P = 0.007, Fisher’s 
Exact test). A significant positive correlation between mRNA and protein expression was 
observed in 75.0% (48/64) of cases (P = 0.018). A negative mRNA expression correlated 
with a negative protein expression in 66.6% (8/12) of cases. Investigation of the 
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discrepant cases found 16 cases with positive MLH1 protein expression had no 
detectable MLH1 mRNA expression present. However, the level of protein expression 
was deemed to be mild in 62.5% (10/16) of these cases. Conversely, four cases with 
negative MLH1 protein expression, showed positive MLH1 mRNA expression. Such 
differences highlight potential variations in half-life between molecules and/or 
sensitivities between technologies. Regarding the discrepant cases between RNAscope 
and IHC, these were relatively evenly spread for gender, tended to include more left 
sided tumour cases at a ratio of 2:1 and were predominately Grade 2. 
I was not able to evaluate these findings in relation to MLH1 mutation or methylation 
status, however, the results further demonstrate the utility of RNAscope for measuring 
gene mRNA expression changes in archival FFPE tissue.  
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Table 3.1 Assessment of MLH1 mRNA expression using RNAscope and MLH1 protein expression scores 













Negative 9 39 0 48 
Positive 4 53 0 57 
No Result Available  1 1 5 7 
Total 14 93 5 112 
 
Table 3.2 Assessment of MLH1 mRNA expression using RNAscope and MLH1 protein expression scores 












 Negative 8 16 24 
Positive 4 48 52 
Total 12 64 76 
 
Further breakdown of RNAscope results relative to four-tier IHC staining scores showed 
concordance between mRNA and protein expression for MLH1. The IHC staining scores 
are based on staining intensity and number of cells stained. The sensitivity for a positive 
RNAscope result to a positive IHC staining score ranges from 52% (11/21 cases) for mild 
IHC staining through to 89% (16/18 cases) for strong IHC staining. The specificity for 




Table 3.3 Assessment of MLH1 mRNA expression using RNAscope relative to MLH1 protein expression 
scores using IHC from colorectal tumour samples with a positive control score of >2+.  
  IHC 








 Negative 8 10 4 2 24 
Positive 3 11 22 16 52 
Total 11 21 26 18 76 
 
 
Figure 3.2 Images of MLH1 protein expression from CRC TMA cores at 4x magnification (inset images 
at 40x magnification). A) Negative staining, B) Mild positive staining, C) Moderate positive staining, D) 
Strong positive staining.    
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3.4.3 Comparison between Copy Number Alterations and mRNA 
expression levels. 
Previous results showed that the RNAscope assay can be performed on FFPE material, 
with good concordance with protein expression for MLH1 as a technical comparison. I 
then investigated the possible use of RNAscope assay as a means to validate potential 
gene biomarkers proposed in a study carried out by The Cancer Genome Atlas Network 
(TCGA). 
The genes selected from the TCGA were GFI1 and TNFRSF11A (The Cancer Genome 
Atlas Network, 2012). Both genes were found to have reduced expression associated 
with poor prognostic outcomes. GFI1 was ranked 1st equal as a gene associated with 
poor prognostic outcomes. TNFRSF11A was ranked 12th. TNFRSF11A was a key 
candidate gene selected as it is located at 18q; a region that is also deleted in aggressive 
tumours. However, it is the highest ranked gene which is also affected by a change in 
copy number due its position on the chromosome arm 18q. Deletion of 18q is a known 
molecular alteration necessary in the tumorigenesis of colorectal cancer (for the CIN 
pathway), therefore the negative expression of TNFRSF11A is likely to be due to a 
change in copy number versus post-translational modifications affecting its expression. 
This approach may circumvent non-reproducibility issues associated with tumour 
heterogeneity as detection of copy number changes, especially DNA copy loss, is less 
likely if only present in a small proportion of tumour cells. Candidate prognostic gene 
markers that show a correlation between expression and copy number changes are 
likely to be evident across a significant proportion of the tumour cells.  
To confirm the possibility that mean mRNA expression levels for TNFRSF11A and/or 
GFI1 can be affected by CNA, analysis of mRNA expression levels and CNA was 
performed using TCGA data. From a total of 629 patients, 218 had DNA copy number 
and gene expression data. GFI1 and TNFRSF11A, showed a significant association 
between predicted gene CNA and expression levels for both GFI1 (average difference 
between loss and neutral was -0.39, CI -0.70 - -0.08, P =  0.01) and TNFRSF11A (average 
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difference between loss and neutral was -0.78, CI -1.06 - -0.50, P = 2.5E-07 ) with a trend 
of CNA deletions being associated with mRNA downregulation (Figure 3.3). 
 
Figure 3.3 Comparison of mRNA expression relative to copy number from combined TCGA datasets. 
For the respective genes A) GFI1 B) TNFRSF11A. Significant p-values are:  < 0.001 = ***, < 0.05 =* (Morley-
Bunker et al., 2019). 
3.4.4 RNA in situ hybridisation assessment of GFI1 and TNFRSF11A 
expression in colorectal cancer patients. 
I observed both homogenous and heterogeneous GFI1 and TNFRSF11A mRNA 
expression patterns across the 112 colorectal cancer patient tumour cohort. For GFI1, 
there were 3 cases with homogenous mRNA patterns and 9 cases with heterogeneous 
expression. For TNFRSF11A, a homogenous expression pattern was observed in 11 
cases, whilst 28 cases showed a heterogeneous expression pattern.  
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3.4.4.1 Analysis of GFI1 and TNFRSF11A mRNA expression in colorectal cancer 
cases with abundant RNA present.   
Associations between mRNA expression and clinicopathological features from the TCGA 
data focused on colorectal adenocarcinoma cases. To allow for valid comparisons to be 
made between the published TCGA data and the RNAscope patient cohort it was 
necessary for the RNAscope patient cohort to undergo a case selection process (Figure 
3.4). This resulted in a patient cohort of 69 colorectal adenocarcinoma cases that had 
abundant, good quality RNA within their samples. A summary of the patient 
characteristics for the RNAscope cohort are provided in (Table 3.4). 
 




Table 3.4 Summary of the clinicopathological features of the RNAscope cohort following case selection 
process. 
 Original RNAscope cohort RNAscope cohort (analysed) 
Clinicopathological Features Number (%) Number (%) 
Patients (n) 112 69 
Mean age (years ± SD) 68.97 ± 12.13 71.11±9.30 
Gender   
Male 69 (62%) 41 (59%) 
Female 41 (37%) 28 (41%) 
ND  2 (1%)  
Histology   
Adenoma 10 (9%) - 
Adenocarcinoma 99 (88%) 69 (100%) 
Carcinoma 1 (1%) - 
ND 2 (2%) - 
Mean tumour size, mm ± SD 45.31 ± 16.00 43.88 ± 15.89 
Metastasis Present   
Yes 35 (31%) 22 (32%) 
No 72 (64%) 47 (68%) 
ND 5 (5%)  
Site   
Left (Distal) 61 (54%) 34 (49%) 
Right (Proximal) 49 (44%) 31 (45%) 
ND 2 (2%) 4 (65) 
Primary Site   
Ascending 42 (38%) 29 (42%) 
Caecum 5 (4%) 5 (7%) 
Hepatic Flexure - - 
Transverse 1 (1%) - 
Descending 12 (11%) 8 (12%) 
Sigmoid 21 (19%) 15 (22%) 
Rectosigmoid Junction - - 
Splenic Flexure - - 
Rectum 28 (25%) 12 (17%) 
ND 3 (3%)  
Tumour Grade   
1 5 (4%) 4 (6%) 
2 72 (64%) 51 (74%) 
3 17 (15%) 13 (19%) 
Adenoma 10 (9%)  
ND 8 (7%) 1 (1%) 
AJCC Pathologic Tumour Stage   
T0 9 (8%)  
T1 5 (4%) 4 (6%) 
T2 22 (20%) 18 (26%) 
T3 64 (57%) 42 (61%) 
T4 9 (8%) 5 (7%) 
ND 3 (3%)  
AJCC Nodal Stage   
N0 72 (64%) 45 (65%) 
N1 21 (19%) 12 (17%) 
N2 16 (14%) 12 (17%) 
ND 1 (1%)  
AJCC Metastatic Stage   
M0 2 (2%) 66 (96%) 
M1 5 (4%) 3 (4%) 
MX 98 (88%)  
ND 5 (4%)  
AJCC Tumour Stage Group   
0 9 (8%)  
1 21 (19%) 16 (23%) 
2 42 (38%) 29 (42%) 
3 33 (29%) 22 (32%) 
4 4 (4%) 2 (3%) 
ND 3 (2%)  
Abbreviations: n, Number of; SD, standard deviation; ND, No Data; AJCC, American Joint Committee on Cancer 
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Following the case selection process, the median age for the RNAscope cohort was 71 
years old. This age was used to classify patients into young and older age groups 
originally. However as colorectal cancer occurs at a greater incidence in aging 
population, adjusting for age in multivariate analysis could easily affect the significance 
of the result. To get a better representation of young vs older from clinical point of view, 
I investigated the age distribution of the cohort. Subsequently, the patients were 
reclassified into tertiles with an approximate even number of patients spread across the 
three groups. The cut-off ages for the age-groups were “30-65 years”, “66 – 75 years” 
and “76+ years”. These age groups were subsequently used in examination of significant 
associations for mRNA expression and clinicopathological features of colorectal cancer 
patients, with association confirmed with univariate and multivariate analysis (adjusting 
for age and gender). Additionally, small number of positive cases were observed 
distributed across the AJCC Pathologic Tumour Stage category. To minimise the effect 
of small number of cases unduly affecting the statistical significance of associations 
whilst maintaining clinically relevant information, cases were reassigned into either a 
low-grade or high-grade tumour stage grouping for subsequent analysis. Low-grade 
tumour stage consisted of T1 and T2 stage cases and are represented as “T1” in result 
tables. High-grade tumour stage consist of T3 and T4 stage cases and are represented 
in subsequent result tables as “T4”.  
Colorectal adenocarcinoma cases were analysed for associations between GFI1 or 
TNFRSF11A mRNA expression and clinicopathological features. Significant associations 
between negative GFI1 mRNA expression and age groups (CI 0.55 - 12.27, P = 0.05), 
grade (CI 0.003 - 0.91, P = 0.05), left-sided tumours (CI 1.21– 21.45, P = 0.02), and rectal 
tumours (CI 0.07 – 2.26, P = 0.04) were observed by univariate analysis (Table 3.5). 
Subsequent multivariate analysis of the initial observations between negative GFI1 
expression and age and grade were non-significant. Both age and gender affected the 
results when added as covariates in the instance for age, but it appeared gender alone 
was responsible for grade. The significant associations between negative GFI1 mRNA 
expression and left-sided tumours and primary site origin became non-significant after 
adjusting for age and gender (Table 3.5). Both age (older age groups 66-75 and 76+) and 
gender (Male) were responsible for the non-significant result. However, a significant 
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association between negative GFI1 mRNA expression and gender was found (CI 0.46 - 
6.14, P = 0.02) following multivariate analysis with the older age-groups.  
Analysis of TNFRSF11A mRNA expression and clinicopathological features showed 
significant associations for negative TNFRSF11A mRNA expression and presence of 
metastasis (CI 0.13 – 1.04, P = 0.05), and AJCC Nodal Stage involvement (CI 0.11 – 0.92, 
P = 0.03) (Table 3.6 ). Multivariate analysis was subsequently performed to determine 
if the initial univariate results remained statistically significant when adjusting for the 
co-variates, age and gender. Multivariate analysis found the association for metastasis 
(P=0.05) and AJCC nodal stage involvement (P = 0.03) became non-significant after 
adjusting for age and gender. However, statistically significant associations for tumour 
grade (CI 0.02 – 2.60, P = 0.02), grade status (CI 0.16-1.86, P=0.02), AJCC Pathologic 
Tumour Stage (CI 0.16 - 1.29, P = 0.03), and AJCC Tumour Stage Group (CI 0.05 – 0.84, P 
= 0.03) were found (Table 3.6). Tumour grade was driven by grade and male gender; 
grade status driven by male gender; tumour stage was driven by T3 and T4 stage 
tumours and male gender; AJCC Tumour Stage Group driven by Stages 3 and 4 and male 
gender. 
No associations were observed between expression of GFI1 and/or TNFRSF11A with the 
clinicopathological features, histology, tumour size, lymphocytic infiltrate. No 
information relating to histological type (mucinous versus non-mucinous) was available 





Table 3.5 GFI1 mRNA expression and association with clinicopathological features from colorectal 
adenocarcinoma cases from the RNAscope cohort that had an RNAscope positive control score of >2. 
 
a RNAscope data has univariate P value from Logistic regression.  
bP(adj), RNAscope data has adjusted P value from Logistic regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval.  
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Table 3.6 TNFRSF11A mRNA expression and association with clinicopathological features from 
colorectal adenocarcinoma cases from the RNAscope cohort that had an RNAscope® positive control 
score of >2. 
 
a RNAscope data has univariate P value from Logistic regression.  
b RNAscope data has adjusted P value from Logistic regression with covariates for age and gender.  




3.4.4.2 Comparison between RNAscope cohort data and the TCGA published data.  
RNAscope results were compared with those from the published results from the TCGA 
study (The Cancer Genome Atlas Network, 2012) for GFI1 and TNFRSF11A mRNA 
expression and their associations with poor prognostic features. Significant associations 
with clinicopathological features from the RNAscope cohort for GFI1 differed with those 
reported by the TCGA network (Table 3.7). No significant associations between reduced 
GFI1 expression and lymphatic invasion, tumour stage, fraction of positive lymph nodes 
and distant metastasis were observed in the RNAscope cohort compared to the TCGA 
paper. However, the RNAscope cohort showed a similar non-significant association for 
vascular invasion to that reported by the TCGA paper. No information in the RNAscope 
cohort was available regarding histological type, mucinous or non-mucinous or for MSI 
status.  
In contrast, the results for TNFRSF11A were more consistent with those published by 
the TCGA network (Table 3.7). Both studies showed a significant associations for the 
positive lymph nodes. Furthermore, I observed indirectly significant associations for 
distant metastasis between the TCGA network and the RNAscope cohort, in relation to 
the AJCC Tumour Stage Group (“3+4”) (Table 3.6),  which represents tumours with 
reported nodal and/or distant metastasis. A trend towards significance was observed 
for tumour stage in the RNAscope cohort compared to the TCGA tumour stage. No 
significant association was reported for lymphatic invasion and vascular invasion in the 
TCGA study which was consistent with our results. No information in the RNAscope 




Table 3.7 Comparison of the associations of GFI1 and TNFRSF11A mRNA expression with 
clinicopathological features between the TCGA study (The Cancer Genome Atlas Network, 2012) and 
the RNAscope analysed cohort. 
Study TCGA RNAscope TCGA RNAscope 
Gene Biomarker GFI1 GFI1 TNFRSF11A TNFRSF11A 




















-1 N/A -1 N/A 
Compound p-value 1.00E-16 N/A 8.18E-11 N/A 
Lymphatic Invasion 0.0475 0.93 0.149 0.27 
Histological Type 1.91E-10 N/A 1.06E-05 N/A 
Vascular Invasion 0.207 0.47 0.593 0.07 
Fraction Positive Lymph 
Nodes 
1.54E-05 0.73 2.12E-06 0.03 
Tumor Stage 6.96E-07 0.37 1.27E-05 0.07 
Distant Metastasis 3.86E-06 0.26 6.03E-04 0.57 
Also in MSS and MSI-L subset 1 N/A 1 N/A 
Abbreviations: ISH  in-situ hybridisation, MSS microsatellite instability stable; MSI-L microsatellite instability – low; N/A not available 
 
3.4.5 Investigation of Public Colorectal Datasets through the cBioPortal 
network.  
To investigate whether the differences in results for GFI1 and TNFRSF11A were due to 
a lack of power in the RNAscope cohort and/or whether other significant associations 
identified in the RNAscope cohort may be present in the TCGA study, the TCGA dataset 
was reanalysed through accessing the cBioPortal. As the TCGA network published their 
initial results in 2012, it was hoped that reanalysis of the TCGA dataset from the 
cBioPortal would also include additional cases. Additionally, more clinical data is 
available for analysis than was published in 2012.This allowed further matching of 
clinicopathological features with those in the RNAscope cohort of colorectal cancer 
patients. However, no information relating to grade and grade status was available with 
the TCGA dataset. Only adenocarcinoma cases from the TCGA were included for 
comparative purposes. For analysis purposes this dataset was called “cBioPortal-TCGA 
dataset” and provided a basis for subsequent investigations between the RNAscope 
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cohort. A summary of these investigations are presented in Figure 3.5 and expanded 
upon in the following results sub-sections. 
 
Figure 3.5 Summary of the investigations taken involving RNAscope cohort and the cBioPortal-TCGA 
dataset. 
 
3.4.5.1 Analysis of GFI1 and TNFRSF11A mRNA expression levels and 
clinicopathological feature associations from the cBioPortal-TCGA dataset. 
Investigation of associations between mRNA expression levels of GFI1 and TNFRSF11A 
with clinicopathological features and patient outcomes from the cBioPortal-TCGA 
dataset was performed.  
Univariate analysis of the cBioPortal-TCGA dataset showed statistically significant 
associations for negative GFI1 mRNA expression and age (CI -0.78—0.06, P=0.03), 
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metastasis present (CI 0.15 – 0.69, P=0.003), site (CI -1.16 - -0.55, P=2.08E-08), primary 
site (CI 0.51 – 1.20, P=1.6E-07), AJCC Nodal Stage (CI 0.14 – 0.68, P=0.0004) and AJCC 
Tumour Stage Group (CI -0.64, 0.58, P = 0.02) (Table 3.8). Multivariate analysis of the 
cBioPortal-TCGA dataset showed these significant associations remained except for age 
becoming non-significant, while AJCC Metastatic Stage became statistically significant 
(CI -0.05, 0.74, P = 0.03) when the co-variates age and gender were adjusted (Table 3.8).   
Univariate analysis of the cBioPortal-TCGA dataset showed statistically significant 
associations for negative TNFRSF11A mRNA expression and metastasis present (CI 0.03 
– 0.55, P = 0.04), site (CI -0.77 - -0.09, P = 0.005), primary site (CI -0.17 - -0.84, P = 0.007), 
and AJCC Nodal Stage (CI 0.03 – 0.55, P = 0.04) (Table 3.9). Multivariate analysis of the 
cBioPortal-TCGA dataset showed the initial significant associations for metastasis 
present and AJCC Nodal Stage became non-significant when age and gender were 





Table 3.8 GFI1 mRNA expression and association with clinicopathological features from colorectal 
adenocarcinoma cases from the cBioPortal-TCGA dataset. 
 
a TCGA data has univariate P value from linear regression.  
b  TCGA data has adjusted P value from linear regression with covariates for age and gender. 






Table 3.9 TNFRSF11A mRNA expression and associations with clinicopathological features from 
colorectal adenocarcinoma cases from the cBioPortal-TCGA dataset. 
 
aTCGA data has univariate P value from linear regression.  
bTCGA data has adjusted P value from linear regression with covariates for age and gender. 




3.4.5.2 Comparison between the RNAscope cohort data and the cBioPortal-TCGA 
dataset.  
Following analysis of the cBioPortal-TCGA dataset and the identification of significant 
associations between the candidate prognostic genes (GFI1 and TNFRSF11A) and 
clinicopathological features, these were compared to the RNAscope data to confirm the 
initial associations and differences between the two datasets. 
Comparing the univariate analysis of the RNAscope cohort with the cBioPortal-TCGA 
dataset for GFI1, showed that RNAscope identified half the number (3/6) of significant 
associations that the cBioPortal-TCGA dataset identified. Consistent results between 
the datasets were for reduced GFI1 expression and age, left-sided and rectal tumour 
(Table 3.10).  
Differences between significant associations were found for metastasis present; AJCC 
nodal involvement and AJCC Tumour Stage groups, all of which were found statistically 
significant within the cBioPortal-TCGA dataset. No associations were found in both 
datasets for gender; AJCC Pathologic Tumour Stage; AJCC metastatic stage and survival. 
These results were not found in the RNAscope cohort following multivariate analysis, 
although gender became statistically significant in the RNAscope cohort and the 
cBioPortal-TCGA dataset (CI -0.28 – 0.27, P=0.05). The clinicopathological features that 
were non-significant in both datasets were lymphovascular invasion, AJCC Pathologic 
Tumour Stage, and survival. Similarly, the RNAscope cohort identified half the number 
(2/4) of significant associations identified by the cBioPortal-TCGA dataset. Consistent 
results between the two datasets were also found for reduced TNFRSF11A expression 
with metastasis present and AJCC Nodal Stage (Table 3.11).  
By comparison, age, gender, lymphovascular invasion, AJCC Pathologic Tumour Stage, 
AJCC Metastatic stage and AJCC Tumour Stage Group were not significant between the 
two datasets following univariate analysis. The clinicopathological features of site and 
primary site were the only features that differed between the two datasets, both being 
significant only in the cBioPortal-TCGA dataset. Performing multi-variate analysis found 
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that the features of metastasis and AJCC Nodal Stage between both datasets became 
non-significant. Furthermore no clinicopathological features were statistically 
significant between the two datasets (Table 3.11). Comparing the multivariate analysis 
from the RNAscope cohort showed, AJCC Pathologic tumour stage and AJCC Tumour 
Stage Group become statistically significant. Multivariate analysis of the cBioPortal-
TCGA dataset showed site and primary site remained statistically significant. 
Interestingly, multivariate analysis showed no statistically significant associations within 
the cBioPortal-TCGA dataset for AJCC Pathologic Tumour Stage, AJCC Nodal Stage, AJCC 
Metastatic Stage, AJCC Tumour Stage Group all of which were previously reported as 
statistically significant in the TCGA study. 
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Table 3.10 Comparison between the RNAscope cohort and cBioPortal-TCGA dataset for GFI1 mRNA expression and associations with clinicopathological features from 
colorectal cancer cases.   
 
a P value from logistic regression (univariate). badjusted P value from logistic regression with covariates for age and gender.  
cd P value from linear regression (univariate). d adjusted P value from linear regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval; NA, Information Not Available. 
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Table 3.11 Comparison between the RNAscope cohort and cBioPortal-TCGA dataset for TNFRSF11A mRNA expression and association with clinicopathological features 
from colorectal cancer cases  
 
aP value from logistic regression (univariate). b adjusted P value from logistic regression with covariates for age and gender.  
c P value from linear regression (univariate). d adjusted P value from linear regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval; NA, Information Not Available.
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3.4.6 Assessing the comparability of the RNAscope cohort and the 
cBioPortal-TCGA dataset. 
Initial results from the RNAscope cohort showed statistically significant associations 
with clinicopathological features, along with some associations approaching statistical 
significance. Comparisons between the RNAscope cohort and the cBioPortal-TCGA 
dataset showed that the RNAscope cohort identified half the number of significant 
associations than the cBioPortal-TCGA dataset. The number of differences between 
significant associations and clinicopathological features may reflect the sample size of 
the RNAscope cohort and the power associated with the study. To confirm that the 
significant associations and differences identified in the RNAscope cohort were a true 
representation, I sought to increase the power of the RNAscope cohort. I achieved this 
by combining the RNAscope cohort data with the cBioPortal-TCGA dataset, where the 
microarray gene expression data for each gene in the cBioPortal-TCGA dataset was 
normalised using the mean z-score for each individual gene mean z-score. For analysis 
purposes, the combined datasets was called “Dataset-A”. It was hypothesised that any 
differences between the RNAscope cohort and cBioPortal-TCGA dataset are minimised 
with increasing patient numbers to obtain a better representation and detection of 
effects. No information was available for grade and grade status from the cBioPortal-
TCGA dataset. Similarly, no information was available from the RNAscope cohort 
regarding histology.   
3.4.6.1 Analysis of GFI1 and TNFRSF11A mRNA expression levels and 
clinicopathological feature associations from Dataset-A. 
Results from Dataset-A showed significant associations for negative GFI1 mRNA 
expression and age (CI 1.00 – 3.40, P = 0.03); left sided tumours (CI 1.60 – 4.60, P = 
0.0002), rectal tumours (CI 0.24 – 0.90, P = 0.0001); AJCC Pathologic tumour stage 
spread (CI 0.43 – 1.28, P = 0.04) and AJCC Nodal Stage (CI 0.31 – 0.89, P = 0.02) were 
found using univariate analysis (Table 3.12). However, these significant associations 
disappeared upon multivariate analysis with adjustment for age and gender, with only 
a significant association appearing with male gender (CI 0.70 – 1.87, P = 0.03).  
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Significant associations for negative TNFRSF11A mRNA expression and left-sided 
tumour (CI 1.11 – 3.12, P = 0.02); AJCC Nodal stage (CI 0.28 – 0.75, P = 0.002), and the 
AJCC Tumour Stage Group (CI 0.22 – 0.80, P = 0.01) were found in Dataset-A following 
univariate analysis (Table 3.13). However, following multivariate analysis no significant 




Table 3.12 GFI1 mRNA expression and association with clinicopathological features from Dataset-A  
 
a Dataset-A data has univariate P value from Logistic regression.  
b Dataset-A data has adjusted P value from Logistic regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval.  
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Table 3.13 TNFRSF11A mRNA expression and association with clinicopathological features from 
Dataset-A  
 
a Dataset-A data has univariate P value from Logistic regression.  
b Dataset-A data has adjusted P value from Logistic regression with covariates for age and gender.  




3.4.6.2 Comparison of Dataset-A relative to the RNAscope cohort and cBioPortal-
TCGA dataset. 
Dataset-A was compared to the RNAscope cohort and cBioPortal-TCGA dataset to 
confirm that the initial results from the RNAscope cohort were a true representation 
and were not affected by the power of the study.  
Results from Dataset-A for GFI1 mRNA expression showed consistent findings between 
the RNAscope cohort and the cBioPortal-TCGA dataset (Table 3.14). Significant 
associations for age, site and primary site were observed across all three datasets 
following univariate analysis. Significant associations were found between Dataset-A 
and the cBioPortal-TCGA dataset for AJCC nodal. Interestingly, a significant association 
for AJCC Tumour stage was found that had not been present in either the RNAscope or 
cBioPortal-TCGA dataset. Conversely, no significant association for metastasis present 
was found in Dataset-A which was present in the cBioPortal-TCGA dataset. Following 
multivariate analysis, the only significant association present across all three datasets 
was for gender. While the significant associations present in Dataset-A became non-
significant in a similar manner to the RNAscope cohort. Contrastingly, significant 
associations were observed in the cBioPortal-TCGA dataset for metastasis present, site, 
primary site, AJCC nodal stage, AJCC metastatic stage and AJCC tumour stage group.  
Results from Dataset-A for TNFRSF11A mRNA expression showed a consistent 
significant association with AJCC nodal stage across all three datasets following 
univariate analysis (Table 3.15). A significant association was found between Dataset-A 
and cBioPortal-TCGA dataset for site. A significant association was observed for AJCC 
Tumour Stage group only in Dataset-A. No significant associations were observed in 
Dataset-A following multivariate analysis. Interestingly no significant association was 
found for metastasis present which had been present in both the RNAscope and 
cBioPortal-TCGA datasets. In the RNAscope cohort, significant associations for AJCC 
Pathologic Tumour Stage and AJCC Tumour Stage group were observed, while 




The odds ratios from the RNAscope cohort and Dataset-A appeared to follow similar 
directions for both GFI1 (Figure 3.6) and TNFRSF11A (Figure 3.7). It can be seen that the 
RNAscope cohort confidence intervals for the odds ratios are greater in range reflecting 
the small patient numbers in the cohort. In comparison smaller confidence intervals are 




Table 3.14 Comparison of significant associations for reduced GFI1 mRNA expression and clinicopathological features across the different datasets, RNAscope cohort; 
cBioPortal-TCGA dataset and the combined dataset, Dataset-A. 
 
a RNAscope and Dataset-A data has univariate P value from Logistic regression.  
b RNAscope and Dataset-A data has adjusted P value from Logistic regression with covariates for age and gender.  
c cBioPortal-TCGA dataset data has univariate P value from linear regression.  
d cBioPortal-TCGA dataset data has adjusted P value from linear regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval. 
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Table 3.15 Comparison of significant associations for reduced TNFRSF11A mRNA expression and clinicopathological features across the different datasets, RNAscope 
cohort; TCGA dataset and the combined dataset, Dataset-A. 
 
a RNAscope and Dataset-A data has univariate P value from Logistic regression.  
b RNAscope and Dataset-A data has adjusted P value from Logistic regression with covariates for age and gender.  
c cBioPortal-TCGA dataset data has univariate P value from linear regression.  
d cBioPortal-TCGA dataset data has adjusted P value from linear regression with covariates for age and gender.  





Figure 3.6 Forest plots of the odds ratios from the RNAscope cohort and Dataset-A identifying 




Figure 3.7 Forest plots of the odds ratios from the RNAscope cohort and Dataset-A identifying 
associations between TNFRSF11A mRNA expression and clinicopathological features.  
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3.4.7 Adoption of a new scoring system for microarray expression data.  
Differences between the RNAscope cohort dataset and the cBioPortal-TCGA dataset 
may be due to methods used to measure mRNA expression levels. The RNAscope 
method used in this study, measured mRNA expression in a binary fashion (“Negative”, 
“Positive”), whilst the mRNA expression levels in the cBioPortal-TCGA dataset are from 
a microarray platform that measured mRNA expression in a continuous numerical 
fashion. To determine if these differences in methodology could explain the different 
associations with clinicopathological features, I applied a binary approach to categorise 
the microarray gene expression values to replicate RNAscope scoring. This was achieved 
by taking the cBioPortal-TCGA dataset z-scores and assigning the lowest quartile as 
“Negative” and the remaining quartiles as “Positive’. For analysis purposes, this 
reclassified cBioPortal-TCGA dataset was called “Dataset-B”. I hypothesised that the z-
scores within the lowest quartile would be more likely to be comparable to a “Negative” 
score using the RNAscope. This study compared mRNA expression measured by 
RNAscope to the microarray expression data categorised as either positive or negative 
based on their quartiles.   
3.4.7.1 Comparison between Dataset-B and the RNAscope cohort data.  
Results from Dataset-B showed significant associations between GFI1 mRNA expression 
and site (CI 3.53 – 43.99, P < 0.001), primary site (CI 0.02 – 0.26, P < 0.001) following 
univariate analysis (Table 3.16). The significant associations for site and primary site 
were consistent with those identified in the RNAscope cohort. However, following 
multivariate analysis these associations became statistically non-significant which were 
consistent with the RNAscope cohort.  
Contrastingly, results from the Dataset-B showed no significant associations for 
TNFRSF11A mRNA expression and clinicopathological features following both univariate 
and multivariate analysis (Table 3.17 ). This differed to those significant associations 
identified in the RNAscope cohort. Observations from RNAscope cohort and the various 
datasets investigated thus far showed the RNAscope cohort identified a smaller number 
of significant associations with clinicopathological features compared to those 
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identified in the cBioPortal-TCGA dataset and others. Additionally, the RNAscope cohort 
produced associations that approached statistical significance. To determine if the 
RNAscope data trended in a similar manner to the other datasets, forest plots were 
constructed to compare the odds ratios and confidence intervals between the datasets.   
The odds ratios for associations between GFI1 mRNA expression and clinicopathological 
features from the RNAscope cohort and Dataset-B trend close to one another in 
magnitude and direction (Figure 3.8). Similar observations for the odds ratios between 
TNFRSF11A mRNA expression and clinicopathological features from RNAscope cohort 
and Dataset-B were seen (Figure 3.9). Interestingly, the odds ratios and confidence 
intervals from Dataset B appear similar to those of the RNAscope cohort and Dataset A.   
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Table 3.16 Comparison between the RNAscope cohort and Dataset-B for associations between GFI1 mRNA expression and clinicopathological features. 
 
a RNAscope and Dataset-B data has univariate P value from Logistic regression.  
b RNAscope and Dataset-B data has adjusted P value from Logistic regression with covariates for age and gender. 
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval. 
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Table 3.17 Comparison between the RNAscope cohort and Dataset-B for associations between TNFRSF11A mRNA expression and clinicopathological features. 
 
a RNAscope and Dataset-B data has univariate P value from Logistic regression.  
b RNAscope and Dataset-B data has adjusted P value from Logistic regression with covariates for age and gender.  




Figure 3.8 Forest plots of odds ratios from the RNAscope cohort, Dataset-A and Dataset-B identifying 





Figure 3.9 Forest plots of odds ratios from the RNAscope cohort, Dataset-A and Dataset-B identifying 





3.4.7.2 Comparison of the Hybrid dataset relative to Dataset-A and Dataset-B.  
To assess the comparability between the RNAscope cohort and Dataset-B, I investigated 
whether combining the RNAscope cohort with Dataset-B produced the same 
associations to Dataset-B alone. For analysis purposes the combining of the RNAscope 
and Dataset-B together was called “Hybrid” dataset.  
Results from the Hybrid dataset for GFI1 showed statistically significant associations for 
site (CI 1.17- 3.48, P = 0.01) and primary site (CI 0.26 – 0.95, P= 0.005) which were the 
same for the Dataset-B (Table 3.18). However, following multivariate analysis these 
associations became statistically non-significant. 
Results from the Hybrid dataset for TNFRSF11A showed statistically significant results 
for gender (CI 0.31- 0.92, P = 0.02), metastasis present (CI 0.35-1.01, P=0.05), AJCC 
Pathologic Tumour Stage (CI 0.27-0.98, P=0.04) and AJCC Nodal Stage (CI 0.32-0.91, 
P=0.02) which were in contrast to Dataset-B (Table 3.19). Multivariate analysis showed 
gender became statistically non-significant (P=0.47). However, the following additional 
clinicopathological features became statistically significant age (CI 0.74 – 2.84, P = 0.04), 
grade (P=0.02), grade status (CI 0.16, 1.86, P = 0.02), AJCC Metastatic Stage (CI 0.31-
1.40, P=0.02), AJCC Tumour Stage Group (CI 0.19 – 0.90, P=0.01) and Survival (CI 0.28-




Table 3.18 Comparison between the Hybrid dataset and Dataset-B for associations with GFI1 mRNA expression and clinicopathological features.  
 
a Dataset-B and Hybrid dataset has univariate P value from Logistic regression.  
b Dataset-B and Hybrid dataset has adjusted P value from Logistic regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval. 
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Table 3.19 Comparison between the Hybrid dataset and Dataset-B for associations with TNFRSF11A mRNA expression and clinicopathological features.  
 
a Dataset-B and Hybrid dataset has univariate P value from Logistic regression.  
b Dataset-B and Hybrid dataset has adjusted P value from Logistic regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval. 
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3.4.7.3 Comparison of the Hybrid dataset relative to the RNAscope cohort and the 
cBioPortal-TCGA dataset.   
To assess the comparability of the Hybrid dataset (RNAscope cohort + Dataset-B; Figure 
3.5) to the RNAscope cohort alone and the cBioPortal-TCGA dataset alone, I compared 
the associations found using each dataset. Results from the Hybrid dataset showed 
significant associations between GFI1 mRNA expression and site along with primary site 
following univariate analysis. These associations were consistent with those in the 
RNAscope cohort and in the cBioPortal-TCGA dataset (Table 3.20). However, following 
multivariate analysis, these associations became statistically non-significant. This was 
consistent with the RNAscope cohort but contrasted with those identified in the 
cBioPortal-TCGA dataset and also with the TCGA paper. 
Results from the Hybrid dataset showed significant associations between negative 
TNFRSF11A mRNA expression and gender, metastasis present, AJCC Pathologic Tumour 
stage, AJCC nodal stage, AJCC Tumour Stage group following univariate analysis. These 
associations appeared consistent between the RNAscope cohort and the TCGA dataset 
for metastasis present, AJCC nodal stage (Table 3.21). The Hybrid dataset showed that 
the majority of its significant associations were still present following multivariate 
analysis and identified a significant association for negative TNFRSF11A mRNA 
expression and survival outcomes. Furthermore, there were more significant 
associations at a multivariate level compared to the cBioPortal-TCGA dataset and the 
RNAscope cohort. Interestingly, these significant associations match those associations 
presented in the TCGA study (The Cancer Genome Atlas Network, 2012).  
Similar to previous comparison between RNAscope cohort and datasets (Dataset-A and 
Dataset-B), the odds ratios of the Hybrid dataset followed the same trend to other 
datasets for GFI1 (Figure 3.10) and TNFRSF11A (Figure 3.11). 
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Table 3.20 Comparison between the RNAscope cohort, Hybrid dataset and the cBioPortal-TCGA datasets for associations with GFI1 mRNA expression and 
clinicopathological features.  
 
a RNAscope and Hybrid dataset has univariate P value from Logistic regression.  
b RNAscope and Hybrid dataset has adjusted P value from Logistic regression with covariates for age and gender.  
c cBioPortal-TCGA dataset data has univariate P value from linear regression.  
d cBioPortal-TCGA dataset data has adjusted P value from linear regression with covariates for age and gender.  
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval. 
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Table 3.21 Comparison between the RNAscope cohort, Hybrid dataset and the cBioPortal-TCGA datasets for associations with TNFRSF11A mRNA expression and 
clinicopathological features. 
 
a RNAscope and Hybrid dataset has univariate P value from Logistic regression.  
b RNAscope and Hybrid dataset has adjusted P value from Logistic regression with covariates for age and gender.  
c cBioPortal-TCGA dataset data has univariate P value from linear regression.  
d cBioPortal-TCGA dataset data has adjusted P value from linear regression with covariates for age and gender. 





Figure 3.10 Forest plots of odds ratios from the RNAscope cohort, Dataset-A, Dataset-B and the Hybrid 





Figure 3.11 Forest plots of odds ratios from the RNAscope cohort, Dataset-A, Dataset-B and the Hybrid 





Gene expression studies facilitated by microarray technologies and with the advent of 
next-generation sequencing have increased our understanding of CRC development. 
Translating potential gene biomarkers from these studies into clinical use for diagnostic, 
prognostic and predictive purposes has typically relied on PCR-based technology and 
IHC. However, these techniques often suffer from limitations because of tumour 
heterogeneity, or a lack of correlation between protein and corresponding mRNA 
transcript levels. RNAscope is capable of overcoming these limitations (Scoazec, 2006). 
Advantages of RNAscope as a method make it an attractive alternative for validating 
and translating biomarkers based on integration of gene expression and CNA status.  
The aims of this chapter sought to establish an RNA in-situ hybridisation method 
(RNAscope®) capable of demonstrating mRNA expression levels within FFPE histological 
sections. The study also aimed to determine if RNAscope could be successfully used to 
validate potential colorectal cancer biomarkers based on integration of gene expression 
and CNA status. Using histological colorectal cancer cases, RNAscope was successfully 
performed to demonstrate mRNA expression levels for MLH1, GFI1 and TNFRSF11A. 
Analysis of the RNAscope results showed good concordance with IHC and showed 
associations with clinicopathological features associated with poor prognostic 
outcomes. Confirmation of these associations was provided through the use of public 
colorectal datasets supporting the use of RNAscope as a method to validate potential 
gene biomarkers for colorectal cancer.  
3.5.1 RNA in-situ hybridisation on FFPE material. 
Results demonstrated that RNAscope can be used successfully to demonstrate mRNA 
expression for MLH1 on FFPE specimens whilst maintaining tissue morphology. 
Following the manufacturer’s protocols, no background staining or contamination was 
evident on the histological FFPE sections. This allowed for successful visualisation and 
interpretation of mRNA expression levels.  
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3.5.2 Comparison between RNA in-situ hybridisation and 
immunohistochemistry for MLH1. 
Analysis of MLH1 copy number and/or expression, using either PCR analysis and/or IHC 
is important clinically to prioritise patients that may have a hereditary form of cancer 
(Lynch syndrome) or sporadic forms of CRC which are characterised by MSI. The 
prevalence of sporadic MSI CRC ranges between 10-15%. Of which 12% of MSI CRC 
cancers are sporadic involving epigenetic hypermethylation of the CpG island promotor 
region of MLH1 or germline mutations of MLH1 involved in 3% of MSI CRC cancer (Lynch 
syndrome) (Fearon, 2011; Al-Sohaily et al., 2012; Shia et al., 2013; Bogaert and Prenen, 
2014; Yuan et al., 2015) 12% of sporadic CRC manifest MSI with MLH1 methylation being 
the dominant mechanism in a background of CpG island hypermethylation (Shia et al., 
2013). 
The correlation between mRNA and protein expression in cancer tissue has shown 
moderate to strong correlations but is tissue dependent (de Sousa Abreu et al., 2009). 
RNAscope has been shown to perform at similar levels, if not better, than IHC as well as 
silver-enhanced in-situ hybridisation (SISH) for determining ERBB2 (HER2) 
overexpression in gastric carcinomas (Kim et al., 2013) and breast cancer 
(Vassilakopoulou et al., 2014), p16 INK4a in head and neck cancer (Ukpo et al., 2011; 
Bishop et al., 2012; Schache, Liloglou, Risk, Jones, X. J. Ma, et al., 2013), and cervical 
cancer (Evans et al., 2014). The strong correlation between gene and protein expression 
has allowed RNAscope to be effective in resolving discrepant cases between DNA status 
and protein expression for colorectal cancer (Dawson et al., 2014) and for head and 
neck cancer (Bishop et al., 2012). Comparing my results from the RNAscope data with 
IHC showed good concordance between RNA and protein levels for MLH1, 
demonstrating the utility of RNAscope against an established diagnostic tool.  
However, despite the use of a positive control gene to ensure RNA integrity in each 
core, some discrepancies between detection of mRNA and protein expression were 
encountered. A drop-out rate of 25/112 cases (22%) from the patient cohort was 
attributed to poor quality RNA with cases with a semi-quantitative score of 0 or 1 for 
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the PPIB control probe using RNAscope. There are number of possible explanations that 
could account for this. They include post-translation modifications and degradation of 
proteins, RNA degradation and pre-analytical variables with TMA and IHC staining.  
It is likely that not all MLH1 mRNA is translated into protein due to post-translational 
modifications or through protein degradation (Chen et al., 2002; de Sousa Abreu et al., 
2009). Various reports have shown that during the process of translation, modifications 
can occur that can affect the amount of protein produced within cells (Chen et al., 
2002). The correlation of protein expression to mRNA expression can be as low as 30%. 
The opposite was seen using a TMA of CRC cases with the amount of mRNA expression 
observed to be lower than the amount of protein expression. This could imply that 
protein expression is less prone to degradation and remains longer within tissue relative 
to mRNA expression.  
Limitations with using RNA in situ hybridisation include potential issues surrounding 
RNA recovery and degradation in FFPE material, which have been well documented and 
encompass pre-analytical variables of  specimen fixation, processing and storage prior 
to TMA construction (Hewitt et al., 2008; Hara et al., 2015; Landolt et al., 2016). These 
factors are known to influence the quality and abundance of RNA within FFPE samples 
(Landolt et al., 2016), However, the RNAscope probes are specifically designed to 
overcome these issues (Wang et al., 2012). 
In this study, archival FFPE material ranging between 5-15 years old was used. Despite 
the age of FFPE material, quality mRNA was present in the majority of the TMA cores. 
However, negative or low expression for positive control mRNA did exist in a minority 
of cases indicating sub-quality, and therefore low amounts of detectable RNA. Although 
not available at the time from the manufacturer, the inclusion of an alternative positive 
control probe, POLR2A - designed for low expressing target genes could help determine 
if the RNA was of poor quality or if the expression of the control gene, PPIB, may be 
affected in some cases. Additionally, no information regarding pre-analytical variables 
(e.g. tissue handling; tissue fixation times; tissue processing procedures) was available 
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that could help account for these observations. Notwithstanding, these same pre-
analytical variables could also have affected the MLH1 IHC sensitivity and specificity for 
the TMA and affect concordance levels between RNAscope and MLH1 IHC. As was seen 
with 62.5% of the discrepant cases showing mild protein expression levels.   
Additionally, tumour stage-related changes may also affect mRNA expression levels 
during tumour progression (Chen et al., 2002; The Cancer Genome Atlas Network, 
2012). Interestingly, there is the possibility that pathogenic missense mutations in 
MLH1 could still confer antigenically active protein (Shia et al., 2013). This may have 
contributed to discrepant cases between negative RNAscope cases and positive MLH1 
protein cases. This has been shown in earlier studies predicting MSI status using MLH1 
IHC (between 1999-2006), which detected loss of MLH1 protein in 74% of cases (Shia et 
al., 2013).That is why testing with other MMR genes is recommended which has 
brought up sensitivity to 93% and specificity near perfect for predicting MSI (Shia, 2015). 
A common limitation associated with IHC is that it can be difficult to interpret MLH1 
protein staining in equivocal cases, because decisions are based on whether or not there 
is the presence of a “blush” to the cells. These equivocal cases may be referred on for 
PCR or next-generation sequencing to determine MLH1 pathogenic variant status and 
confirm MSI status of a patient. RNAscope could potentially provide a quicker solution 
to resolve this dilemma. Identification and quantification of MLH1 mRNA transcripts 
within tumour epithelial cells using RNAscope could clarify the presence or loss of 
MLH1. MSI status could then be confirmed with next generation sequencing which 
would also establish specificity of RNAscope relative to current IHC methods for MLH1. 
It maybe that RNAscope could replace or complement the use of IHC to determine MSI 
status. This experiment was done prior to the commercial release of methods that allow 
combined RNAscope and IHC on the same section, but a combined approach may 
resolve this question quickly with the visualization of the MLH1 mRNA transcripts 
present in the cell while there is no discernible visualization of the MLH1 protein using 
IHC. Further studies are required to confirm RNAscope specificity for differentiating 
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between a microsatellite stable (MSS)/ microsatellite instability-low (MSI-L) phenotype 
from a microsatellite instability-high (MSI-H) phenotype. 
Although potential limitations exist associated with pre-processing, TMA age, and 
correlation between IHC and RNAscope in our study, my results along with other studies 
demonstrate the utility of RNAscope against an established diagnostic tool such as IHC.  
3.5.3 Correlation between Copy Number Alterations and mRNA 
expression levels.  
A TCGA study comprehensively characterized the molecular landscape of a patient 
cohort of colon and rectal cancer cases and produced a substantial gene list with over 
1300 genes ranked in statistical significance for their association with poor prognostic 
outcomes(The Cancer Genome Atlas Network, 2012). However, translation of potential 
gene biomarkers into clinical practice has seen limited success (Morley-Bunker et al., 
2016). Numerous genomic profiling studies have proposed individual genes as potential 
biomarkers, but very few overlap between studies (De Sousa et al., 2013). One strong 
reason for this is tumour heterogeneity. 
Establishing a means to better identify and select potential gene biomarkers would be 
advantageous to circumvent non-reproducibility associated with tumour 
heterogeneity. One method used in this study was to select candidate prognostic gene 
markers that show a correlation between gene expression levels and copy number 
alterations (CNA). Gene expression levels from microarray and RNA-seq data, 
demonstrate how much a tumour is expressing that gene. However, there is no 
indication as to how many cells within that tumour are expressing that gene. 
Conversely, there is no indication whether all the cells within the tumour have the same 
copy number for that gene. Incorporating copy number as a criterion potentially makes 
a clear distinction that changes in gene expression levels are due to CNA versus changes 
associated with gene regulatory machinery .  
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Analysis of the data downloaded from the cBioPortal demonstrated a statistically 
significant association between negative mRNA expression and gene copy number loss 
for both GFI1 and TNFRSF11A gene. Therefore, an association between reduced mRNA 
expression and clinicopathological features may reflect reduced CNA status driving 
reduced expression within our study, especially for TNFRSF11A which was selected 
based on this premise. Indeed, results did show, TNFRSF11A had the strongest 
association between the mRNA expression levels and CNA status, showing the greatest 
difference in mRNA expression levels between CNA status. However, this did not result 
in more significant associations being identified in the cBioPortal-TCGA dataset 
compared to GFI1. Although the strength of the association and the magnitude of the 
difference may have contributed to the increased number of significant associations 
identified in the Hybrid dataset compared to GFI1 when using a new scoring system for 
mRNA expression levels. This might suggest that using the gene selection process in 
conjunction with a gene expression scoring system similar to that used by RNAscope 
provides an effective system to investigate associations between mRNA expression 
differences and clinicopathological features. Further studies are required to clarify this 
possibility particularly to investigate overexpression of mRNA as a result of CNA. This 
would help determine how aligned the RNAscope scoring system is for scoring mRNA 
overexpression as a result of CNA changes. Future application of DNA targeted in situ 
technologies will complement RNAscope for profiling gene copy number and expression 
at the single cell level. 
3.5.4 Investigation of RNA in-situ hybridisation associations with 
clinicopathological features for candidate prognostic markers.  
This study successfully utilised RNA in situ hybridisation (RNAscope) to quantify mRNA 
expression of candidate prognostic markers GFI1 and TNFRSF11A and their association 
with clinicopathological features from FFPE colorectal tumour tissue.  
The gene GFI1 codes for a zinc-finger protein that in complex with chromatin modifying 
enzymes e.g. HDAC can acts as a transcriptional repressor by binding to DNA sequences 
within promoter-enhancer sites of proto-oncogenes and cytokines genes to modify 
130 
 
their transcription and expression. The function of GFI1 has been identified in 
hematopoietic development, neutropenia, lymphomagenesis and oncogenesis 
(Zweidler-McKay et al., 1996; Phelan et al., 2011). For intestinal sites, its primary 
function involves cell differentiation of progenitor cells into enteroendocrine, goblet or 
Paneth cells. It is an antagonist of Notch-signalling by working downstream and in 
collaboration of Notch-regulated ATOH1 and ASCL1 to direct cell fate (Shroyer et al., 
2005).  
TNFRSF11A is a protein of the TNF-receptor superfamily. It is involved in regulating 
interactions between T cells and Dendritic cells and also in bone homeostasis (Walsh 
and Choi, 2014). Mutations of the gene have been associated with autosomal recessive 
osteoporosis, familial expansile osteolysis, and Paget’s disease (Walsh and Choi, 2014). 
Its expression has also been associated with other solid tumours including breast cancer 
(Casimiro et al., 2013; Nolan et al., 2016), prostate and bone metastases (Li et al., 2014).  
Results from the RNAscope cohort of colorectal cancer cases found significant 
associations for negative mRNA expression and clinicopathological features. Significant 
associations were found for negative GFI1 expression and age groups, high grade, left-
sided and rectal tumours using univariate analysis (Table 3.5), while negative 
TNFRSF11A mRNA expression was associated with presence of metastasis and AJCC 
nodal stage involvement (Table 3.6 ). Following multivariate analysis, adjusting for age 
and gender rendered the previous associations statistically non-significant, whilst 
producing a significant association for gender for GFI1. Similarly, tumour grade, grade 
status, AJCC Pathologic tumour stage, and AJCC Tumour Stage group became 
statistically significant for TNFRSF11A, which appears to be driven by male gender and 
cases in the T4 Stage groups. 
Comparing these results with those reported in the TCGA study (The Cancer Genome 
Atlas Network, 2012) showed differing results for both GFI1 and TNFRSF11A and 
clinicopathological features. For GFI1, only vascular invasion shared a similar result 
between the datasets, whilst TNFRSF11A showed similar results for lymphatic invasion 
131 
 
and the fraction positive lymph nodes. A trend towards significance was also observed 
for Tumour Stage in the RNAscope cohort compared to the TCGA Tumour Stage. The 
TCGA study (The Cancer Genome Atlas Network, 2012), appeared to report only those 
p-values from univariate analysis. Therefore, comparisons made with RNAscope used 
univariate p-values. 
The initial results between RNAscope and the TCGA paper suggested similarities. 
However, the limited clinicopathological features and follow-up data reported by the 
TCGA paper, prompted me to confirm my initial findings by reanalysing the TCGA data 
obtained through the cBioPortal, which allowed me to access additional 
clinicopathological features and follow up data.  
3.5.5 Assessment of potential CRC prognostic biomarkers with RNA in-
situ hybridisation. 
Results from the cBioPortal-TCGA dataset verified the majority of the significant 
associations published in the TCGA paper for univariate analysis and produced 
significant associations for additional clinicopathological features (age, gender, site, 
primary site, AJCC Tumour Stage Group) previously not published. Comparison of the 
reanalysed data with the RNAscope data showed significant associations existed for 
clinicopathological features and poor prognostic outcomes between the two datasets. 
The significance of the results from the RNAscope cohort showed the use of RNAscope 
provides a means to measure mRNA expression levels and relate associated differences 
in expression levels to clinicopathological features. The results also showed the 
potential of RNAscope to confirm significant associations with clinicopathological 
features previously observed using microarray gene expression platforms.  
Data from both RNAscope and cBioPortal-TCGA datasets show that reduced expression 
of GFI1 was significantly associated with left sided tumours and the tumour’s primary 
site (Table 3.10 ). This is in contrast to the observation that left-sided colorectal cases 
have a better prognosis than right-sided tumours, even when adjusting for possible 
differences in screening practices and treatment (Wong, 2010). My results could be 
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identifying a subset of distal tumours that have poor prognostic outcomes, reflecting 
differences in tumour biology. Further studies are required to confirm these findings.  
Reanalysis of the cBioPortal-TCGA dataset for TNFRSF11A confirmed the previous 
associations reported in the TCGA paper except for tumour stage, and found additional 
significant associations for Site and Primary Site (Table 3.11). The only significant 
associations consistent with the RNAscope cohort was for presence of metastasis and 
AJCC nodal stage involvement following univariate analysis (Table 3.11). The RNAscope 
data did show reduced TNFRSF11A expression for gender and grade trended towards 
statistical significance, and these were not mentioned in the TCGA paper. This could be 
a potential gender specific association for a poor prognostic clinicopathological feature. 
Interestingly, the association for AJCC tumour stage group in the RNAscope cohort 
trended towards significance as reported in the TCGA paper, but was not found in the 
cBioPortal-TCGA dataset. This may be a reflection of the influence that CNA status has 
on driving negative mRNA expression in respect to TNFRSF11A when using the 
RNAscope method to measure mRNA expression levels in only carcinoma cells 
compared to microarray methods.  
Further observations from the multivariate analysis on the cBioPortal-TCGA dataset for 
TNFRSF11A found that those initial significant associations became statistically non-
significant, especially for the poor prognostic features published in the TCGA paper. In 
contrast, the RNAscope cohort showed statistically significant associations for grade, 
grade status, AJCC Pathologic Tumour Stage and AJCC Tumour Stage Group following 
multivariate analysis, which was not found in the cBioPortal-TCGA dataset.  
Differences in results may reflect differences in statistical approaches. The results 
published from the TCGA network were from univariate analysis alone. The TCGA data 
used either the Fishers Exact Test, ANOVA F-test, or F-test before calculating a weighted 
compound p-value. In contrast, this RNAscope study used a logistic regression model 
for univariate analysis and performed multivariate analysis adjusting for age and 
gender. To allow reliable comparisons with the RNAscope cohort, a linear regression 
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model was used for univariate analysis (adjusted for age and gender) of the TCGA data 
obtained via the cBioPortal. Therefore, differences in results between the RNAscope 
dataset and the cBioPortal-TCGA dataset could reflect differences in statistical 
methodology and/or a lack of power in the RNAscope cohort (69 patient cases) 
compared to the TCGA network (276 patient cases). Additionally, differences between 
the published TCGA results and the cBioPortal-TCGA dataset may relate to potential 
missing data or the raw data used in the TCGA publication having been “cleaned” before 
being uploading onto the cBioPortal site.  
Compared with the cBioPortal-TCGA dataset, the RNAscope cohort had a weighting 
towards more male patients, tumours that were in Stage Groups 1, 2 and 3. In contrast, 
the cBioPortal-TCGA dataset had more patients with a metastasis present and a more 
even distribution of patients across all four Tumour Stage Groups including those 
patients Stage 4 (Distant Metastases) disease (15% vs 3% RNAscope) and included more 
rectal adenocarcinoma cases. Therefore, multivariate analysis was performed to 
account for this weighting towards gender. As a consequence, the RNAscope results for 
GFI1 mRNA expression may be more gender specific and site specific, favouring females 
and left-sided tumours.  
3.5.5.1 Effects of increasing the power of the RNAscope cohort through combining 
datasets. 
The significant associations identified in the RNAscope cohort and those associations 
approaching statistical significance, provided encouraging signs that the use of 
RNAscope could potentially be used to validate potential gene biomarkers from gene 
expression studies. Combining the RNAscope cohort with the cBioPortal-TCGA dataset 
into Dataset A provided a means to increase the power of the RNAscope cohort and 
assess the comparability between RNAscope and the cBioPortal-TCGA datasets. As a 
result, the initial significant associations remained, whilst additional significant 
associations were identified for reduced expression of GFI1 and TNFRSF11A and poor 
prognostic outcomes. These were consistent with those significant associations present 
in the cBioPortal-TCGA dataset. Although it was observed that the RNAscope data did 
not produce the same number of significant associations as the TCGA data, the odds 
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ratios for some clinicopathological features (metastasis; nodal stage; tumour stage and 
overall tumour staging) representing poor prognosis were encouragingly in the same 
direction and magnitude as those from Dataset A. This indicates, that, despite the 
relatively small sample size of the RNAscope cohort, the RNAscope technology is 
capable of detecting trends and significant associations. Similarly, the odds ratios 
identified with the use of Dataset A are reassuring when compared to the TCGA dataset, 
that any differences between dataset characteristics have minimal effect on the 
associations observed.  
The significance of these results confirms the potential for the RNAscope method to 
identify significant associations with clinicopathological features that are observed 
using microarray gene expression platforms but were initially limited by the power of 
the study by small patient numbers. However, this inference of results are limited to 
the univariate analysis results as multivariate analysis adjusted for age and gender 
affected these results. Further studies with different patient cohorts will help clarify 
these results. 
3.5.5.2 RNAscope and Microarray differences in categorizing gene expression data. 
Different scoring systems to measure gene expression levels could also affect the 
significant associations between RNAscope and the cBioPortal-TCGA dataset. To 
investigate the comparability of the scoring systems between RNAscope and 
microarray, I chose to adapt the microarray platform scoring system to replicate the 
RNAscope system. I achieved this by reassigning the bottom quartile of the cBioPortal-
TCGA dataset as “negative expression” and the remaining quartiles as “positive 
expression”.  
With this approach I found that Dataset-B (the reclassified cBioPortal-TCGA dataset) 
data for GFI1 produced the same significant associations for site and primary site as the 
RNAscope cohort data. Therefore, it could be suggested that this approach closely 
approximates the RNAscope scoring system in this instance. This was not evident for 
TNFRSF11A in Dataset-B although there were associations approaching statistical 
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significance. Similarly to previous datasets, the odds ratios for Dataset-B trended in the 
same direction as the RNAscope cohort and Dataset-A.  
To investigate if those associations approaching statistical significance could be affected 
by an increase in patient numbers, the RNAscope cohort and Dataset B were combined 
to make the Hybrid dataset. Results from the Hybrid dataset confirmed the significant 
associations for GFI1, but interestingly showed an increased number of significant 
associations for negative TNFRSF11A mRNA expression levels and clinicopathological 
features. These significant associations were more than those identified in any of the 
previous datasets and remained statistically significant following multivariate analysis. 
Remarkably, the significant associations produced in the Hybrid dataset for TNFRSF11A 
matched those significant associations reported in the published TCGA study (The 
Cancer Genome Atlas Network, 2012) and included a significant association for survival, 
confirming the fact that reduced TNFRSF11A expression is associated with poor 
prognostic outcomes. 
The significance of these results suggest that employing a dichotomous scoring system 
for a microarray gene expression platform based similarly to the definition for negative 
expression in the RNAscope assay, showed potential in producing the same significant 
associations identified using RNAscope. This was based on the observation that 
significant associations identified in Dataset-B and the Hybrid dataset at univariate and 
multivariate levels were consistent with identified between the RNAscope and the 
cBioPortal-TCGA datasets. The differences in results encountered for GFI1 and 
TNFRSF11A between RNAscope and the datasets, Dataset-B and Hybrid dataset, 
potentially reflect the over-simplification of reclassifying microarray data based on 
quartiles. Although this does provide a starting point to try to align the microarray and 
RNAscope scoring systems together. Differences in results between RNAscope and 




Differences in significant associations between RNAscope and microarray data may also 
be due to the effects intra-tumour and inter-tumour heterogeneity may have on gene 
expression levels. The TCGA study selected cases that contained approximately 70% 
tumour present, while in this study the RNAscope assessed mRNA expression in tumour 
cancer cells only. How much of an effect that the remaining 30% of the sample, 
comprising other cell types, contributed to in the TCGA microarray data remains 
uncertain but could help explain the differences in associations between the TCGA and 
RNAscope cohorts. It could be considered that the use of RNAscope is more specific for 
determining associations within tumour cells compared to microarray platforms.   
Differences between the TCGA and RNAscope results may also reflect differences in the 
types of samples used. The TCGA used fresh frozen material while the RNAscope used 
archival FFPE specimens. The observation that the RNAscope odds ratios are trending 
in the same direction as the TCGA, provides reassurance that RNAscope can be utilised 
on FFPE to validate potential gene biomarkers identified from fresh-frozen material.  
The overall implication from all the analyses carried out thus far, show the ability of the 
RNAscope method to validate potential gene biomarkers identified from microarray or 
RNAseq studies. The RNAscope assay combined with the gene selection process 
adopted in this study to validate the potential gene biomarkers GFI1 and TNFRSF11A 
found significant associations as those previously reported in the TCGA (The Cancer 
Genome Atlas Network, 2012), and from  the cBioPortal-TCGA dataset. When these 
associations from the RNAscope were investigated further by increasing the power of 
the cohort or adapting gene expression scoring systems, either the associations 
remained or the odds ratios trended in the similar direction. This reaffirms the capability 





In conclusion, this study shows the advantages of an mRNA in situ hybridisation 
technique (RNAscope) for validating potential gene expression biomarkers identified by 
published studies, circumventing the potential limitations associated with qRT-PCR and 
IHC. This study demonstrates RNAscope as a promising method to visualise and quantify 
mRNA expression of candidate biomarkers on archival FFPE colorectal cancer cases 
from whole histological sections or in part of a TMA cohort. This will allow researchers 
to carry-out retrospective studies on archival FFPE material, which have a wealth of 
pathological, clinical and follow-up information available, to investigate and validate 
candidate biomarkers. The selection of candidate biomarkers using copy number 
changes provided a possible approach to implement across different patient cohorts 
that potentially reduces the impact of tumour heterogeneity. This study found 
significant associations for altered mRNA expression for the genes, GFI1 and 
TNFRSF11A, with a selection of poor prognostic features that were consistent with 
those identified by the large TCGA study (The Cancer Genome Atlas Network, 2012). 
Future larger studies are required to confirm the link between GFI1 and TNFRSF11A and 





Chapter 4. RNAscope combined with Image Analysis 
4.1 Introduction. 
Tumour heterogeneity has been recognised as a major limitation that has hampered 
the translation of potential genomic biomarkers from genomic profiling studies into 
clinical practice (De Sousa et al., 2013; Morley-Bunker et al., 2016). Another significant 
factor that can affect both PCR-based technologies and IHC results is the human 
component. A heavy reliance is placed on Pathologists and scientists to correctly assess 
specimen adequacy, select representative tumour regions for molecular testing, 
interpret morphological features, assess and measure IHC staining patterns (Viray Dr. 
et al., 2013; Carvajal-Hausdorf et al., 2014a; Hamilton et al., 2014; Smits et al., 2014). 
These aspects are highly subjective and can be poorly reproducible (Hamilton et al., 
2014).  
A greater emphasis is now being placed on using quantitative gene expression 
measurements and quantifying IHC expression levels to correctly identify patients that 
would benefit from treatment, or to triage patients into appropriate clinical trials e.g. 
HER2; PD-1 and PD-L inhibitors (Carvajal-Hausdorf et al., 2014a; Hamilton et al., 2014; 
Schalper et al., 2014). This has led to the development of commercial image analysis 
software to utilize image segmentation and feature extraction-based signal 
quantification methods within cells or tissue regions to provide quantitative 
measurements of IHC (Carvajal-Hausdorf et al., 2014a). Notable advantages that image 
analysis tools provide, include standardised tissue measurements, automation, and 
improved productivity and efficiency (Hamilton et al., 2014).The ability to combine 
molecular data, image analysis techniques and phenotypic data has the potential to 
facilitate greater understanding between genotype and phenotype (Gurcan et al., 2009; 
Hamilton et al., 2014; Cooper et al., 2015) and provide opportunities for biomarker 
discovery, validation and assay development (Himmel et al., 2018).  
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RNAscope has shown a strong correlation with quantitative PCR for the measurement 
of mRNA expression (Wang et al., 2013) whilst also providing a suitable platform for 
quantitative image analysis measurements to be performed. These features make 
RNAscope an attractive method to utilise as we move into a personalised medicine 
approach which requires precise disease classification, identification of companion 
biomarkers and drug targets for individual patients (Gurcan et al., 2009; Hamilton et al., 




4.2 Hypotheses and Aims. 
This study was designed to investigate what quantifiable information could be 
ascertained from performing the RNAscope assay on FFPE colorectal tumours and 
colorectal cancer cell lines targeting the genes MLH1, GFI1 and TNFRSF11A.  
My hypotheses are that RNAscope can be 1) utilised in a similar manner to IHC for the 
demonstration of mRNA expression levels on FFPE samples, and 2) combined with 
image analysis methods to quantify mRNA expression levels in a similar manner to qRT-
PCR.  
Specific objectives involved measuring RNAscope hybridisation signals (i.e. gene 
expression levels) for MLH1, GFI1 and TNFRSF11A:  
1) in FFPE tumour sections using a semi-quantitative scoring system.  
2) in FFPE tumour sections using the image analysis programme, ImageJ.  
3) in FFPE tumour sections using image analysis programmes including ImageJ with 
Colour Deconvolution method, SpotStudio, WEKA, and the LEICA Imagescope 
RNA ISH V2 algorithm and compare level of agreement to ImageJ with Cell 
Counter plugin.  
4) in colorectal cancer cell lines WiDr and SW480 using ImageJ with Cell Counter 
plugin, SpotStudio, WEKA and the LEICA ImageScope RNA ISH V2 algorithm and 




4.3 Methods and Materials. 
Aims 1-3 involved using 10 FFPE colorectal cancer tumours cases represented by whole 
histological sections (Chapter 2 Materials and Methods) and performing the RNAscope 
assay on the sectioned slides. Aim 4 involved culturing the colorectal cell lines, WiDr 
and SW480 at 37˚C in 5% CO2 (Chapter 2, Section 2.2). Each cell line were harvested 
once cells had reached 60-80% confluency and split into two aliquots of equal cell 
concentrations. One aliquot was used to perform qPCR for RNA expression levels on 
MLH1, GFI1, TNFRSF11A and the housekeeping gene PPIB. The other aliquot was used 
to make cytospin slides consisting of a monolayer of cells which were then subjected to 
RNAscope analysis. 
 
4.3.1 RNA in situ hybridisation and image analysis. 
RNAscope was carried out targeting MLH1, GFI1 and TNFRSF11A in addition, a positive 
control, PPIB, and a negative control (the bacterial gene DAB) were also included at the 
time assays were performed.  
After completion of the RNAscope assay on the sectioned slides, these were 
counterstained with Haematoxylin and coverslipped before being microscopically 
assessed using a Zeiss Apotome Microscope. For each FFPE case, three representative 
brightfield images of 1) tumour epithelial cells; 2) normal mucosal epithelium; 3) 
lymphocytes within stromal areas and germinal centres; 4) stromal cells within areas 
adjacent to tumour invasion and in muscularis major were digitally captured for each 
individual gene probe. In summary, a total of 12 micrographs were captured for each 
gene probe per case. The number of probe signals in approximately 100 cells were 
counted per image were counted and data were recorded on a Microsoft Excel 
spreadsheet. 
The image analysis software platforms used to assess mRNA expression levels included: 
ImageJ with Cell Counter plugin and Colour Deconvolution method, SpotStudio, WEKA, 
and the LEICA ImageScope RNA ISH V2 algorithm (LEICA). 
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4.3.2 Statistical analysis. 
All statistical analyses were conducted in the statistical programming environment R (R 
Development Core Team, 2013). A p-value of <0.05 was considered to be significant. 
Univariate analysis (ANOVA and Tukey HSD (honest significant difference) test was used 
to investigate differences in mean mRNA expression levels and cell types. The Bland-





4.4  Results. 
4.4.1 Semi-quantitative analysis of RNAscope mRNA expression levels in 
FFPE colorectal cancer cases.  
RNAscope was successfully applied to the whole histological FFPE sections of the 10 
colorectal cancer cases, demonstrating mRNA expression as brown punctuate dots 
within cell types (Figure 4.1 and Figure 4.2). Clean backgrounds were observed with no 
cross hybridisation or artefacts present on the slides that could make visualisation of 
mRNA expression difficult. Following visualisation of the slides, focusing on the tumour 
carcinoma cells, a semi-quantitative score was assigned to each case as per the 
manufacturers scoring system for RNAscope (Figure 2.1 and Table 4.1). The majority of 
cases displayed low levels of mRNA expression for all genes, MLH1, GFI1 and TNFRSF11A 
with a score of 1 being assigned to cases. This score equated to 1-3 probe signals being 
present per cell within the colorectal cancer tumour. A minority of cases showed 
moderate levels of mRNA expression with a score of “2” representing 4-10 probe 
signals/cells. 
Positive MLH1 mRNA expression was observed in six of the 10 cases with four cases 
scored as “1” and the remaining two cases scored as “2”. Similarly, positive GFI1 mRNA 
expression was observed in six of the 10 cases, with four cases scored at “1” and two 
cases were scored at “2”. Finally, positive TNFRSF11A mRNA expression was observed 
in six of the 10 cases which were all lowly expressed and scored as “1”. All remaining 
cases were observed to show no expression and were assigned the score of “0”, this 
was despite having scored 2 on the positive control indicating good RNA integrity and 
abundance.   
From these observations, an overview of mRNA expression present within the sample 
was obtained using the RNAscope technology, ranging from no expression through to 
low and moderate levels of mRNA expression. Due to the relative ease of performing 
the RNAscope assay and clear visualisation of mRNA probe signals encouraged me to 
progress further and attempt to use image analysis methods to quantify mRNA 
expression levels of the respective genes. I also decided to quantify mRNA expression 
144 
 
levels of the genes in different cell types present within the sample. This would provide 
a means to validate the manufacturer’s claim that RNAscope can provide quantifiable 
mRNA expression information within a sample and on a per-cell basis.  
I chose to use the freeware image analysis programme, ImageJ, with which I had 
previous experience. ImageJ (and its prior versions) is considered a pioneer of image 
analysis and has been freely available for over 30 years (Schneider, Rasband and Eliceiri, 
2012). It has a simple interface and has a community-driven development model which 
can help meet user requirements(Schneider, Rasband and Eliceiri, 2012). ImageJ 
analysis was performed on 10 FFPE histological colorectal cancer cases to measure 
mRNA expression levels for MLH1, GFI1 and TNFRSF11A. To ensure representative 
sampling, and to minimise bias, each case had three representative images taken for 
each cell type present in and around the tumour. One hundred cells were counted from 
each of these images resulting in a combined total of 3000 cells per cell type that were 




Figure 4.1 Representative images of RNAscope performed on FFPE CRC cases (40x magnification). 
(A) Positive Control (PPIB), (B) Negative Control (DAB only), (C) MLH1, (D) GFI1, (E) TNFRSF11A. Positive 




Figure 4.2 Representative images of mRNA expression using RNAscope on an FFPE whole tissue section 
in different cell types from CRC cases (40x magnification). 
(A) MLH1 in normal epithelial cells (B) MLH1 in stromal cells (C) MLH1 in lymphoid cells (D) GFI1 in normal 
epithelial cells (E) GFI1 in stromal cells (F) GFI1 in lymphoid epithelial cells (G) TNFRSF11A in normal 
epithelial cells (H) TNFRSF11A in stromal cells (I) TNFRSF11A in lymphoid cells. 
Table 4.1 RNAscope semi-quantitative scores for MLH1, GFI1 and TNFRSF11A mRNA expression levels 







1 1 1 1 
2 0 0 0 
3 1 0 0 
4 0 0 0 
5 0 0 0 
6 1 1 1 
7 0 1 1 
8 2 1 1 
9 2 2 1 
10 1 2 1 
Scores: “0” – no mRNA signals per cell; “1” – 0-3 mRNA probes signals per cell; “2” – 4 – 6 mRNA probe signals per 
cell; “3” - >10+ mRNA signals per cell at 40x magnification “4” - >10 mRNA signals per cell occupying >10% of slide or 
at 20x magnification with clusters   
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4.4.2 Quantitative analysis of RNAscope mRNA expression levels in FFPE 
colorectal cancer cases. 
Quantification of the mean mRNA expression levels for MLH1, GFI1 and TNFRSF11A in 
tumour epithelial cells relative to other cell types was able to be performed using the 
ImageJ (Manual Cell Counter plugin) method on the 10 CRC cases (Figure 4.3 and 
Appendix B, Table S1). This involved counting 100 cells from each representative image, 
so that a total of 300 cells per case were counted with the dots per cell calculated (refer 
to Section 2.5.1.1). 
Cases that were semi-quantitatively scored a “1” or “2” for mRNA expression in tumour 
cells were assessed as being positive for mRNA expression. Those cases that semi-
quantitatively scored “0” for mRNA expression were assessed as having no expression. 
Correlation between the semi-quantitative scores and the quantification of mRNA 
expression levels showed good to strong correlation between the two methods for 
measuring gene mRNA expression levels (Figure 4.4). The correlation for MLH1 was 
r=0.59 (Figure 4.4a), GFI1 was r=0.82 (Figure 4.4b) and TNFRSF11A was r= 0.73(Figure 
4.4c).The correlation for MLH1 trended towards statistical significance (p=0.074), whilst 
the correlations for GFI1 and TNFRSF11A were both statistically significant respectively 
(p=0.004 and p= 0.017). 
Using the quantitative information, a threshold value could possibly be used to 
differentiate between cases that scored a 1 or 2 from those cases with no mRNA 
expression. From the data points observed, setting a threshold at 0.25 for MLH1 could 
achieve correct classification between cases scored as 1 or 2 from those cases scored 
as 0 (Figure 4.3a and Figure 4.5a). For GFI1 this threshold would be 0.145 (Figure 4.3b 
and Figure 4.5b) and for TNFRSF11A a threshold score of 0.138 (Figure 4.3c and Figure 
4.5c) would classify all cases scored as 0 correctly. However, one case (Case 8) scored 
as 1 would be reclassified as 0 for TNFRSF11A mRNA expression if applying the arbitrary 
threshold (Figure 4.3c). Alternatively, setting the threshold to the upper limit of the 
negative expressing cases (mean + SD) may be produce higher specificity in correctly 
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classifying cases as negative, conversely setting the lower limit to the positive cases 





Figure 4.3 Mean mRNA expression levels across different cell types for 10 CRC FFPE cases for the 
respective genes A) MLH1, B) GFI1, C) TNFRSF11A.  
Dotted line represents a threshold value that separates cases with low to moderate mRNA expression 




Figure 4.4 Correlation between semi-quantitative and quantitative mRNA expression levels for 10 CRC 
FFPE cases for the respective genes A) MLH1, B) GFI1, C) TNFRSF11A.   
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Collectively, the means and variances across the different cell types for MLH1, GFI1 and 
TNFRSF11A were statistically significant using ANOVA (p value < 0.001) (Table 4.2 and 
Figure 4.5). The mean mRNA expression levels within tumour carcinoma cells were 
significantly higher compared to other cell types for each gene respectively (MLH1: F= 
9.87, P = 9.91-05; GFI1: F = 10.81, P = 3.29-05 and TNFRSF11A: F=9.74, P = 7.64-05).  
Using the Tukey HSD test, multiple pairwise comparisons were made to determine 
which mean expression values were significantly different from each other. In all 
instances, the mean expression of MLH1, GFI1 and TNFRSF11A in tumour carcinoma 
cells was statistically significant from all other cell types at a p-value <0.01 (Table 4.2 
and Figure 4.5). The mean expression levels for MLH1 in tumour carcinoma cells was 
almost 6-fold higher than surrounding cell types (0.47 vs 0.06 signals/cell; CI 0.12 – 0.68, 
P = 0.010). For GFI1 tumour carcinoma cells this was 4.7-fold higher than surrounding 
cell types (0.33 vs 0.07 signals/cell; CI 0.08 – 0.44, P = 0.009). TNFRSF11A in tumour 
carcinoma cells was 7-fold higher than surrounding cell types (0.35 vs 0.05 signals/cell; 
CI 0.09 – 0.51, P = 0.009). With respect to differences between other cell types for each 





Figure 4.5 ImageJ manual method quantitative measurements of mRNA expression across different 
cells types for 10 CRC FFPE cases for the respective gene A) MLH1 B) GFI1 C) TNFRSF11A 
(Significant p-values are:  < 0.001 = ‘***’, <0.01 = ‘**’, < 0.05 = ‘*’).
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Table 4.2 Comparison of the mean mRNA expression levels on a per cell basis between different cell 
types for MLH1, GFI1 and TNFRSF11A.  








Carcinoma vs All Cell Types 0.47 vs 0.06 0.12,-0.68 0.010* 9.87 6.91E-05 
Carcinoma vs Normal 0.47 vs 0.09 0.13, 0.62 0.001#   
Carcinoma  vs Lymphocytes 0.47 vs 0.06 0.16, 0.65 4.47E-04#   
Carcinoma vs Stromal 0.47 vs 0.04 0.18, 0.66 2.44E-04#   
Normal vs Lymphocytes 0.09 vs 0.06 -0.03,-0.27 0.992#   
Normal vs Stromal 0.09 vs 0.04 -0.29, -0.20 0.963#   
Stromal vs Lymphocytes 0.04 vs 0.06 -0.26, -0.23 0.997#   
 








Carcinoma vs All Cell Types 0.33 vs 0.07 0.08, 0.44 0.009* 10.81 3.29E-05 
Carcinoma vs Normal 0.33 vs 0.09 0.08, 0.41 0.001#   
Carcinoma  vs Lymphocytes 0.33 vs 0.11 0.06, 0.38 0.004#   
Carcinoma vs Stromal 0.33 vs 0.01 0.16, 0.49 2.25E-05#   
Normal vs Lymphocytes 0.09 vs 0.11 -0.19, 0.14 0.971#   
Normal vs Stromal 0.09 vs 0.01 -0.24, 0.08 0.538#   
Stromal vs Lymphocytes 0.01 vs 0.11 -0.27, 0.05 0.296#   
 










Carcinoma vs All Cell Types 0.35 vs 0.05 0.09,0.51 0.009* 9.74 7.64E-05 
Carcinoma vs Normal 0.35 vs 0.11 0.05, 0.43 0.001#   
Carcinoma vs Lymphocytes 0.35 vs 0.03 0.13, 0.32 3.63E-04#   
Carcinoma vs Stromal 0.35 vs 0.01 0.15, 0.34 1.49E-04#   
Normal vs Lymphocytes 0.11 vs 0.03 -0.11, 0.08 0.641#   
Normal vs Stromal 0.11 vs 0.01 -0.30, -0.11 0.459#   
Stromal vs Lymphocytes 0.01 vs 0.03 -0.21, -0.02 0.991#   
Abbreviations: CI, (Confidence Intervals); HSD (honest significant difference). 
 *P-value for Carcinoma tested against All cell types from a 2 sample t-test, 
 # P-value for all other tests from Tukey’s HSD tests. 
To test to see if the variance between the different cell types were equal the Levene 
test was performed. Results showed that the variances for MLH1 between the cell types 
were found to be statistically significant with a p-value = 1.047e-05. Similar findings 
were found for both GFI1 (p-value = 4.381e-07) and TNFRSF11A (p-value = 5.077e-05) 
and their variances between cell types.  
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The Coefficient of Variation (CV) was also assessed for the different cell types across the 
three genes. The CV provides a measure of variability in relation to the population 
mean. The CVs for all cell types showed a similar level of variance to each other. The 
CVs for tumour cells ranged between 75-83%, normal epithelial cells ranged between 
82-121%, stromal cells ranged between 105 – 131%, and lymphoid cells ranged between 
55 – 96%.  
Pairwise comparisons of MLH1, GFI1 and TNFRSF11A mRNA expression between cases 
that scored “1” or “2” for low or moderate mRNA expression and cases that scored “0” 
for no expression were investigated. Results showed a statistically significant difference 
for mRNA expression in tumour epithelial cells for cases with low to moderate mRNA 
expression and those cases with no mRNA expression for MLH1, GFI1 and TNFRSF11A 
respectively (Figure 4.6). The mean MLH1 mRNA expression levels for positive cases 
were 5-fold higher than cases with no expression (0.69 vs 0.13 signals/cell; CI 0.19 – 
0.91, P = 0.009). For GFI1, mean expression levels were 4.8-fold higher (0.48 vs 0.10 
signals/cell; CI 0.16 -0.59, P =0.0056) and for TNFRSF11A over 5-fold higher (0.51 vs 
0.10; CI 0.13 – 0.67, P = 0.010) in positive cases versus cases with no expression. No 
other statistically differences were observed amongst the other cell types. These 
results, show that the differences associated in MLH1, GFI1, and TNFRSF11A mRNA 
expression for cases are primarily due to the expression levels within tumour epithelial 





Figure 4.6 Pairwise comparison of mean mRNA signals per cell across different cell types between 
positive and negative cases A) MLH1 B) GFI1 C) TNFRSF11A.  
156 
 
4.4.3 Quantitative analysis of RNAscope using different Image Analysis 
methods. 
The image analysis method (ImageJ) was successfully used to generate quantifiable 
RNAscope data from the digital images of FFPE histological sections of colorectal cancer 
cases. However, the quantitative nature of the image analysis method required manual 
counting of 3000 cells and their mRNA probe signals for MLH1, GFI1 and TNFRSF11A 
respectively. This process was also reliant on human interpretation of mRNA probe 
signals and cells to be included in the analysis. To try and minimise the impacts that 
these factors may have on producing quantifiable data from RNAscope assays, I sought 
to determine the suitability of other image analysis methods that could be employed in 
combination with RNAscope.  
To determine the suitability of combining image analysis methods with RNAscope for 
the detection and quantification of gene expression levels, I used digital images from 
the 10 histological FFPE colorectal cancer cases displaying MLH1 mRNA expression as 
detected by RNAscope. MLH1 was selected for this analysis as it showed a wide range 
of expression levels compared to GFI1 and TNFRSF11A, thus providing a range of mRNA 
expression levels for testing each of the image analysis methods. Additionally, MLH1 is 
used diagnostically so that any findings produced from image analysis methods maybe 
transferrable to a diagnostic setting. Finally, selecting one gene versus three genes for 
assessment of image analysis methods was a time-saving measure that would produce 
equally valid findings from one gene as opposed to three genes. The quantitative 
features measured were the same features used with ImageJ to quantify the amount of 
mRNA expression level in a sample and on a per-cell basis. These were the total number 
of cells, total number of MLH1 mRNA probe signals, and the mean number of MLH1 
mRNA probe signals per cell. The quantitative data was then compared back to the 
ImageJ method data. Comparing image analysis method showed that only the Colour 
Deconvolution method counted the same number of cells as the ImageJ method, with 
the WEKA method showing the greatest difference (50%) (Table 4.3, Figure 4.7 and 
Appendix B, Table S2). By comparison, when assessing the number of probes counted, 
the WEKA method showed greatest similarity to the ImageJ method (7% difference), 
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and SpotStudio showed the greatest difference (104%). The image analysis method that 
quantified the average number of probes per cell closest to that of the ImageJ method 
was the Colour Deconvolution method (35% difference)), with SpotStudio showing the 
greatest difference (92%). 
 
Figure 4.7 Summary of quantitative measurements from the 10 CRC cases. 




Table 4.3 Summary of the quantitative features quantified by Image Analysis methods using #Photo 1 
of MLH1. 
Method 
Number of Cells 
(Mean +/- SD) 
Number of Probes 
(Mean +/- SD) 
Average Probes per Cell 
(Mean +/- SD) 
ImageJ 100.00 ± 0.0 51.10 ± 41.96 0.51 ± 0.42 
Colour Deconvolution 100.00 ± 0.00 33.40 ± 32.28 0.33 ± 0.32 
SpotStudio 120.8 ± 29.56 104.70 ± 85.02 0.98 ± 0.96 
WEKA 150.1 ± 35.24 47.60 ± 42.68 0.32 ± 0.29 
LEICA 109.0 ± 24.59 81.40 ± 35.90 0.78 ± 0.33 
Abbreviations: SD, Standard deviation 
 
To establish the level of agreement between the four image analysis tools and ImageJ, 
I utilised the Bland Altman method for plotting the data (Altman and Bland, 1983). Bland 
Altman plots are regarded as better measures to assess the agreement of two methods, 
as it measures the difference between these methods and establishes levels of 
agreement. This in contrast to correlation studies that provide a relationship between 
two methods (Giavarina, 2015). 
The Bland-Altman plot is an XY scatter plot with the y-axis showing the difference in 
measurements between the two image analysis methods and the x-axis shows the 
average measurement from the two methods. The horizontal lines were drawn at the 
mean difference and at the upper and lower limits (95% confidence intervals) of 
agreement (LOA). The smaller dashed horizontal line drawn at 0 on the y-axis is the “line 
of equality” and represents no difference in the measurement between the two 
methods. The distance between the mean difference horizontal line and the line of 
equality represents a difference between the two measurements, indicating bias 
associated with the second method. The 95% CI of the mean difference is represented 
as the grey highlighted area drawn about the mean difference. If the 95% CI of mean 
difference does not overlap with the line of equality then there is a significant 
systematic difference in the measurements of the second method. The 95% CI of the 
LOA also provides an indication of the sampling error, for good agreement between the 
methods, 95% of the data points should lie within the LOA. The magnitude of the 95% 
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CI about the mean difference and the LOA show how sampling error can affect the 
measurements, the more precise the sampling, the smaller the 95% CI indicating closer 
precision. 
For these analyses, the ImageJ method was considered the “Reference” method on the 
basis that it allowed cells of interest to be selected for measurement thus avoiding 
potential tumour heterogeneity effects. To determine which image analysis method 
compared similarly to the ImageJ method I assessed the total number of mRNA probe 
signals and the average number of mRNA probe signals per cell. 
Results showed that the WEKA method produced the smallest mean difference (3.5 
mRNA probe signals), that is the least amount of bias for the measurement of mRNA 
probe signals and had the smallest LOA (Table 4.4 and Figure 4.8(c)). SpotStudio method 
produced the greatest mean difference (53.55 probe signals) and the greatest LOA. 
(Table 4.4 and Figure 4.8(b)). The WEKA method was the only method in agreement 
with the ImageJ method. The Colour Deconvolution; SpotStudio and the LEICA methods 
showed a significant difference to ImageJ as their 95% CI of the mean difference did not 
overlap with the line of equality. Determining if these significant differences are 
analytically, biologically, and clinically relevant remains to be determined.  
Table 4.4 Summary of Bland-Altman results for the total number of mRNA probe signals counted by 
image analysis methods versus the ImageJ Method.  




Figure 4.8 Bland-Altman plots comparing different image analysis methods to the ImageJ method for 
the quantification of mRNA probe signals. 




Results showed that the Colour Deconvolution method produced the smallest mean 
difference (0.18 mRNA probe signals) for the average number of mRNA probe signals 
per cell (Table 4.5 and Figure 4.9(a)) while SpotStudio produced the greatest mean 
difference (0.47 mRNA probe signals) (Table 4.5 and Figure 4.9(b)). The WEKA method 
had the smallest range in LOA (Table 4.5 and Figure 4.9(c)) while SpotStudio had the 
largest LOA range (Table 4.5 and Figure 4.9(b)). SpotStudio was the only method to be 
in agreement with ImageJ for measuring the average number of mRNA probe signals 
per cell.  
Table 4.5 Summary of Bland-Altman results for average number of mRNA probe signals per cell for 
various Image analysis methods versus ImageJ method. 
Abbreviations:  CI, Confidence Intervals; LOA, Limits of Agreement 
 
 
Figure 4.9 Bland-Altman plots comparing different image analysis methods to the ImageJ method for 
the quantification of the average number of mRNA probe signals per cell. 




4.4.4 Comparison of mRNA expression levels using qRT-PCR vs Image 
Analysis methods for colorectal cell lines.  
Initial observations from using the image analysis methods on histological samples 
identified a number of issues that could affect the quantification of mRNA expression 
levels. These included determining cell boundaries for overlapping cells (Figure 4.10a); 
differentiating mRNA probe signals from dark staining clumped chromatin (Figure 
4.10b) or prominent nucleoli within cell nuclei (Figure 4.10c), which required careful 
quality control of cells and signals. These observations prompted questions about how 
sensitive and specific the relative image analysis methods are to each other, and how 
accurate are they in comparison to a common diagnostic tool, qRT-PCR. To answer 
these questions, gene expression measurements for MLH1, GFI1, and TNFRSF11A were 
taken from identical cultures of the colorectal cell lines SW480 and WiDr using qRT-PCR 




Figure 4.10 Representative images of potential issues affecting interpretation and quantification of 
cells and mRNA probe signals from FFPE histological sections. 
A) overlapping cells, B) dark granular chromatin, C) prominent nucleoli (examples, indicated by red 
arrows in each figure).  
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Quantitative analysis was performed using the image analysis methods SpotStudio, 
WEKA, LEICA and ImageJ for each cell line. The results for each individual image and 
gene measured are present in Appendix C, Table S3. The parameters measured include 
“The Average Probes per Cell” the “Target/Reference Gene Ratio” and the “Relative 
Expression of PPIB”. 
4.4.4.1 Assessment of gene expression levels as determined by qRT-PCR and image 
analysis methods.  
The level of MLH1, GFI1 and TNFRSF11A mRNA expression present within each of the 
colorectal cell lines, was determined using relative quantification to the housekeeping 
gene, PPIB. A Target/Reference gene ratio of ≥ 1 indicates that there is more target gene 
of interest being expressed than reference gene. A ratio of ≤ 1 indicates there is more 
reference gene being expressed than the target gene of interest.  
A summary of the data from the SW480 and WiDr cell lines for the Target/Reference 
gene ratios generated from qRT-PCR and Image analysis methods for each of the 
respective genes are presented in Figure 4.11 and Appendix C, Table S4. Significant 
differences between the means for all the image analysis methods and qRT-PCR existed 
for each of the individual genes, MLH1, GFI1 and TNFRSF11A in the colorectal cell line 
SW480 and WiDr following ANOVA analysis (Table 4.6).  
Results from Tukey HSD test for MLH1 in the WiDr cell line found the means for all image 
analysis methods to be significantly different (P < 0.05) to qRT-PCR and from each other, 
except between WEKA and LEICA. For GFI1, significant differences existed between qRT-
PCR vs SpotStudio, qRT-PCR vs LEICA, and between LEICA vs WEKA and LEICA vs ImageJ. 
Significant differences existed for TNFRSF11A between qRT-PCR vs LEICA, SpotStudio vs 
LEICA; LEICA vs WEKA and LEICA vs ImageJ. 
Results from MLH1 in the SW480 cell line found the means for all image analysis 
methods were found to be significant different to one another (P <0.05) except for qRT-
PCR vs SpotStudio, qRT-PCR vs ImageJ, and SpotStudio vs WEKA. In GFI1 the means were 
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found to be significantly different for all image analysis methods and qRT-PCR, except 
for qRT-PCR vs LEICA. For TNFRSF11A, results found significantly different except 
between qRT-PCR vs WEKA; qRT-PCR vs ImageJ; SpotStudio vs LEICA and WEKA vs 
ImageJ.  
Observations show a trend for the ImageJ and WEKA methods to have smaller variation 
in measurements compared to the larger variations observed with SpotStudio and LEICA 
image analysis methods (Figure 4.11 and Appendix C, Table S4). It would appear no 
method dominated across both cell lines and for all the respective genes measured to 
produce the closest Target/Reference gene ratios to that of qRT-PCR.  
Results from the WiDr cell line showed that the ImageJ method produced the closest 
Target/Reference gene ratio closest to qRT-PCR for MLH1 (ratio of 0.09 arbitrary units 
(a.u.)) (Figure 4.11(a) and Appendix C, Table S4) while SpotStudio produced the greatest 
difference 0.23 a.u.) (Figure 4.11 (a) and Appendix C, Table S4). For GFI1, the ImageJ and 
WEKA methods (0.0018 a.u.) both produced a ratio closest to qRT-PCR (Figure 4.11 (b) 
and Appendix C, Table S4) while LEICA (0.0119 a.u.) produced the farthest. For 
TNFRSF11A, the SpotStudio (0.0035 a.u.) method produced a ratio closest to qRT-PCR 
(Figure 4.11(c) and Appendix C, Table S4) whilst the LEICA (0.0262 a.u.) produced the 
furthest (0.0262 a.u.).  
Results from the SW480 cell line showed the method that produced the closest 
Target/Reference gene ratio to qRT-PCR for MLH1 was the ImageJ method (0.2205 a.u) 
(Figure 4.11(d) and Appendix C, Table S4) with the LEICA method (0.1546 a.u) the 
farthest. For GFI1, the LEICA method produced the closest ratio (0.0175 a.u) to qRT-PCR 
(Figure 4.11(e) and Appendix C, Table S4) with the WEKA the furthest (0.0842 a.u). For 
TNFRSF11A, the WEKA method produced the closest ratio (0.0003 a.u) to qRT-PCR 
(Figure 4.11(f) and Appendix C, Table S4) with the LEICA method the furthest (0.0054 




Figure 4.11 Target/Reference gene ratios as calculated by qRT-PCR and Image analysis methods. 
(A-C) WiDr cell line MLH1, GFI1, and TNFRSF11A, (D-F) SW480 cell line MLH1, GFI1, and TNFRSF11A (Plots are for the Mean and Standard Error (SEM)). 
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Table 4.6 Summary of ANOVA analysis of gene expression levels as measured by qRT-PCR and image 
analysis methods in colorectal cell lines SW480 and WiDr for MLH1; GFI1 and TNFRSF11A.  
Cell Line Gene ANOVA (p-value) ANOVA (F-statistic) 
SW480 MLH1 <0.0001 33.21 
 GFI1 <0.0001 141.70 
 TNFRSF11A <0.0001 11.08 
    
WiDR MLH1 <0.0001 58.19 
 GFI1 <0.0001 11.42 
 TNFRSF11A <0.0001 10.25 
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4.4.4.2 Correlation of gene expression levels as determined by qRT-PCR and image 
analysis methods. 
A strong correlation was shown between qRT-PCR and all image analysis tools when 
using the Target/Reference gene ratio as a measure of gene expression for all genes in 
both cell lines (Figure 4.12). The method with the highest correlation coefficients was 
ImageJ (r=0.99) followed by SpotStudio (r=0.98); WEKA (r = 0.97) and the LEICA 
method (r=0.95) (Figure 4.12).  
 
Figure 4.12 Correlation of Image Analysis methods vs qRT-PCR for the Target/Reference Gene ratios. 
A) SpotStudio B) WEKA C) ImageJ D) LEICA (Data groupings along x-axis are from left to right, GFI1, 
TNFRSF11A, MLH1 and PPIB).  
4.4.4.3 Comparison of image analysis methods to qRT-PCR for the measurement of 
gene expression levels.  
To determine the level of agreement and bias imparted by the image analysis methods 
for the measurement of gene expression levels relative to qRT-PCR, I constructed 
Bland-Altman plots. For the measurement of Target/Reference gene ratio the Bland-
Altman analysis results are summarised in Table 4.7 and Figure 4.13.  
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Results found that all four image analysis methods had a negative mean difference 
(negative bias) when calculating the Target/Reference gene ratio relative to qRT-PCR 
for all genes across both cell lines. The LEICA method produced the least amount of 
bias -0.0096 a.u. (Table 4.7 and Figure 4.13(d)) with SpotStudio producing the greatest 
-0.0312 a.u. (Table 4.7 and Figure 4.13(a)). The ImageJ method gave the smallest LOA 
with 0.2812 a.u. (Table 4.7 and Figure 4.13(c)), while the LEICA method gave the largest 
LOA 0.5150 a.u. (Table 4.7 and Figure 4.13(d)). Interestingly, from an analytical point 
of view, the 95% CI for both the LEICA and ImageJ methods overlapped with the line 
of equality indicating no significant difference with qRT-PCR measurements. 
Therefore, the LEICA and ImageJ methods could be used as alternative to qRT-PCR. 
Contrastingly, the mean differences of the WEKA and SpotStudio were significantly 
different from qRT-PCR measurements. Whether these differences prevent WEKA and 
SpotStudio from being used an alternative to qRT-PCR for quantifying gene expression 
levels remains to be determined.  
Table 4.7 Summary of the Mean Bias associated with Image analysis methods relative to qRT-PCR 
measurements for Target/Reference Gene Ratios for all genes in SW480 and WiDr cell lines. 





Figure 4.13 Bland-Altman plots for the Target/Ref Gene Ratio as measured by different image analysis 
methods relative to qRT-PCR. 
(A) SpotStudio, (B) WEKA, (C) ImageJ, (D) LEICA. Grey highlighted area represents the 95% CI for the 
Mean difference. 
The Bland-Altman plots for all the image analysis methods showed data-points lying 
beyond the limits of agreement (Figure 4.13), which could affect the mean difference 
(bias) produced by the image analysis methods. It is possible that the mean difference 
(bias) and the outliers produced by each image analysis method maybe dependent on 
the level of gene expression. I therefore investigated how the image analysis methods 
compared to qRT-PCR for measuring genes with differing levels of expression. I did this 
by constructing Bland-Altman plots for each of the image analysis methods for each 
individual gene with the PPIB gene representing a highly expressed gene, MLH1 a 
moderately expressed gene, and GFI1 and TNFRSF11A as both lowly expressed genes. 
Measuring the Target/Reference gene ratio for PPIB, results showed the ImageJ 
method produced the smallest mean difference (1.2e-8)(Table 4.8 and Figure 4.14(c)) 
while the WEKA method produced the greatest mean difference (-1.5e-5) (Table 4.8 
and Figure 4.14(b)). SpotStudio had the smallest LOA. (Table 4.8 and Figure 4.14(a)) 
while LEICA had the greatest LOA (Table 4.8and Figure 4.14(d)). The 95% CI for mean 
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difference for all image analysis methods overlapped with the line of equality (Figure 
4.14). Therefore each image analysis method could be used as an alternative to qRT-
PCR for measuring highly expressed genes.  
Table 4.8 Summary of the Mean Difference associated with Image analysis methods relative to qRT-
PCR measurements for Target/Reference Gene Ratios for PPIB in SW480 and WiDr cell lines. 
Abbreviations: a.u., arbitrary units; CI, Confidence Intervals; LOA, Limits of Agreement 
 
 
Figure 4.14. Bland-Altman plots for the Target/Ref Gene Ratio of PPIB as measured by different image 
analysis methods relative to qRT-PCR.  
(A) SpotStudio, (B) WEKA, (C) ImageJ, (D) LEICA. Grey highlighted area represents the 95% CI for the 
Mean difference. 
For MLH1, results showed the LEICA method produced the smallest mean difference 
(-0.02a.u (Table 4.9 and Figure 4.15(d)), while SpotStudio produced the greatest (-0.12 
a.u.) (Table 4.9 and Figure 4.15(a)). The WEKA method produced the smallest LOA. 
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(Table 4.9 and Figure 4.15(b)) while LEICA had the greatest LOA (Table 4.9 and Figure 
4.15(d)). Only the 95% CI of the mean difference from the LEICA method overlapped 
with the line of equality (Table 4.9 and Figure 4.15(d)). This indicates that the LEICA 
method does not differ significantly from qRT-PCR measurements and could be used 
as an alternative to qRT-PCR for measuring moderately expressed genes. The 95% CI 
of the mean difference did not overlap with the line of equality for remaining image 
analysis methods, SpotStudio, WEKA and ImageJ. This indicates that significant 
differences to qRT-PCR exist for measuring moderately expressed genes. Whether the 
differences are analytically, biologically, clinically relevant remains to be determined. 
Table 4.9 Summary of the Mean Difference associated with Image analysis methods relative to qRT-
PCR measurements for Target/Reference Gene Ratios for MLH1 in SW480 and WiDr cell lines. 





Figure 4.15 Bland-Altman plots for the Target/Ref Gene Ratio of MLH1 as measured by different image 
analysis methods relative to qRT-PCR. 
(A) SpotStudio, (B) WEKA, (C) ImageJ, (D) LEICA. Grey highlighted area represents the 95% CI for the 
Mean difference. 
 
Measuring the Target/Reference gene ratio for GFI1, showed the LEICA method 
produced the smallest mean difference (-0.01 a.u.) (Table 4.10 and Figure 4.16(d)) 
while WEKA produced the greatest mean difference (-0.04 a.u.) (Table 4.10 and Figure 
4.16(b)) SpotStudio produced the smallest LOA (Table 4.10 and Figure 4.16(a)) while 
the WEKA method had the largest LOA (Table 4.10 and Figure 4.16(b)). For all image 






Table 4.10 Summary of the Mean Difference associated with Image analysis methods relative to qRT-
PCR measurements for Target/Reference Gene Ratios for GFI1 in SW480 and WiDr cell lines. 
Abbreviations: a.u., arbitrary units; CI, Confidence Intervals; LOA, Limits of Agreement 
 
 
Figure 4.16 Bland-Altman plots for the Target/Ref Gene Ratio of GFI1 as measured by different image 
analysis methods relative to qRT-PCR. 
(A) SpotStudio, (B) WEKA, (C) ImageJ, (D) LEICA. Grey highlighted area represents the 95% CI for the 
Mean difference. 
Results for TNFRSF11A, showed the SpotStudio produced the smallest mean difference 
(0.0003 a.u.) (Table 4.11 and Figure 4.17(a)) while LEICA produced the greatest mean 
difference (-0.0114 a.u.) (Table 4.11 and Figure 4.17(d)) The method with the smallest 
LOA was the ImageJ method (Table 4.11 and Figure 4.17(c)) while LEICA had the largest 
LOA (Table 4.11 and Figure 4.17(d)). Both SpotStudio and WEKA 95% CI for the mean 
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difference overlapped with the line of equality (Table 4.11 and Figure 4.17(a, b)). This 
indicates SpotStudio and the WEKA methods did not differ significantly from qRT-PCR 
and could be used as alternative methods to qRT-PCR for measuring low expressing 
genes. The ImageJ and LEICA method 95% CI of the mean difference did not overlap 
with the line of equality. This suggests that these methods are significantly different 
to qRT-PCR for the measurement of lowly expressed genes. These results for the 
ImageJ method and the LEICA method were also seen for the measurement of GFI1.  
Table 4.11 Summary of the Mean Difference associated with Image analysis methods relative to qRT-
PCR measurements for Target/Reference Gene Ratios for TNFRSF11A in SW480 and WiDr cell lines. 
Abbreviations: a.u., arbitrary units; CI, Confidence Intervals; LOA, Limits of Agreement 
 
Figure 4.17 Bland-Altman plots for the Target/Ref Gene Ratio of TNFRSF11A as measured by different 
image analysis methods relative to qRT-PCR. 




4.4.4.4 Ranking of Image Analysis method performance across different gene 
expression levels for Target/Reference gene ratio. 
To determine the suitability of each image analysis method, each method was ranked 
according to the amount of mean difference (bias) and LOA produced from Bland-
Altman analysis. This was achieved by using arbitrary scoring system which awarded 
points: 0 point, 1 point, 2 points, or 3 points awarded to each image analysis method 
for each variable measured, with the highest points awarded to the smaller amount 
(Table 4.12). The image analysis methods were then ranked on the total number of 
points accrued. In situations, where two or more image analysis methods achieved the 
same amount of points, then an assessment on the usability of the methods was 
factored in to recommending the more suitable method. 
Table 4.12 Scoring system used for the ranking of image analysis method based on the amount of bias 
and precision achieved.  
 Variables 












3 (Smallest) 3 (Smallest) 
2 2 
1 1 
0 (Largest) 0 (Largest) 
 
Results of this analysis showed a variety of rankings differing between individual genes 
(Table 4.13). The overall performance of the Image Analysis methods would follow a 
ranking of 1st = ImageJ (16 points); 2nd = SpotStudio (14 points); 3rd = LEICA (11 points) 




Table 4.13 Image analysis methods ranked according to the least amount of bias and smallest limits 
of agreement for each respective gene. 










































With respect to PPIB a highly expressed gene, the ImageJ method was chosen to 
allow better visual confirmation of mRNA probe signal detection (Table 4.14). For 
MLH1, a moderate expressing gene, three methods ImageJ, WEKA and LEICA had the 
same number of points. In this instance, two methods were recommended: the 
ImageJ method for its better overall performance for mean bias and LOA, followed 
by the LEICA method which was able to quantify moderate to higher expressing 
genes relatively quickly. Similarly, the LEICA method proved to have better 
performance compared to SpotStudio for detecting mRNA probe signals for GFI1 a 
lowly expressing gene in comparison to MLH1 and PPIB. However, for measuring 
TNFRSF11A, another lowly expressed gene, the ImageJ method performed best with 





The aims of this chapter sought to investigate the level of information RNAscope could 
provide when performed on FFPE histological sections of colorectal cancer cases and 
to determine the suitability of image analysis methods for the detection and 
quantification of mRNA expression levels. Using both histological and cytospin 
preparation of colorectal cancer cell lines, RNAscope was successfully used to detect 
mRNA probe signals for a variety of genes e.g. MLH1 as used in the diagnostic setting 
for determining MSI status; GFI1 and TNFRSF11A as potential gene biomarkers for 
colorectal cancer. A variety of image analysis methods are available for quantifying 
mRNA expression levels, however, further efforts are required to assess their validity.  
4.5.1 Semi-quantitative and Quantitative analysis of RNAscope. 
Identifying and validating tissue-based biomarkers is a difficult proposition given that 
normal tissue comprises a variety of different cell types at various functional states. 
This becomes even more difficult for tumour tissue due to its altered biological state 
with variable expression levels of gene mRNA and proteins. However, this complex 
intra-tissue heterogeneity remains a rich source of potential data to analyse for better 
understanding of biological and functional states of tissue-based biomarkers (Carvajal-
Hausdorf et al., 2014a).  
IHC is often considered the pathology standard for the demonstration of tissue-based 
biomarkers due to its simplicity and low cost to perform. The information produced by 
IHC is predominately used in a binary manner to report the presence or absence of a 
tissue based maker dependent on the context where it is observed. With the 
increasing development of anti-cancer therapies e.g. Herceptin, there will be an 
increasing requirement to quantify biomarkers to triage patients correctly to increase 
their likelihood of a positive response or cure when using such therapies. This has 
relied on developing guidelines by expert panels to standardise the IHC process. 
However, IHC has been slow to move towards providing quantitative measurements 
mainly due to the difficulties associated with the subjective and highly variable nature 
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for determination of expression compounded further with the minimal tissue-based 
standardisation procedures (Carvajal-Hausdorf et al., 2014a; Hamilton et al., 2014). 
The development of novel RNA in-situ technologies such as RNAscope has provided 
the necessary means to investigate RNA as potential tissue-based biomarkers. The 
advantages of RNAscope with its high level signal amplification, multiplexing ability of 
probes, reduced noise whilst retaining tissue morphology allows for quantification and 
co-localisation studies of RNA as potential tissue-based markers that carries biological 
information about function that can be inferred from its location (Carvajal-Hausdorf et 
al., 2014a) . 
This study showed that RNAscope can be used successfully to demonstrate mRNA 
expression levels for MLH1, GFI1 and TNFRSF11A whilst maintaining tissue 
morphology. Using the manufacturer’s stated protocols, no background staining or 
contamination was evident when RNAscope was performed on FFPE histological whole 
slide sections, thus, allowing successful visualization and quantification of mRNA 
expression within cells. This makes RNAscope an attractive method to use for 
investigating tissue based biomarkers producing spatial and contextual information of 
the biomarker.  
At a semi-quantitative level, RNAscope provided an overview of mRNA expression 
levels within 10 CRC samples. Expression patterns were evident in the sample e.g. 
homogenous expression; heterogeneous expression or spatially located expression 
within different cell types. For the genes used it was appreciable that different levels 
of mRNA expression were present between samples and also between different genes 
e.g. MLH1 vs TNFRSF11A. 
Quantitative information can potentially be gathered by combining RNAscope with 
commercial or freeware image analysis software platforms. Benefits of using image 
analysis methods, include the additional information that can be collected beyond 
semi-quantitative data, such as morphological features (e.g. cell and nuclear area, 
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perimeter, diameter, staining intensities) from individual cells and cell types present 
within samples. This information could be collected and used in various situations to 
determine if quantifiable data is associated with clinicopathological features and 
outcomes.  
Quantification of mean mRNA probe signals per cell for the respective genes showed 
varying expression levels. MLH1 was expressed at a higher level compared to GFI1 and 
the lowly expressed TNFRSF11A. Good correlation was achieved between semi-
quantitative and quantitative methods for measuring mRNA expression levels. This 
indicates that the semi-quantitative scoring method provides a good measure of 
mRNA expression and can be used confidently depending on the level of information 
required. Quantified gene expression levels provided the basis for the successful 
application of a “threshold” score to be used to differentiate between cases exhibiting 
mRNA expression from cases that showed no expression. An advantage that this 
quantifiable information provides is that it could be used to set diagnostic thresholds 
for classification, prognosis or predictive purposes. For example, quantifying MLH1 
mRNA expression using image analysis methods could be clinically relevant for 
determining a patient’s MSI status and or differentiating between Hereditary Lynch 
Syndrome and a sporadic form of MSI-H. 
Assessment of mRNA expression levels across different cell types within cases was 
performed. This provided an assessment of the molecular variation or intratumoural 
heterogeneity of mRNA expression between cell types for each sample. For each 
respective gene, the majority of cases displayed higher levels of mean mRNA 
expression in tumour carcinoma epithelial cells compared to normal epithelial cells 
and other cell types (Figure 4.3). Closer analysis of the mean expression levels between 
positive and negative cases at cell-type specific levels showed that differences 
associated in MLH1 mRNA expression for cases are primarily due to the expression 
levels within tumour carcinoma epithelial cells, rather than being affected significantly 
by other cell types. These data also showed GFI1 and TNFRSF11A were expressed at a 
significantly higher level in carcinoma cells compared to non-carcinoma cells 
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(lymphocytes, stromal cells and normal cells). Thus, by analysing tumours at the 
cellular level we were able to demonstrate that reduced mRNA expression levels 
measured in patients with poorer prognosis were specifically due to carcinoma cells 
within the tumour and not due to contamination of tumour samples with non-
carcinoma cells. However, distinguishing cell types is reliant on human interpretation 
of morphological features. Consideration to the location of cells and their possible 
interactions with other cell types with respect to carcinoma cells is required in drawing 
conclusions about intratumoural mRNA expression levels for samples. Therefore, 
targeted location sampling e.g. tumour centre, invasive tumour front, tumour margins 
and distal sites, maybe required. Additionally, the inclusion of specific cell type 
markers as either part of RNAscope multiplexing or with IHC may aid with cell type 
identification.   
Another feature that can be used from the quantification of mRNA expression levels is 
to look at the variability (standard deviation) of expression levels between tumour and 
normal epithelial cells and how that may contribute to gene regulation within samples. 
Furthermore, how does the level of variability between tumour and normal epithelial 
cells correlate with clinical outcomes? Unpublished breast cancer research from this 
laboratory has shown that BRCA1 and BRCA2 does not significantly differ in expression 
levels across all body sites, yet produces the greatest lifetime risk of developing cancer 
in the breast and ovaries (Mr G. Wiggins, personal communication). This research is 
investigating whether the risk between genotype and disease is due to the variation in 
gene expression rather than the amount of gene expression. 
However, there are limitations associated with quantifying the number of mRNA probe 
signals present within each case. These limitations include the heavy reliance on 
human interpretation in differentiating between cell types, and distinguishing mRNA 
signals from other morphological features e.g. nucleoli, chromatin granules, apoptotic 
bodies, and mitotic figures. The subjective nature of visually interpreting these types 
of features and “human error” has been shown to produce inconsistences between 
pathologists and institutions (Hamilton et al., 2014; Irshad et al., 2014). This 
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underscores the high level of training and experience required by pathologists to 
correctly identify tissue and cellular features to reliably make diagnostic decisions from 
complex images (Hamilton et al., 2014). Thereby, this method of manually quantifying 
mRNA signals is potentially subject to bias. To minimize the amount of the bias in this 
study, three images representative of each cell type were used, and 100 cells were 
counted within each image. Moreover, the criteria used to select cells were that the 
cell should be in focus and the cell outlines discernible (or as best fit by the user), 
mRNA probe signals needed to be brown/brown-black, and if a cluster was observed 
an estimate of the number of mRNA signals present was based on the average size of 
neighbouring signals. This method afforded a balance between analysing a 
representative population of cells in a short period of time versus manually annotating 
thousands of cells from numerous images. 
The ability for RNAscope and image analysis methods to produce quantifiable data 
presents opportunities to devise alternative measures of mRNA expression. This could 
be total mRNA expression levels per tumour, total mRNA expression within selected 
tumour regions or through an artificial approach by quantifying mRNA expression 
within a superimposed grid of squares over the image representing known dimensions 
e.g. 10µm = 1 cell per grid square. These measurements may be easier to apply and 
may assist with tumour classification, prognostic/predictive purposes. Furthermore, 
these RNAscope approaches could be used in a complementary manner to IHC to 
provide further information on the relationships between the abundance and the 
location of mRNA and proteins e.g. cytoplasmic IHC staining, membrane IHC staining.  
Therefore, it can be ascertained from this body of work that RNAscope does provide 
both semi-quantitative information akin to IHC, and quantifiable information similar 
to qRT-PCR but has the advantages of providing information relating to intertumour 




4.5.2 Quantitative analysis using different Image analysis methods. 
 
Establishing suitable image analysis platforms for the quantification of mRNA probe 
signals produced by the RNAscope assay, whilst overcoming the limitations associated 
with manual counting would be beneficial to researchers. This study was restricted to 
assessing the following free or low budget image analysis platforms: ImageJ, Colour 
Deconvolution, SpotStudio, WEKA and LEICA RNA ISH v2 algorithm.  
The primary/initial criteria used to assess whether an image analysis platform was 
suitable for use with RNAscope was establishing a level of accuracy by which the image 
analysis platforms quantify the number of mRNA probe signals to a known reference. 
Results showed the WEKA method to be the most accurate method for quantifying the 
total mRNA probe signals and had the smallest range of LOA indicating greater 
precision than other methods. These results collectively resulted in the WEKA method 
to be the only image analysis method to lie within agreement with ImageJ. In contrast, 
Colour Deconvolution > LEICA > and the SpotStudio showed significant differences to 
ImageJ for quantifying mRNA probe signals.  
For quantifying the mean mRNA probe signals, SpotStudio was the only method to lie 
in agreement with ImageJ. However, the Colour Deconvolution method and WEKA 
method had the smallest amount of bias. WEKA had the smallest range for LOA, 
indicating greater precision compared to the Colour Deconvolution method. A 
technical difficulty encountered in the haematoxylin stained sections was 
differentiating between brown DAB mRNA probe signals from dark haematoxylin 
chromatin granules within the cell nuclei. It is known that the haematoxylin and the 
DAB stains have overlapping spectral wavelengths (Ruifrok and Johnston, 2001) so that 
one stain “bleeds” into the other which makes visually distinguishing between DAB 
and haematoxylin difficult in instances where a section has been overstained. Spectral 
separation can resolve this to a certain degree.  
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From the 10 CRC cases, the Colour Deconvolution bias was relatively close in 
agreement to ImageJ for quantifying the average number of mRNA probe signals. 
Colour Deconvolution method works by requiring settings to be optimised 
(thresholding) by visually inspecting the image to see if particles are sufficiently 
selected within the image. This will affect the sensitivity and specificity of counting of 
the particles (an element of over-counting or under-counting exists with results 
produced). Advantages that Colour Deconvolution offer are 1) the compatibility with 
the ImageJ platform (freeware), 2) images produced can be saved for future analysis, 
3) regions of interest can be inspected, saved and overlaid onto original versions of 
image, and 4) the ability for the workflow processes to be programmed into a macro 
for future work (Table 4.14).   
SpotStudio is an automated image analysis platform that was released as a 
complementary image analysis platform with the release of RNAscope in 2012. 
Variable results for the number of cells and probes counted were obtained using this 
software tool. I observed large differences in counts between the SpotStudio and the 
ImageJ method. SpotStudio produced a negative bias when quantifying total number 
of mRNA probe signals and average number of mRNA probes signals per cell relative 
to ImageJ. The magnitude of bias produced by SpotStudio was larger in magnitude 
compared to other image analysis methods. SpotStudio also displayed more 
variability in quantifying mRNA signals with the 95% limits of agreement having a 
large range and the plots showed a trend for increasing differences with increasing 
average. The performance of SpotStudio can be explained by the initial observations 
involving difficulties faced when differentiating between dark chromatin granules 
from DAB signals, nucleoli being classified as clusters, and segmentation of cells. 
Minimising the effects of these difficulties was achieved by performing quality 
control on the cells and excluding them from the final count. Despite this, the 
performance of SpotStudio was significantly different to ImageJ. Further optimisation 
of settings is required to improve the SpotStudio performance measuring the 
number of cells and probe signals to obtain equivalent results to that of ImageJ. 
However, SpotStudio did provide a feature that could be advantageous in providing a 
measure of heterogeneity which involved counting and placing the number of cells 
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expressing x-number of mRNA signals into respective “bins” based on the number of 
signals per cell (Table 4.14).  
The WEKA image analysis platform performed overall the best with regards to 
accuracy to ImageJ. Furthermore, the limits of agreement and standard error 
associated with WEKA were the smallest, providing greater consistency/certainty. A 
key advantage of WEKA is its machine learning capability allowing for ongoing 
training of the classifier to segment cells and mRNA probe signals (Table 4.14). A 
probability map of the classifier can be used to assess the performance of the 
classifier as a means of quality control, this allows adjustment of settings to better 
select, mRNA signals and cells. Visually inspecting the WEKA method performance, 
showed no gross discrepancies in segmenting and classifying objects in this study at 
the minimum probability of 80%. A further advantage that WEKA provides is that it 
can be trained on a stack of images to develop a more representative classifier. This 
could then be used on large numbers of images, or at different times to minimise 
inter-assay variability. However, a limitation that future studies will need to be aware 
of is that the resulting images produced by WEKA, still require further processing by 
turning the images into a binary format before the mRNA probe signals and cells can 
be counted using the ImageJ analyse particles function. This will be time dependent 
on how well the WEKA classifier was setup to begin with.  
The LEICA RNA ISH algorithm performs in a manner similar to WEKA with the user 
able to control for a multitude of cellular and mRNA probe signal features to train the 
algorithm to detect and identify cells and mRNA probe signals (Table 4.14). From the 
results, the LEICA RNA ISH algorithm performed comparatively well to ImageJ. This 
tool also had a smaller range of limits of agreement and standard deviation 
compared to SpotStudio which is a similar automated image analysis platform. A 
limitation associated with results from the LEICA RNA-ISH algorithm is that the 
images used were captured using microscopy facilities available within the University 
of Otago Christchurch, and not an APERIO Slide Scanner. The RNA –ISH algorithm has 
been designed to be primarily used with the APERIO Slide Scanners taking into 
186 
 
consideration specific slide setup including brightness and focus of the scanner. 
However, it is possible to use the LEICA RNA-ISH algorithm on digital images from 
other microscopes (Ms Marie-Louise Loupart, personal communication). To ensure 
that the LEICA RNA-ISH algorithm is able to operate at a high level of accuracy on 
digital images from the Zeiss Apotome microscope, I ensured that correct Koehler 
illumination was set on the microscope to provide optimal brightness and focus for 
the taking of digital images. 
Assessing the various image analysis platforms based on accuracy and user ability, the 
following methods would be recommended from this study: WEKA and the LEICA RNA-
ISH algorithm. The reason for recommending the WEKA method is that it provides a 
more standardised method to follow if working with a small set of images. WEKA also 
provided the closest agreement to ImageJ with greater consistency achieved with 
smaller bias and limits of agreement. However, WEKA still requires an investment in 
time and user input in training the classifier and post-processing images for 
quantification of mRNA signals and cells. This method maybe more suited to lower 
expressing genes and a smaller set of images. Recommending the automated LEICA 
RNA-ISH algorithm may be more appropriate for quantifying expression levels in 
higher expressing genes or for a larger set of images The LEICA RNA-ISH algorithm 
compared well to ImageJ. Although similar to WEKA in requiring the user to invest time 
in setting-up the algorithm, it does not require any post-processing steps before 
quantification. Alongside the general quantifiable information relating to number of 
cells and mRNA probe signals present the LEICA RNA-ISH algorithm also provides 
quantifiable information that can be used for heterogeneity purposes by binning the 
number of cells based on predefined number of mRNA probe signals present.  
4.5.3 Comparing qRT-PCR vs RNAscope + Image analysis methods. 
The method, qRT-PCR, is a highly sensitive and specific method for the quantification 
of RNA level from samples (Nolan, Hands and Bustin, 2006). The aim of this experiment 
was to compare quantitative gene expression data between qRT-PCR and RNAscope 
using different image analysis platforms.  
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Assessing which image analysis method produced the Target/Reference gene ratios 
closest to qRT-PCR, ImageJ method returned the closest while the LEICA method 
returned the furthest across both cell lines. Determining whether WEKA or SpotStudio 
was most similar to the ImageJ method was cell line dependent. WEKA performed 
better on the WiDR cell line, while SpotStudio performed better for the SW480 cell 
line. A possible explanation for this observation, was the heavier use of quality control 
on the original SpotStudio segmentation results. SpotStudio had the tendency to 
incorrectly detect and segment cells along with mRNA probe signals, possibly due to 
staining variations and differentiation of cells. The quality control process helped 
produce a closer range of values similar to qRT-PCR. The ImageJ and WEKA methods 
measurements had the least variation/spread compared to the more automated 
image analysis methods of SpotStudio and LEICA. This reflects that the ImageJ and 
WEKA methods rely strongly on visual confirmation of what is perceived to be a true 
mRNA probe signal and the segmentation of cells present in the sample. Conversely 
the SpotStudio and LEICA are more automated and rely on the chosen algorithms to 
establish segmentation of cells using the average distances between cell nuclei for 
segmentation of cells and the use of stain intensity for the detection of the mRNA 
probe signals. Overall, strong correlation coefficients(r > 0.95) for all image analysis 
methods across both colorectal cell lines were achieved which is comparable to other 
studies comparing RNA-ISH results with qRT-PCR (Wang et al., 2013; Porichis et al., 
2014). 
To better compare the level of accuracy from a diagnostic perspective, Bland Altman 
analysis method was used. Results from this analysis showed that when calculating the 
Target/Reference gene ratios for all genes in the SW480 and WiDr cell lines, the LEICA 
RNA ISH method imparted the least amount of bias. However, this tool had the 
greatest range for its LOA reflecting more variability in producing results. However, the 
mean bias attributed by the LEICA method was not found to be significant from an 
analytical point of view suggesting that the LEICA method could be used as an 
alternative to qRT-PCR. The ImageJ method was the second best with the least amount 
of bias but had the smallest range for its LOA compared to all the other methods, 
reflecting better consistency with its precision of measurements. My results indicate 
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that the ImageJ method could be used as an alternative to qRT-PCR. The WEKA method 
followed by SpotStudio were the next methods with the least amount of bias. Data 
from both methods showed a significant difference when compared with results from 
qRT-PCR. Whether this significant difference in measurements is clinically relevant 
remains to be determined.   
Observations from the Bland-Altman plots (Figure 4.13), showed a trend associated 
with all the image analysis methods, that the difference in gene expression 
measurements increased as the average increased along with the variation in data-
sampling points This is a reflection of the different levels of expression for each of 
the genes, with MLH1 and PPIB being the more highly expressed genes compared to 
GFI1 and TNFRSF11A, which was found when the results were stratified on the basis 
of gene expression levels. The magnitude of the trend suggests that the suitability of 
different image analysis methods for RNAscope analysis may be dependent on gene 
expression levels of target genes. To determine which image analysis method 
performed the best in relation to individual genes and overall, I adopted a points 
scoring system to rank the image analysis methods performance. No image analysis 
method was clearly superior to others. For PPIB, MLH1 and GFI1, two or more image 
analysis methods returned the same amount of points predominately ImageJ and 
SpotStudio but either WEKA or LEICA also performed to a similar level. This provides 
the user with the option of selecting between image analysis methods. Choosing 
between two image analysis methods may require the user to factor in the intended 
use of the image analysis method and the advantages and disadvantages of the 
methods, time per analysis and cost, Table 4.14. For example, the user may prefer to 
have greater control and visual confirmation of mRNA probe signal detection and 
choose ImageJ or WEKA based methods, while the LEICA method may be more 
desirable for high throughput quantification of mRNA probe signals and cells 
involving high expressing genes. However, this did not apply for the TNFRSF11A gene 





Table 4.14 Summary of the differences between Image analysis methods.  
 
Abbreviations: semi, semi-automated. 
Further work is necessary to optimise and confirm these initial recommendations for 
suitable image analysis methods to use with RNAscope. One possibility is to select the 
best features of the analysis platforms and use them in a combination approach with 
one another e.g. colour deconvolution for segmenting cells and WEKA for counting 
mRNA probe signals. This example was recently described as standard workflow 
approach in a recent webinar from the manufacturer of RNAscope (ACD). This may 
satisfy usability and improve performance for quantifying RNAscope assays.  
To minimise inter-assay variability, further steps will involve the standardisation and 
automation of RNAscope protocols that can be deployed onto current clinical used IHC 
platforms e.g. Roche Ventana Benchmark ULTRA System. Additionally, the 
manufacturer has introduced further control probes that are specific for target genes 
with low-expressing RNA that can be included to resolve technical interpretation of 
signal abundance and detection. Image analysis methods/platforms will also need to 
undergo robust validation of their performance to accommodate inter-assay 
variability. Finally, expert panels or accreditation bodies will be required to finalise 
protocols for RNAscope and image analysis methods/platforms before being 
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introduced into routine clinical settings. Together, these steps will greatly assist 
towards providing a high level of sensitivity and specificity for performing RNAscope 
and image analysis on numerous tissue types. 
Together these results show that RNAscope combined with image analysis methods 
can produce results similar to qRT-PCR for quantification of mRNA expression levels of 
genes. Using Bland Altman analysis I showed that LEICA produced the least amount of 
bias and gave results that were most comparable to qRT-PCR, followed by the ImageJ 
method. By comparison WEKA method and SpotStudio methods had mean bias levels 
that were deemed to be most dissimilar to qRT-PCR results. Taking into account 
advantages and disadvantages, and the operation of the methods, these results 
suggest that any of the image analysis methods could be used depending on the 
expected gene expression levels and the research/clinical question being asked of 
RNAscope. For example, the LEICA method would be more suited to measuring the 
mRNA levels of moderate to highly expressing genes, while the ImageJ method is more 
appropriate for lowly expressing genes. ImageJ and the WEKA method may be more 
appropriate when specificity is important while LEICA and SpotStudio more 





RNAscope can be successfully used for the investigation of mRNA expression in FFPE 
sections and cultured cell-lines for lowly expressed genes in CRC. RNAscope combined 
with image analysis platforms can be used in a similar manner to qRT-PCR to elucidate 
further quantifiable information to assess the level and interactions of mRNA 
expression within a tissue dependent context.  
Further examination of cases displaying positive or negative mRNA expression using 
RNAscope showed statistically significant differences in mean mRNA expression levels. 
This presents a potential use for attributing threshold levels to distinguish between 
positive and negative tumour cases and their clinicopathological outcomes. 
Additionally, although a level of tumour heterogeneity existed in our cases, results 
show the low levels of mRNA expression in other cell types had minimal effect on 
influencing mRNA expression levels in carcinoma cells for positive and negative 
tumour cases. RNAscope also provides a measure of tumour heterogeneity which 
could also be useful as a prognostic biomarker of disease. Thus, RNAscope and image 
analysis can help researchers investigate the genotype-phenotype relationships by 
integrating genomic descriptors of tissue with image-derived data. Such studies have 
the potential to improve our understanding of the biologic basis of disease and refine 





Chapter 5. TNFRSF11A siRNA gene Knockdown 
5.1 Introduction. 
Results from Chapter 3 showed significant associations for negative TNFRSF11A mRNA 
expression and various clinicopathological features associated with poor prognostic 
outcomes. These associations identified by RNAscope were consistent with those 
reported by the TCGA paper and also from the reanalysis of the TCGA data downloaded 
from the cBioPortal website. This shows the versatility of the RNAscope assay to 
validate microarray and RNA-seq findings using FFPE material.  
TNFRSF11A was a key candidate selected on the basis that is was the first gene listed in 
the TCGA study (The Cancer Genome Atlas Network, 2012) that was associated with 
poor CRC prognosis by reduced expression and copy number alterations at 18q. 
Deletion of 18q is known to be necessary in colorectal tumorigenesis (Al-Sohaily et al., 
2012; Grady and Pritchard, 2014; Kudryavtseva et al., 2016).  
5.1.1 TNFRSF11A Gene function. 
TNFRSF11A also known as RANK belongs to the Tumour Necrosis Factor Receptor 
(TNFR) superfamily (Owen et al., 2013; Renema et al., 2016). It is a transmembrane 
receptor for the RANK ligand (RANKL). Binding of the RANKL to TNFRSF11A initiates the 
trimerization of TNFRSF11A and leads to the activation of the Tumour Necrosis Factor 
receptor (TNFR) associated factor (TRAF) dependent signalling pathways. The level of 
activation is controlled by osteoprotegrenin (OPG), a decoy receptor for RANKL which 
blocks interactions between RANKL and TNFRSF11A (Owen et al., 2013; Renema et al., 
2016). TNFRSF11A has been shown to be involved in the development of tumorigenesis 
and metastasis, especially to the bone in a variety of cancers (Renema et al., 2016). 
Breast and prostate cancer with high TNFRSF11A expression has been associated with 
poor prognosis and for those patients with bone metastases (Zhang et al., 2012; Park et 
al., 2014; Pfitzner et al., 2014). However, with osteosarcoma, reduced TNFRSF11A 
expression was associated with better overall survival although no difference was found 
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between TNFRSF11A expression status and response to chemotherapy (Trieb and 
Windhager, 2015). In contrast, the TCGA 2012 study has shown that reduced 
TNFRSF11A expression was associated with poor prognostic features (The Cancer 
Genome Atlas Network, 2012). The reason for these contrasting results is unclear. No 
information is currently available from in-vitro studies regarding the role of TNFRSF11A 
in colorectal tumorigenesis or its involvement with the TNFRSF11A /RANKL/OPG 
signalling pathway in colorectal cancer. However, limited information is available from 
an in-vivo study. Santini et al investigated the level of TNFRSF11A expression in a series 
of solid tumours and their associated bone metastases. For colorectal cancer, they 
found TNFRSF11A to be expressed in the majority of tumour cells (median 75%) within 
primary tumours and at a similar level (60% of cells) in matched bone metastasis, and 
this was a similar finding in other solid tumours (Santini et al., 2011). Interestingly, 
TNFRSF11A expression has been shown to be elevated in the colonic mucosa of patients 
with Crohn’s disease, however, expression appeared more prevalent in T-lymphocytes 




5.2 Hypotheses and Aims. 
This study was designed to investigate how the reduction of TNFRSF11A expression in 
colorectal cancer lines affects cell proliferation, viability and migration. This was done 
to replicate the reduced TNFRSF11A expression levels and the associations with poor 
prognostic outcomes as observed in the TCGA and RNAscope cohorts in order to better 
understand the role that TNFRSF11A plays in CRC tumorigenesis.  
My hypotheses are that reduced TNFRSF11A expression produces an increase in cell 
proliferation and migration in colorectal cancer cell lines.  
Specific Objectives were as follows: 
1) Establish siRNA gene knockdown of TNFRSF11A in WiDr colorectal cell line. 
 
2) Perform gene knockdown of TNFRSF11A in WiDr colorectal cell line, and 
measure cell viability, proliferation and migration.  
 







5.3 Methods and Materials. 
5.3.1 siRNA gene knockdown. 
Gene knockdown of TNFRSF11A was performed on the WiDr cell line using the methods 
described in Chapter 2. Briefly, the TNFRSF11A siRNA constructs were combined with 
the transfection reagent, RNAiMAX, and added in a forward transfection manner to 
WiDr cells according to the manufacturer’s instructions (Section 2.7.2). Cells were 
harvested and collected for qRT-PCR analysis. 
5.3.2 qRT-PCR analysis. 
RNA extraction was performed as described in Section 2.9, followed by cDNA synthesis 
using the Invitrogen Superscript III Universal qPCR FAST kit (Section 2.10). qRT-PCR was 
then performed as specified in Section 2.11.   
5.3.3 Cell-based Functional Assays. 
Cultured WiDr cells were seeded into plates and left for 24hrs to settle and attach 
before siRNA transfections were performed on the cells as specified in Section 2.7.2. 
Cell proliferation was performed using the CyQuant NF assay (Molecular Probes, 
Invitrogen Corp., USA) according to the manufacturer’s instructions (Section 2.8.1). Cell 
viability was confirmed using the MTT assay as specified in Section 2.8.2. Measurements 
for both assays were performed using a Varioskan® Flash microplate reader (Thermo 
Scientific, Waltham, MA, USA). Cell migration was performed using the scratch test 





5.4.1 Optimisation of TNFRSF11A siRNA gene knockdown in WiDr 
colorectal cells. 
Optimisation experiments were carried out to determine which siRNA construct 
achieved maximum gene knockdown in the WiDr colorectal cell line at different 
concentrations. Results from qRT-PCR analysis showed siRNA gene knockdown of 
TNFRSF11A expression correlated with increasing siRNA concentrations (Figure 5.1). For 
siRNA construct #1, a maximum gene knockdown of 99% was achieved using a 
concentration of 10nM. For siRNA construct #2 maximum gene knockdown of 83% was 
achieved with 20nM, whilst siRNA construct #3 had a maximum of 92% at 30nM (no 
results were returned for the siRNA construct #2 at 30nM and for siRNA construct #3 at 
50nM). However, variation was observed between siRNA concentration levels and 
between siRNA sequence types. From the initial optimisation of the siRNA constructs, 
the siRNA construct #1 was selected for future experiments for its ability to achieve 
maximum levels of gene knockdown at the lowest concentration. 
 
Figure 5.1 TNFRSF11A expression levels following siRNA transfection using three different siRNA 
constructs at varying concentrations.  
Further optimisation assays were performed to replicate the initial optimisation results 
and to determine which siRNA concentration gave optimal gene knockdown. Results 
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showed that the average gene knockdown across the different siRNA concentrations 
was 30-35% (Figure 5.2), which differed significantly from the previous experiment. The 
variation in gene knockdown encountered between optimisation assays prompted a 
review of the siRNA transfection procedure and qRT-PCR analysis. Areas that were 
focused upon were RNA extraction methods. 
 
Figure 5.2 Remaining gene expression levels of TNFRSF11A following 48 hour siRNA transfection at 
varying siRNA concentrations for siRNA construct#1 (n=3 experiments, Mean ± SEM).  
5.4.1.1 Trouble-Shooting siRNA knockdown experiments. 
Observations from qRT-PCR analysis showed instances of poor amplification curves, 
high Cp values for both PPIB and TNFRSF11A, and invalid results being returned for 
some assays. One of the possible reasons identified related to the effectiveness of the 
RNA extraction method used, as a change in RNA extraction methods had been made 
on the basis of reagents costs. This change had occurred between the second and third 
optimisation assay. The first two optimisation assays had used the QIAGEN RNeasy Mini 
kit (QIAGEN), while the third optimisation assay used the RNAGEM TissuePlus 
(RNAGEM) method in combination with the RNAlater reagent (see Materials and 
Methods Chapter, Section 2.9).  
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A comparison between the different RNA extraction methods was performed to 
determine if comparable qRT-PCR results could be produced. The following 
comparisons were made between RNA extraction kits:  
 QIAGEN method versus RNAGEM method  
  QIAGEN + RNAlater method versus RNAGEM + RNAlater method.  
Results produced by the QIAGEN and RNAGEM methods show that the RNAGEM 
method returned TNFRSF11A gene expression levels two-fold higher relative to the 
QIAGEN method (Figure 5.3). However, when the RNAlater reagent is added prior to 
RNA extraction using the two methods, the results showed that RNAGEM + RNAlater 
extraction method returned TNFRSF11A gene expression levels three-fold smaller to the 
QIAGEN + RNAlater extraction method.  
 
Figure 5.3 TNFRSF11A gene expression levels generated by qRT-PCR using different RNA extraction 
methods (Mean + SEM, with three technical replicates). 
To verify that the two extraction methods without the addition of RNAlater reagent 
could be used to produce similar qRT-PCR results from a gene knockdown experiment, 









































































that >50% gene knockdown was detected when using different RNA extraction methods 
(Figure 5.4). No statistical difference between gene knockdown using the TNFRSF11A 
siRNA 10nM was detected between the two methods (P = 0.13, CI -0.30 – 0.06). 
 
Figure 5.4 TNFRSF11A gene expression levels generated from qRT-PCR analysis for samples transfected 
with siRNA using different RNA extraction methods (Mean + SEM, n=1 with 3 technical replicates). 
Results from this troubleshooting exercise identified that both the QIAGEN and 
RNAGEM extraction methods returned similar qRT-PCR results from samples 
transfected with or without siRNA. Additionally, the use of RNAlater produced qRT-PCR 
results with great variability especially when used with the RNAGEM method. Taking 
into consideration these results, reagent costs and time, it was decided to proceed with 
the use of the RNAGEM extraction method without the use of RNAlater.  
5.4.2 Cell Based Functional Assays. 
Previous results from Chapter 3 showed that in our patient cohort, reduced TNFRSF11A 
mRNA expression was associated with poor prognostic features such as metastasis and 
nodal involvement (Chapter 3, Table 3.6). This was in keeping with those findings from 
the TCGA dataset downloaded from the cBioPortal. To investigate the phenotypic 
changes of reduced TNFRSF11A mRNA expression on colorectal epithelial cells, an in-
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vitro model was developed and assessed using cell based functional assays for cell 
proliferation and migration.  
The WiDr colorectal cell line was chosen from Chapter 4 to use due to its higher level of 
TNFRSF11A mRNA expression compared to the SW480 cell line. Therefore, the effects 
from performing TNFRSF11A siRNA would produce a greater reduction in TNFRSF11A 
mRNA expression and result in significant detectable changes to cell proliferation, 
viability and migration.  
5.4.2.1 Cell Proliferation. 
An 80% reduction in TNFRSF11A mRNA expression was achieved in the WiDr cells 
transfected with 10nM of TNFRSF11A siRNA construct#1 for 48 hours (Figure 5.5).  
 
Figure 5.5 TNFRSF11A expression levels in WiDr colorectal cancer cells following 10nM TNFRSF11A 





Cell viability showed no significant differences (P = 0.99) after 48 hours following 
TNFRSF11A siRNA transfections between the various sample conditions (Figure 5.6).  
 
Figure 5.6 Cell Viability of WiDr colorectal cancer cells following a 48 hour TNFRSF11A siRNA 
transfection relative to Cells only (Mean ± SEM, n =2, 3 technical replicates for each sample). 
Cell proliferation following siRNA transfections showed no statistical significant 
difference (P = 0.61) between the mean CyQuant NF fluorescence for the respective 
samples (Figure 5.7). This shows that despite an 80% gene knockdown of TNFRSF11A 
mRNA expression no change in cell proliferation was induced.  
 
Figure 5.7 Cell Proliferation of WiDr colorectal cancer cells following a 48 hours TNFRSF11A siRNA 
transfection (Mean ± SEM, n =2 Experiments, 3 technical replicates for each sample).  
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5.4.2.2 Cell Migration. 
To investigate if the WiDr colorectal cell line displays a natural tendency for cells to 
migrate, a scratch-test assay was performed on WiDr cells free of siRNA.  
Results from the scratch test assay showed that the WiDr cells showed little to no 
natural migratory activity across the wound (Figure 5.8) when cultured in different FBS 
concentrations. The amount of wound closure after 24 hours post-scratch showed no 
statistically significant difference between the different FBS concentrations (P = 0.85, CI 
-7.39 – 8.18) (Figure 5.9).  
 
Figure 5.8. Representative images of wound closure for WiDr cells cultured in different FBS conditions. 
A) FBS positive control (DMEM + 10% FBS) at 0hrs, B) FBS positive control (DMEM+10%FBS) at 24hours 




Figure 5.9 Summary of wound closure (%) after 24 hours for WiDr cells with different FBS 
concentrations. 
The scratch-test (wound closure) assay was performed to measure the cell migration 
rate following TNFRSF11A siRNA transfection. Results showed that a gene knockdown 
was achieved with the cells transfected with TNFRSF11A siRNA with a 20% reduction in 
TNFRSF11A mRNA expression (Figure 5.10). 
 
Figure 5.10 Gene expression of TNFRSF11A in WiDr colorectal cancer cells following 24 hour siRNA 
transfection (n= 1, Mean + SEM, 3 technical replicates). 
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Observations made between the baselines photos and the various time-points showed 
no discernible evidence of cell migration occurring (Figure 5.11). The amount of wound 
closure at 8 hours and 24 hours post-scratch showed no statistically significant 
differences between samples transfected with TNFRSF11A siRNA and control samples 
((P = 0.98 and P = 0.25) (Figure 5.12)). 
Observations from performing the initial scratch-test (wound closure) assay for cell 
migration showed that non-treated cell, and cells treated with a negative siRNA control, 
did not migrate into the wound area.  
 
Figure 5.11 Representative images of wound closure following 24hr siRNA transfection. 
A – C) Control siRNA at 0hrs; 8hrs and 24hrs. D – F) 10nM TNFRSF11A siRNA at 0hrs; 8hrs and 24hrs. 
 
Figure 5.12 Summary of wound closure (%) for WiDr colorectal cancer cells at 8hrs and 24hrs following 




In this chapter, in vitro studies were used to investigate the effects of reduced 
TNFRSF11A mRNA expression on colorectal cancer cell phenotype and function. Using 
the colorectal WiDr cell line, siRNA were transfected into cells to produce a level of 
transient knockdown of TNFRSF11A mRNA expression. The reduced TNFRSF11A 
expression produced no significant differences in cell proliferation, viability or 
migration.  
5.5.1 Optimisation of siRNA in WiDr colorectal cell line. 
Advantages from using siRNA include the ability to investigate post-transcriptional gene 
function and the development of gene-based therapeutics (Elbashir et al., 2001; Singh, 
Trivedi and Jain, 2018). This has led to intensive research in using siRNA as part of RNA-
interference methods to treat cancer by suppressing tumour cell growth and invasion 
(Singh, Trivedi and Jain, 2018). However, there are technical factors that affect the 
siRNA delivery and associated effects on the expression of the targeted gene within a 
cell that need consideration. Such factors include designing siRNA target sequence to 
avoid unwanted off-target effects, choosing appropriate delivery systems, and 
obtaining stability by avoiding nuclease degradation (Alagia and Eritja, 2016; Fakhr, Zare 
and Teimoori-Toolabi, 2016). 
To address these factors, I choose the Stealth RNA interference siRNAs manufactured 
by Invitrogen. The benefits of using the Stealth siRNAs are that they offer high levels of 
gene knockdown, reduced off-target products, greater siRNA stability offering longer 
periods of knockdown and less cellular toxicity (ThermoFisherScientific, 2018). This type 
of siRNA had previously been successfully used to knockdown TNFRSF11A for studying 
the interactions of TNFRSF11A/TNFSF11 and the development of drug resistance in 
multiple myeloma cell lines (Tsubaki et al., 2016). The Stealth siRNA platform comprises 
of three different siRNA constructs that target different exons of the TNFRSF11A gene. 
The constructs can either be pooled or used individually to effect gene knockdown. 
Initial attempts using the siRNA constructs individually were encouraging, showing that 
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each construct produced gene knockdown >70% after 48 hours, although at differing 
concentrations.  
Verification of the initial optimisation results was performed using the siRNA construct 
#1. Further optimisation assays were performed to achieve consistent levels of gene 
knockdown at a consistent concentration. Results from these assays showed that the 
level of gene knockdown lowered from the initial optimisation assay of >90% gene 
knockdown to an average of > 34% gene knockdown. The amount of variation appeared 
similar across the various siRNA concentrations. The reducing effects of gene 
knockdown over the first three optimisation experiments prompted a review of the 
siRNA transfection process and qRT-PCR analysis to identify possible sources of 
variation that could be responsible for the reduced levels of gene knockdown. 
Reviewing the optimisation assays methods identified a change in RNA extraction 
methods had occurred, which could have been the main source for the inconsistent 
results. This involved changing from the QIAGEN RNasy kit to using the RNAGEM 
TissuePlus method with the addition of RNAlater. Changing methods had been made on 
the basis of cost and in-house laboratory results from another project demonstrating 
similar levels of gene knockdown being detected using the RNAGEM TissuePlus kit 
(personal communication George Wiggins).  
Comparing extraction methods showed that the addition of RNAlater greatly affected 
the amount of RNA extracted, particularly with the use of RNAGEM method. This is 
important for a lowly expressed gene that is being knockdown to be able to reliably 
detect it. Reassuringly, the TNFRSF11A/PPIB (Target/Reference) expression ratios 
between QIAGEN and RNAGEM were not significantly different from each other when 
no RNAlater was added. It was found that the level of gene knockdown following 
TNFRSF11A siRNA transfection was comparable between the two extraction methods, 
with >50% gene knockdown achieved. This retrospectively confirmed that changing 
RNA extraction methods was possible, but not when you add RNAlater.   
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5.5.2 The effects of TNFRSF11A siRNA transfection on cell proliferation 
rate of WiDr cells. 
Results from TCGA study (The Cancer Genome Atlas Network, 2012) and those from 
Chapter 3 showed that reduced TNFRSF11A mRNA expression was associated with poor 
prognostic outcomes for patients with colorectal cancer. Results from the patient 
cohort used in Chapter 3 specifically showed that reduced TNFRSF11A mRNA expression 
was associated with the presence of metastasis and nodal involvement.  
Cancer cell lines are an important preclinical model that provide insights into the 
molecular and biological nature of tumour cells (Mouradov et al., 2014) (Ahmed et al., 
2013). Cell proliferation assays provide a simple and effective means to investigate cell 
phenotypic behaviour in response to stimuli. The main hypothesis proposed, is that 
reduced TNFRSF11A mRNA expression would lead to an increase in colon cancer cell 
proliferation, which may contribute to the clinicopathological features of increased 
colon tumour grade and aggressiveness predisposing to metastasis.  
Results from the cell proliferation assays showed no statistically significant difference 
in cell proliferation between negative controls and cells transfected with 10nM 
TNFRSF11A siRNA after 48 hours. Cell viability results showed no significant differences 
between the different cell conditions, showing that the transfection conditions did not 
affect cell viability. This implies that the various reagents e.g. lipid concentration of the 
RNAiMAX had no detrimental effect on cell viability that would cause cell toxicity.  
Interestingly, there was a trend for reduced cell proliferation following siRNA 
transfection. It would be beneficial to continue this experiment over a longer time point 
to establish if this is a true reduction in cell proliferation. My cell proliferation results 
may represent the start of this phenomenon. If a true reduction in cell proliferation 
existed then the main hypothesis would be rejected. The alterative hypothesis would 
suggest cell proliferation behaviour alone is not a true reflection of the 
clinicopathological associations and that other mechanisms may be involved for 
example, the bioavailability of RANKL and OPG and their effects on the 
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TNFRSF11A/RANKL/OPG signalling axis or that for colorectal cancer cells to metastasis, 
the cells undergo epithelial mesenchymal (EMT) transition, where by the cells stop 
proliferating and dedifferentiate to become motile. 
5.5.3 The effects of TNFRSF11A siRNA transfection on cell migration of 
WiDr cells. 
The simplicity and low cost of performing the scratch-test (wound closure) made it an 
attractive method to use to measure cell migration, over more sophisticated methods 
e.g. transwell migration assays/ Boyden chamber (Yue et al., 2010). The main hypothesis 
was that a reduction in TNFRSF11A mRNA expression would promote cell migration in 
colorectal cancer cells reflecting metastatic behaviour.  
Establishing the baseline migration rate for WiDr was performed in a separate scratch–
test experiment. WiDr cells were cultured in either serum-starved conditions to 
promote cell migration or in normal cell culture conditions before performing the 
scratch-test. Results showed almost identical, minimal amounts of wound closure with 
no statistically significant difference found for the migration of WiDr cells in different 
culture conditions.  
Results from the scratch-test following TNFRSF11A siRNA transfection also showed 
minimal amounts of wound closure. No statistical significant difference between the 
negative control and cell samples transfected with TNFRSF11A siRNA after 24hours was 
found, although a trend showing slower cell migration for cells transfected with siRNA 
versus negative samples was observed. My results, from both sets of scratch-test 
assays, contrast with those from the literature that showed WiDr cells ability to migrate 
(Lachmann et al., 1988; Ochiumi et al., 2006). Studies have shown the WiDr cells to 
migrate in various conditions. For example, Suboj et al observed that baseline migration 
of WiDr cells cultured under similar conditions following 24hrs in the scratch-test assay 
approached 28%. Similarly, WiDr cells when stimulated to migrate in the presence of 
PMA, the amount of migration increased to 44% compared to control cells (Suboj et al., 
2012). Therefore, further experiments using WiDr and a different cell migration assay 
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may help clarify the rate of migration expected.  In addition, performing these assays in 
the presence of RANKL, OPG and/or a combination of RANKL and OPG together, may be 
necessary to fully understand the role of TNFRSF11A as a transmembrane receptor on 
colorectal cancer cells. 
Similar to the cell proliferation results, it would be interesting to see if these results 
were to become significant over a longer time-period. However, this would require 
consideration to which migration assay may be more appropriate for a longer-time 
period as cell migration measurements after 24 hours can be influenced by cell 
proliferation. Therefore, adopting the use of a transwell migration method may be 
beneficial in this instance and may have been better to investigate phenotypic changes 
in response to TNFRSF11A knockdown. For example, the transwell migration assay may 
have been better to study migration over a longer period of time in either response to 
higher serum concentrations or in the presence of TNFRSF11A’s ligand, RANKL, or in 
combination with RANKL and OPG or by with OPG alone. Furthermore, the transwell 
migration assay could be modified to study the invasion capability of WiDr cells and how 
this affects cell motility (Kramer et al., 2013). Alternatively, generation of a stable 
TNFRSF11A knockdown colorectal cell line with the use of a shRNA lentiviral or CRISPR-
Cas9 systems would provide uniform knockdown of TNFRSF11A and assist with the 
investigation of cell migration and time-dependent effects. 
Whether reduced TNFRSF11A mRNA expression promotes cell migration may be cell-
line specific. The selection of the WiDr cell line was originally chosen in the previous 
chapters based on its molecular phenotype reflecting a specific molecular pathway 
known to be involved in CRC development. The WiDr cell line is a colon adenocarcinoma 
from a female patient of 78 years of age, DNA fingerprint evidence shows that the WiDr 
cell line is a derivative of the HT-29 cell line (ATCC website). Key molecular characteristic 
of HT-29/WiDr cell lines are that they are MSI-S, CIMP positive; harbour BRAF v600E 
mutation and mutations in other well-known cancer genes e.g. APC and PIK3CA (Ahmed 
et al., 2013; Mouradov et al., 2014). More detailed information from gene expression 
profiling studies has further added to the classification of colorectal cancer patients for 
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prognostic and predictive purposes (Budinska et al., 2013; De Sousa et al., 2013; Marisa 
et al., 2013; Sadanandam et al., 2013; P Roepman et al., 2014; Guinney et al., 2015) and 
led to a better understanding of the biological nature of these colorectal cancers 
(Linnekamp et al., 2018). One such classification system is the Consensus Molecular 
Subtype (CMS) proposed by the Colorectal Cancer Subtyping Consortium (Guinney et 
al., 2015), which places HT-29/WiDr into CMS3 subtype (Berg et al., 2017). The CMS3 
subtype is categorised by significant differences in metabolic deregulation; KRAS 
mutations, mixed MSI status, low chromosomal alterations, and CIMP low compared to 
the other CMS subtypes (Guinney et al., 2015). Furthermore, the gene expression 
profiles of CMS3 colorectal cancers appeared closest to the gene expression profile of 
normal tissue (Guinney et al., 2015). Morphology of WiDr cells are epithelial and well 
differentiated (Berg et al., 2017), which have different gene set enrichment compared 
to undifferentiated colorectal cells (have higher EMT gene-set).  
Therefore, my results using the WiDr cells could be considered representative of the 
CMS3 subtype. The lack of migration of the WiDr cells may closely resemble the 
behaviours of normal colorectal epithelial cells before tumorigenesis given that WiDr 
cells are representative of CMS3 subtype which have gene expression profiles similar to 
normal tissue. Alternatively, the reduction of TNFRSF11A expression may be a 
tumorigenesis promoting event. Performing gene knockdown of TNFRSF11A in a normal 
colorectal cell line would be of interest to establish this possibility rather than using 
cancer cells that have already been transformed. As noted above, TNFRSF11A is lowly 
expressed in alternative cell lines, such as  HT-29 (Sveen et al., 2018), and may be too 
low to demonstrate phenotypic changes. Alternatively, overexpressing TNFRSF11A 
within the WiDr colorectal cell line could also have provided insights into the function 
of TNFRSF11A and CRC tumorigenesis.  
Interestingly, my results imply that the results from the TGCA and RNAscope assessed 
cohort of colorectal cancer patients are not that of the CMS3 subtype, but may reflect 
other subtypes. Applying the CMS classification to the original TCGA results would be of 
interest to determine if the reduced TNFRSF11A mRNA expression associated with poor 
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prognostic outcomes is specific to a particular subtype. This would allow better 
selection of colorectal cell lines to better understand the tumorigenesis process for that 
subtype. Newer classification systems may help better understand CRC biology. For 
example, the CRIS classification system has reportedly performed better than the CMS 
for patient prognostication (Alderdice et al., 2018). 
Another explanation for the results produced, and a possible limitation with the 
experiments, is that the time period was not sufficient enough to observe the 
phenotypic effects of reduced TNFRSF11A mRNA expression on the TNFRSF11A/RANKL 
signalling axis within cells. RANKL binds to TNFRSF11A which leads to intracellular signal 
transduction of the TRAF dependent signalling pathways e.g. PI3K/Akt/mTOR and 
MAPK. The level of activation is controlled by the decoy receptor, OPG, which binds to 
RANKL. OPG reduces the bioavailability of RANKL, inhibiting the intracellular signalling 
transduction of RANKL/TNFRSF11A.  
The TNFRSF11A/RANKL signalling axis is predominately involved in controlling bone 
remodelling and immune responses. Disturbances to this axis have been shown to occur 
in leading to tumour development in a variety of cancers (Gonzalez-Suarez et al., 2010; 
Palafox et al., 2012; Casimiro et al., 2013; Liu et al., 2016). RANKL and OPG can be 
produced by cancer cells and cells within the tumour microenvironment (Ito et al., 2003; 
Renema et al., 2016). Disturbances in favour of RANKL/TNFRSF11A activation leads to 
tumour development, progression and metastasis through induction of ‘stemness’ and 
EMT (Odero-Marah et al., 2008; Casimiro et al., 2013; Renema et al., 2016) . Whereas, 
disturbances in favour of OPG prevents tumour cell apoptosis by binding to TNF related 
apoptosis inducing ligand (TRAIL), thus providing a pro-survival benefit to cancer cells 
(Holen et al., 2002; Renema et al., 2016).   
With respect to colorectal cancer, limited information is available regarding the role of 
TNFRSF11A in tumorigenesis or its involvement with the TNFRSF11A/RANKL/OPG 
signalling pathway. Most studies to date have focused upon OPG protein expression (Ito 
et al., 2003; De Toni et al., 2008; Tsukamoto et al., 2011; Vik et al., 2014). These studies  
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have reported that OPG levels in serum found in higher levels in CRC and for hepatic 
and soft-tissue metastases (Lipton et al., 2002; De Toni et al., 2008; Vik et al., 2014). A 
statistically significant increase in serum OPG levels between Stage 3 and Stage 4 was 
observed (De Toni et al., 2008). This was also reported for OPG mRNA expression 
(Tsukamoto et al., 2011). With overexpression of OPG present at the invasive front of 
colorectal cancer tumours observed (Tsukamoto et al., 2011). This may be a protective 
feature against apoptosis for when cells are beginning to metastasize (De Toni et al., 
2008), and may represent the transition into a progressive and metastatic disease 
(Tsukamoto et al., 2011). High OPG protein expression in gastric cancer has been 
associated with advanced stages, invasion and nodal metastases and poor overall 
survival (Ito et al., 2003). Colorectal cancer cell lines variably express OPG at basal levels 
and can be induced to secrete more OPG in response to pro-inflammatory cytokines 
(typically from stromal fibroblasts and macrophages), which can block TRAIL-induced 
apoptosis providing colorectal cancer cells with a cell-survival advantage (Pettersen et 
al., 2005). OPG can block RANKL, which prevents RANKL-TNFRSF11A activation leading 
to downregulated B-cell maturation, differentiation and antibody response. OPG 
binding to RANKL on T-cells and TNFRSF11A on dendritic cells disrupts survival, OPG 
disrupts myeloid progenitor cell proliferation (Pettersen et al., 2005). OPG within 
colorectal cell lines is regulated by the Wnt/β-catenin pathway (De Toni et al., 2008). 
Whether the increased expression levels in OPG corresponds to a decrease in 
TNFRSF11A (and RANKL) expression remains to be determined. However, Santini et al 
reported the presence of positive TNFRSF11A protein expression in colorectal cancer 
and their matched bone metastases in 13 colorectal cancer patients (Santini et al., 
2011). This contrasts with the findings of the TCGA paper (The Cancer Genome Atlas 
Network, 2012) and my results presented in Chapter 3, which found reduced 
TNFRSF11A mRNA expression associated with poor prognostic outcomes.  
Further efforts are necessary to address technical factors that arose from this study to 
confirm the initial findings. Future studies may need to consider taking a systems 
approach to better understand TNFRSF11A interactions with RANKL and OPG along with 
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utilising a number of cell lines that represent the molecular CRC subtypes to represent 
the heterogeneous nature of CRC. Further investigations involving the effects of 
TNFRSF11A knockdown on protein levels within colorectal cell lines and patient cohorts 
could also help clarify these observations by providing information about RNA and 
protein expression within tumours and molecular CRC subtypes. 
5.6. Conclusion. 
In this study, results show TNFRSF11A mRNA expression levels within WiDr colorectal 
cells could be reduced using siRNA. The reduction of TNFRSF11A mRNA expression 
levels did not promote the phenotypic changes of increased tumour cell proliferation 
and cell migration of WiDr colorectal cells that are believed to closely represent the 
clinicopathological features of increased tumour grade and the presence of metastasis 
along with nodal involvement. The significance of the results are cell-line specific and 
possibly reflect the consensus molecular subtype, CMS3 of colorectal cancer.  
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Chapter 6. General Discussion. 
The presence or absence of a pathological feature in a tumour (e.g. TNM status) has 
been the mainstay of cancer prognostics in a clinical setting. It has proven difficult to 
find biomarkers that can distinguish between phenotypically similar tumours, for 
guiding treatment of patients. Therefore, it is unlikely for us to be able to develop a 
prognostic biomarker feature using a “one size fits all” approach.  
New molecular technologies (e.g. next-generation sequencing) have helped improve 
our molecular understanding of colorectal cancer, and revealed its complex 
heterogeneous nature. Numerous studies have tried to categorise colorectal cancer 
into molecular subtypes in order to identify distinct genes that could be used as 
biomarkers for diagnostic, prognostic, and predictive purposes. However, to date there 
has been a lack of reproducibility between these studies, as well as a paucity of gene 
biomarkers being translated into the clinical setting. A primary reason for these 
challenges is likely the effects of tumour heterogeneity. The development of RNAscope 
technology (Wang et al., 2012) has enabled researchers to investigate RNA expression 
in single cells, to understand how different genes contribute to the development of CRC 
while taking into account tumour heterogeneity. 
The principal goal of this thesis was to investigate whether the use of RNAscope could 
be used to investigate RNA expression of candidate gene markers in relation to CRC 
phenotype. This study resulted in several outcomes: 1) the establishment of the 
RNAscope assay within our laboratory (Chapter 3), 2) technical validation of the 
technology by comparing with IHC (Chapter 3), 3) biomarker validation by comparing 
RNAscope associations with clinicopathological features with those derived using 
publically available microarray findings (Chapter 3), 4) a comprehensive evaluation of 
image analysis methods for determining their usability with RNAscope (Chapter 4), and 
5) a functional assessment of the candidate prognostic biomarker, TNFRSF11A, in an in 
vitro CRC cell line model (Chapter 5).  
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6.1 Chapter 3: RNAscope. 
RNAscope was successfully performed on a small cohort using whole FFPE sections from 
CRC tumours. Visualisation of mRNA expression levels within cells with no loss of 
morphology was easily achieved, thus demonstrating a relatively robust protocol for 
performing RNAscope. 
To investigate the capability of RNAscope as a new diagnostic method it was compared 
to IHC using MLH1 as the diagnostic comparator. Although documented that mRNA 
expression levels may not correlate with protein levels based on a number of factors 
(Chen et al., 2002; de Sousa Abreu et al., 2009), the results between RNAscope and IHC 
for MLH1 showed overall good concordance, although some discordance was 
encountered. Further analyses of MLH1 expression in relation to methylation and 
pathogenic variant status would provide a more comprehensive assessment of 
RNAscope sensitivity and specificity for identifying patients with Lynch syndrome. 
Unlike IHC, RNAscope is not affected by post-translational changes to the protein so 
may have utility resolving equivocal MLH1 IHC cases. Improved diagnostic methods for 
identifying people who are at high-risk of cancer will have important clinical implications 
for patient management and determining appropriate surveillance periods.  
6.1.1 RNAscope assessment of GFI1 and TNFRSF11A mRNA expression 
levels in CRC patient cohort. 
Assessing GFI1 and TNFRSF11A as potential biomarkers in a CRC patient cohort using 
RNAscope produced significant associations, similar to those identified in the TCGA 
study (The Cancer Genome Atlas Network, 2012) and its datasets. The results from this 
study also show the utility of selecting genes on the basis of CNA as a means to 
standardize gene selection and avoid limitations with tumour heterogeneity to validate 
gene biomarkers. The negative expression of GFI1 and TNFRSF11A mRNA in the various 
cohorts is likely driven by reduction in copy number in a significant proportion of the 
cases. However, such a relationship was not investigated in the tumours from this study. 
Selection of these candidate prognostic gene biomarkers led to associations being 
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observed between mRNA expression and clinicopathological features for both the 
RNAscope and the reanalysed TCGA (microarray) cohorts in this study.  
To confirm that the RNAscope findings for GFI1 and TNFRSF11A are representative for 
colorectal cancer patients, a future study involving a larger sample size would be 
warranted. The initial RNAscope patient cohort of 112 patients was reduced to 69 
colorectal adenocarcinoma cases based on the amount and abundance of RNA present 
within each patient sample. Increasing the sample size to a similar level as the TCGA 
study or greater would provide greater confidence in how representative the initial 
RNAscope findings are for colorectal cancer patients. To further this confidence, 
inclusion of more recent FFPE specimens would potentially minimise the number of 
samples excluded on the basis of RNA abundance. Alternatively, the inclusion of fresh-
frozen tumour specimens into the patient cohort could increase numbers and minimise 
RNA abundance issues. This would also provide another level of comparison to the TCGA 
study, which had performed the microarray analysis on fresh-frozen material only (The 
Cancer Genome Atlas Network, 2012). 
RNAscope analysis of candidate gene biomarkers that have previously been shown to 
be overexpressed or underexpressed in genome-wide studies would provide a further 
opportunity to evaluate the usability of this technology to test such biomarkers. For 
example, focal amplifications of ERBB2 and IGF2 from the TCGA study (The Cancer 
Genome Atlas Network, 2012) indicate that these genes may be candidate markers. 
Moreover, ERBB2 and IGF2 act in pathways which may be therapeutically targeted with 
cetuximab and PI3K pathway inhibitors (e.g. alpelisib), respectively (Demuth et al., 
2017; Janku, 2017).  
6.2 Chapter 4: RNAscope combined with Image Analysis. 
There is an increasing need to provide quantification measurements of a biomarker to 
ensure patients are placed on the correct treatment (Carvajal-Hausdorf et al., 2014a; 
Hamilton et al., 2014) or clinical trials (Schalper, 2014). Unfortunately, quantifying 
tissue-based biomarkers with IHC has been slow and difficult due to limitations 
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associated with subjective interpretation, technical variation and methodology, and 
lack of validated antibodies (Bordeaux et al., 2012; Carvajal-Hausdorf et al., 2014a), all 
of which are affected by tumour heterogeneity (Potts et al., 2012; Hamilton et al., 2014).  
Image analysis can play a significant role in tissue-based biomarker research providing 
standardised quantifiable data, automation and improved productivity and efficiency. 
Therefore, combining the image analysis techniques with the molecular data produced 
by RNAscope may allow the identification of new prognostic and predictive tissue-based 
biomarkers (Budinská et al., 2015).  
This thesis study demonstrated the successful application of image analysis with 
RNAscope to investigate and quantify mRNA expression in FFPE sections and cultured 
cells for lowly expressed genes at a cell-specific level. Incorporating image analysis 
methods with RNAscope was also shown to provide quantifiable data to a similar level 
to that obtained using qRT-PCR. The advantages of quantifying gene expression levels 
at a single cell level is that it could be used to set diagnostic thresholds for classification, 
prognosis or predictive purposes. Similar examples include HER2/CEP 17 ratio 
determined by ISH methods to establish HER2 status for Herceptin treatment (Rakha et 
al., 2015; Wolff et al., 2018). In CRC, tumour mutational burden levels >11 mutations 
per megabase has been shown to identify additional patients that would benefit from 
PD1/PD-L1 checkpoint inhibitors that would have been missed with current testing 
methods (Allgäuer et al., 2018; Fabrizio et al., 2018). Similarly, RNAscope could be used 
to provide a quantified level of PD1/PD-L1 mRNA expression within the colorectal 
cancer tumour. Quantified levels of PD1/PD-L1 mRNA expression could then be 
correlated to the tumour response and survival outcomes for patients treated with 
PD1/PD-L1 checkpoint inhibitors to determine diagnostic thresholds. This would 
primarily focus on patients with dMMR status and/or advanced stages of colorectal 
cancer based on their favourable response to PD1/PD-L1 checkpoint inhibitors e.g. 
pembrolizumab (KEYNOTE-16 Phase 2 trial) (Le et al., 2017) and nivolumab and low-
dose ipilimumab (CHECKMATE-142 trial) (Overman et al., 2018). This patient cohort 
could also be stratified by germline dMMR status versus sporadic dMMR status to 
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establish if differences exist in treatment response and survival outcomes. It has been 
suggested that the tumour mutational burden is lower in germline dMMR CRC patients 
compared to sporadic dMMR CRC patients and may explain the variation in treatment 
response for dMMR CRC patients with PD/PD-L1 checkpoint inhibitors (Kalyan et al., 
2018). To provide a comprehensive overview, the patient cohort could be extended to 
include patients with proficient MMR status. Another example involving 
immunotherapy agents that RNAscope could be useful in providing quantified levels of 
RNA expression to set diagnostic thresholds for, is the use of indoleamine 2,3-
dioxygenase (IDO) inhibitors. IDO is an enzyme involved in the conversion of L-
tryptophan into L-kynurenine. Abnormal accumulation of L-kynurenine affects the 
immune response by arresting Tcell growth and inducing Treg suppression proliferation 
(Brandacher et al., 2006; Kalyan et al., 2018). High IDO expression, based on a semi-
quantitative IHC score (proportion and intensity), has been associated with lower CD3+ 
tumour infiltrate and worse poor prognosis (with metastasis to the liver) (Brandacher 
et al., 2006; Kalyan et al., 2018). FDA trials are currently underway investigating the use 
of an IDO1 inhibitor as stand-alone therapeutic agent for treating colorectal cancer 
patients, as well as in combination with pembrolizumab and aziticidine in MSI-stabe 
colorectal cancers (Clinical trial -NCT02959437) (Kalyan et al., 2018).  
RNAscope with image analysis allows further exploration of gene expression–tumour 
phenotype relationships by integrating the mRNA expression levels and location with 
morphological and architectural features. The advantage of this approach, is firstly, the 
ability to assess and better understand gene function and pleiotropic role in 
tumourigenesis and disease progression (Gonzalez-Suarez and Sanz-Moreno, 2016). 
Secondly, information inferred from the spatial relationships and localisation of mRNA 
expression across different cell types can be analysed for associations with disease 
phenotype and clinical outcomes (Carvajal-Hausdorf et al., 2014a). Thirdly, refinement 
of tumour classification can be achieved by taking into account the effect of tumour 
heterogeneity (Dunne et al., 2017). Fourthly, using intra-tumoural heterogeneity as a 
prognostic marker is also feasible (Morris et al., 2016), working on the general 
hypothesis that tumours with greater heterogeneity are more likely to give rise to a 
metastatic or treatment resistant clone leading to worse prognosis in the majority of 
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cancer types (Gay, Baker and Graham, 2016; Morris et al., 2016). Interestingly, the 
contrary is found in colorectal cancer patients with MSI-H status. These patients have a 
higher tumour mutational burden and better prognosis compared to those colorectal 
cancer patients with MSI-stable or low status. However, the rationale for using 
intratumoural heterogeneity as a prognostic marker is still warranted, and needs 
further investigation for colorectal cancer patients. This could be achieved with 
RNAscope combined with image analysis methods to provide an intratumoural 
heterogeneity score, similar to those produced by SpotStudio or the LEICA RNA-ISH 
algorithm. These intratumoural heterogeneity scores could then be correlated to 
treatment responses and survival outcomes of colorectal cancer patients to determine 
the feasibility of using intratumoural heterogeneity scores as prognostic and or 
predictive markers for colorectal cancer.  
Limitations associated with using image analysis methods within this thesis centred on 
cell and nuclei segmentation and mRNA probe signal detection. These are well 
documented issues (Arganda-Carreras et al., 2014; Hamilton et al., 2014; Budinská et 
al., 2015) and are often resolved by manually tracing structures or regions of interest, 
but this is a time consuming process creating delays in image analysis results (Arganda-
Carreras et al., 2014). Open-source and commercial software programmes have 
automated this process, although challenges associated with accuracy and validation 
remain, particularly when compared to human eye perception for manual counting 
(Gurcan et al., 2009; Arganda-Carreras et al., 2014; Hamilton et al., 2014).  
Results from my study showed that each of the image analysis methods produced 
quantifiable data that lay in agreement or very close to the reference standard that it 
was measured against for assessing accuracy. Interestingly, no single method was 
superior to others for measuring mRNA expression levels across different specimens. 
Each method displayed strengths and weaknesses in detecting, segmenting and 
quantifying objects. Therefore, evaluation of image analysis systems depends on the 
ultimate objective that it is being employed for (Gurcan et al., 2009). Alternatively, using 
a combination of image analysis methods provides the best means to answer a research 
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questions e.g. colour deconvolution for segmenting cells and the WEKA for detection of 
mRNA probe signals. Despite the limitations identified, combining image analysis with 
RNAscope makes RNAscope an attractive alternative for translating tissue-based 
biomarkers, as the technology provides method standardisation and quantification, 
particularly when there is a need for companion diagnostics (Bordeaux et al., 2012; 
Carvajal-Hausdorf et al., 2014b). However, clinical implementation of image analysis 
methods will centre on accuracy, usability with minimal manual input/supervision, time 
per analysis and costs. Further assessment of image analysis tools could include tissue 
type segmentation and classification methods. This could provide spatio-temporal 
information, relating the gene expression within tumour cells relative to surrounding 
tissue cell types. Additionally, investigating how gene expression patterns are 
distributed within the tumour tissue (e.g. homogenous versus heterogeneous, or focal 
areas versus whole areas of distribution) could provide a simple method for clinicians 
to use when interpreting gene expression for use in companion diagnostics.  
6.3 Chapter 5: TNFRSF11A siRNA gene Knockdown. 
The successful repurposing of the osteoporosis inhibitor, Denosumab, as a potential 
therapeutic treatment for the management of breast cancer bone metastasis has seen 
renewed research interest in the TNFRSF11A/RANKL/OPG pathway (Gnant et al., 2015; 
Nolan et al., 2016; de Groot et al., 2018). The ranking of TNFRSF11A as 12th highest 
ranked gene associated with poor prognostic outcomes from the TCGA study (The 
Cancer Genome Atlas Network, 2012) was an interesting finding when the majority of 
colorectal cancer cases metastasize to the liver. Surprisingly, there is limited 
information available regarding the specific role of TNFRSF11A in colorectal 
tumorigenesis or its involvement with the TNFRSF11A/RANKL/OPG signalling pathway. 
Overexpression of TNFRSF11A has been associated with bone metastases and poor 
prognostic outcomes in prostate and breast cancer (Casimiro et al., 2013; Li et al., 2014; 
Nolan et al., 2016; Sigl, Jones and Penninger, 2016). TNFRSF11A protein overexpression 
has been associated in patient matched primary and metastatic colorectal cancer cases 
to the bone (Santini et al., 2011). Results of this thesis and those of TCGA (The Cancer 
Genome Atlas Network, 2012) are in contrast to these studies and showed negative 
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TNFRSF11A mRNA expression associated with poor prognostic outcomes. This suggests 
negative TNFRSF11A mRNA expression alters the TNFRSF11A/RANKL/OPG signalling 
pathway to produce different biological responses in colorectal cancer compared to 
other cancers affecting the body. Alternatively, negative TNFRSF11A is indicative of 
metastasis to the liver versus a metastasis to the bone. Finally, the results from the 
RNAscope and TCGA may potentially relate to a colorectal cancer molecular subtype(s).  
Investigating these associations using siRNA TNFRSF11A knockdown on the WiDr cell 
line did not result in an increased cell proliferation or cell migration as was initially 
hypothesised. These results are potentially cell-line specific findings and confirm the 
molecular heterogeneity of CRC. Molecular characterisation of cell lines found the WiDr 
cell line to be representative of the CIMP-pathway (Ahmed et al., 2013; Mouradov et 
al., 2014) and of the CMS3 subtype (Guinney et al., 2015; Berg et al., 2017; Sveen et al., 
2018). Therefore, the results from the RNAscope cohort (Chapter 3) may be 
representative of a particular molecular pathway and subtype. The inclusion of 
additional cell lines in further studies would be beneficial to confirm whether the initial 
findings involving WiDr cell line are indeed cell line specific and reflect particular CMS 
subtypes and molecular pathways. For example, to establish if differences in TNFRSF11A 
mRNA expression is related to CMS subtype, the following cell lines could be included, 
Colo205 for the CMS1 subtype, EB for the CMS2 subtype and Colo678 for the CMS4 
subtype. Collectively, these cell lines are representative of the CIMP pathway as well 
(Berg et al., 2017). To investigate if differences in TNFRSF11A mRNA expression are 
related to molecular subtype, the inclusion of MSI-H cell lines that are representative of 
CMS subtypes as well could include DLD-1 for CMS1 subtype, CCK-81 for CMS2 subtype, 
CL-34 for CMS3 subtype and HCT116 for CMS4 subtype (Berg et al., 2017; Linnekamp et 
al., 2018). Inclusion of a normal colorectal epithelial cell line (e.g. CCD-841) is necessary 
to provide information as to how differences in TNFRSF11A mRNA expression levels and 
phenotypic responses relate to tumour development. Another potential means of 
assisting with this approach would be to reanalyse the TCGA patient datasets and 
stratify according to CMS and molecular subtypes. This would help confirm if reduced 
TNFRSF11A mRNA and poor prognostic outcomes were associated with all or certain 
molecular subtypes. From this information, selection of a colorectal cell line 
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representative of a particular molecular subtype would be possible. Further 
confirmation could be sought by compiling various gene expression studies from the 
GEO data repository and investigating TNFRSF11A mRNA expression and its associations 
with clinicopathological features. 
 
Furthermore, published results from an in vitro model suggest the role of TNFRSF11A in 
tumorigenesis is closely linked with the RANKL and OPG signalling pathway at a cellular 
level and within the tumour microenvironment (Renema et al., 2016). A possible 
explanation is that TNFRSF11A/RANKL interactions on carcinoma cells promotes an 
inflammatory state within the tumour microenvironment, facilitating the recruitment 
of tumour associated macrophages to further promote tumour growth and progression 
(Kianercy and Pienta, 2016). Co-culturing colorectal cancer epithelial cells, subjected to 
TNFRSF11A siRNA knockdown, with macrophages in a transwell system would help 
replicate this scenario. Measurement of protein and mRNA levels along with cell-
signalling pathway assays would provide insight into the TNFRSF11A/RANKL/OPG cell 
signalling pathway interactions and their effects on cell migration and metastasis. This 
could confirm whether the negative TNFRSF11A mRNA expression in the RNAscope and 
TCGA cohorts are due to direct interactions with RANKL, or indirectly through the 
upregulation of the OPG. To collectively study these effects over a longer period of time 
may also require repeated transfections of TNFRSF11A siRNA or the use of lentiviral 
shRNA or CRISPR-Cas9 systems to produce a stable level of negative TNFRSF11A mRNA 
expression in cells.   
6.4 Future Directions. 
There are a number of applications/research questions that presented themselves 
during the course of this thesis that could be investigated further in the future. The good 
concordance between RNAscope and IHC for MLH1 raises the possibility that RNAscope 
could be used in a similar manner to IHC. For CRC, RNAscope could be used for the 
determination of MMR status in suspected cases of Lynch syndrome. No information 
regarding family history, MSI status, DNA status or methylation status was available for 
the patient specimens used in this thesis. Therefore, a future study involving RNAscope 
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could be performed on a patient cohort of colorectal cancer cases with known and 
suspected deficient MMR status. Information regarding family history, MSI status, DNA 
status or methylation status would be included to assist with determining RNAscope 
sensitivity and specificity relative to IHC and qRT-PCR for determining MMR status. 
Additionally, RNAscope does offer alternative possibilities to further examine 
discrepant cases between RNAscope and IHC to help decipher the biological causes 
behind them. A positive IHC and negative RNAscope result may suggest that a germline 
pathogenic missense variant is present which codes an amino acid substitution in the 
protein that is conserved and still antigenically reactive to the antibody developed. 
Conversely, a negative IHC and positive RNAscope result could suggest that post-
translational modifications have occurred e.g. methylation. 
Recently, the novel probe design of RNAscope has been incorporated into ACD newest 
in-situ hybridisation assay called BaseScope™. BaseScope can detect RNA species 
targets down to 50 bases in length. This allows targeting of exon junctions for assessing 
splicing, nucleotide variants and gene fusions. The significance of this new assay for 
colorectal cancer patients suspected of dMMR status is the ability to determine 
whether variants show allele-specific expression and therefore indicate pathogenicity. 
The clinical implications with using RNAscope and BaseScope is that they could assist 
diagnosis of Lynch syndrome and resolve colorectal cancer cases previously placed into 
Lynch-like Syndrome or Familial Colorectal Cancer Type-X groups (i.e. patients with a 
strong familial history but no germline mutations). This would affect the clinical 
management and treatment of colorectal cancer patients. Information from these 
technologies may also identify patients with sporadic dMMR (hypermethylation) 
colorectal cancer that may benefit from receiving immunotherapy checkpoint 
inhibitors. Additionally, clinical trials are underway looking at combination therapy 
using demethylating agents e.g. azacitidine with pembrolizumab (NCT02959437).  
Another approach is to perform RNAscope and IHC on the same slide to determine 
MMR status, thus providing both molecular and protein information on the specimen. 
This may assist with resolving equivocal IHC staining if mRNA expression was 
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demonstrated to be present. Multiplexing of RNAscope probes could also be achieved 
with either fluorescent (4-12 probes) or chromogenic (2 probes) probes. This could 
allow all the MMR genes to be analysed from the one specimen slide. Equally, the 
multiplexing capability of RNAscope could allow for the development of a diagnostic 
panel of RNA targets. Such a diagnostic panel could be employed in the future to 
characterise a colorectal cancer subtype (e.g. CMS molecular subtypes), determine 
prognosis and/or predictive for treatment, and help differentiate histologically difficult 
lesions (e.g. sessile serrated adenomas/polyps from traditional serrated adenomas and 
hyperplastic polyps). 
The quantifiable data produced by RNAscope and image analysis methods provides 
further opportunities to investigate the use of mRNA expression thresholds for 
diagnostic, prognostic and or predictive purposes. Further investigations with 
RNAscope and image analysis could involve generating quantified mRNA expression 
levels of the candidate gene biomarkers for each case in the patient cohort. The WEKA 
or LEICA image platforms could be used to quantify levels of mRNA expression for each 
case. This quantified data could be collated and inspected to determine if a threshold 
for mRNA expression levels of the candidate gene biomarkers are associated with 
clinicopathological features. Additionally, the level of heterogeneity (H-score) for each 
case could be produced and investigated for associations with clinicopathological 
features. The number of associations found with using quantified data could be 
compared to the semi-quantitative scoring system to determine the relative 
performance of the scoring systems. The information from the quantified data could be 
used to adjust the semi-quantitative scoring system if required. Quantified data from 
RNAscope could be correlated with the quantified expression levels generated from 
microarray and RNA-seq platforms to determine the compatibility of quantified data 
from RNAscope with these methods.  
Further uses of quantifiable mRNA expression levels, produced by RNAscope and image 
analysis, includes the investigation of the spatial distribution of RNAscope probes in 
association with clinicopathological features and patient outcomes. Mapping and 
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computational modelling of spatial distribution of RNAscope/BaseScope data could 
provide information on the time of subclonal appearance and its relative fitness in 
relation to driver mutations (Baker et al., 2017). This could provide important 
information for treatment management decisions and monitoring of residual disease 
for treatment resistance. With the development of whole slide scanners and automated 
image analysis platforms, these types of investigations could become more feasible and 
straightforward as evident with the release of 10xGenomics Visium Spatial Gene 
Expression Solution platform (Pleasanton, CA) and the Nanostring GeoMx™ Digital 
Spatial Profiler (Seattle, WA) which incorporates RNAscope’s RNA probe design into its 
system. In time, these investigations may be incorporated into the diagnostic pathology 
workflow. 
6.5 Summary conclusion. 
The work presented in this thesis highlights the ability of RNAscope to investigate mRNA 
expression levels of genes whilst taking into account tumour heterogeneity. Combining 
a gene selection process using CNA with RNAscope provides an alternative method to 
assess and validate potential gene biomarkers. This study also demonstrated that the 
use of different image analysis methods with RNAscope requires careful selection to 
obtain accurate cell-specific information that could potentially be utilised in a research 
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Appendix A Leica ImageScope RNA-ISH (Version 2) 
algorithm. 









Appendix B ImageJ quantitative measurements for 
CRC FFPE cases. 
Supplementary Table 1. Summary of semi-quantitative manual scores and ImageJ 







Supplementary Table 2. Original data for Image Analysis methods quantifying total 
number of cells, total number of mRNA probe signals and the mean number of mRNA 





Appendix C Image analysis quantitative 
measurements for CRC cell lines. 
Supplementary Table 3. Quantitative data for Target/Reference gene ratios and relative expression levels 




Supplementary Table 3 (continued). Quantitative data for Target/Reference gene ratios and relative 





Supplementary Table 3 (continued). Quantitative data for Target/Reference gene ratios and relative 




Supplementary Table 3 (continued). Quantitative data for Target/Reference gene ratios and relative 
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Supplementary Table 3 (continued). Quantitative data for Target/Reference gene ratios and relative 





Supplementary Table 3 (continued). Quantitative data for Target/Reference gene ratios and relative 





Supplementary Table 4. Summary Mean Target/Reference gene ratios (±SE) for the SW480 and WiDr Cell 
lines as measured by qRT-PCR and Image Analysis methods (Mean, SEM). 
 
 
